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Abstract 
 
Molecular mechanisms of LINE-1 retrotransposition inhibition 
By 
Peter A. Larson 
 
Chair: John. V. Moran 
 Long INterspersed Element-1 (LINE-1 or L1) retrotransposons are an ancient 
family of repeated DNA sequences present in all inspected mammalian genomes. L1s 
are the only active autonomous mobile element in the human genome and are present 
at over 500,000 copies, representing ~17% of genomic DNA. A full-length human L1 is 
~6 kb in length and contains an internal RNA polymerase II promoter within its 5’ 
untranslated region (UTR). Following the 5’UTR are two open reading frames (ORF1 
and ORF2) that encode two functional proteins (ORF1p and ORF2p) that are required 
for mobilization (i.e., retrotransposition). L1s end with a 3’UTR and a poly(A) tail. The 
evolutionary success of L1 relies on the reiterative retrotransposition of full-length L1 
RNAs. The vast majority (>99.9%) of genomic L1s are inactive; however, on average, 
~80-100 L1s per diploid genome are capable of retrotransposition. Since, L1 
retrotransposition by its nature is mutagenic, it is likely that cellular host-factors have 
evolved to inhibit or restrict unabated L1 retrotransposition.  
Previous studies identified functional splice donor, splice acceptor, and 
polyadenylation sequences in full-length L1 RNA. Here, I demonstrate that 
retrotransposition of intra-5’UTR or 5’UTR/ORF1 spliced L1 RNAs leads to the 
generation of Spliced Integrated Retrotransposed Elements (SpIREs). Additionally, I 
uncovered a new intra-5’UTR SpIRE that is approximately ten times more abundant 
than previously identified SpIREs. Using biochemical and genetic approaches, I 
definitively demonstrate that intra-5’UTR SpIREs lack cis-acting transcription factor 
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binding sites, resulting in reduced 5’UTR promoter activity compared to a full-length 
5’UTR. Moreover, I demonstrate that 5’UTR/ORF1 SpIREs lack cis-acting sequences 
required for L1 transcription and produce non-functional ORF1p variants. These results 
establish that SpIREs are evolutionary “dead ends,” which are unlikely to contribute to 
additional rounds of L1 retrotransposition. Finally, in agreement with previous 
publications, I demonstrate that a subset of splicing factors may repress L1 expression 
and/or retrotransposition.  
Previous experiments in embryonic human carcinoma-derived cells (hECs) 
revealed that an engineered L1 tagged with a retrotransposition indicator cassette (L1-
reporter) successfully retrotransposed into hEC genomic DNA. However, either during 
or immediately after genomic integration, expression of the L1-reporter is silenced in 
hECs. Previous experiments demonstrated that hEC cells treated with histone 
deacetylase (HDAC) inhibitors swiftly reverse L1-reporter silencing. I sought to identify 
host proteins that may be involved in L1-reporter silencing by developing a forward 
genetic screen using CRISPR/Cas9-based genome editing technology. Using the PA-1 
hEC cell line that permits L1-reporter retrotransposition, but subsequently silences L1-
reporter expression, I identified potential candidate genes that may play a role in L1-
reporter mediated gene silencing. Future work will test whether the candidate genes 
identified in this screen directly or indirectly inhibit L1-reporter mediated gene silencing.  
A continued understanding of the interplay between L1 and host-factors is critical 
to understanding human genomic variation. Additionally, as the L1-host interaction 
largely recapitulates a traditional host-parasite “arms-race,” new insights gained from 
these studies may contribute to our understanding of how L1 retrotransposition 
continues to influence human health and disease.   
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Chapter 1 
Introduction 
 
 
Thesis Overview 
This thesis asks the question, “What cellular mechanisms inhibit unabated 
human L1 retrotransposition?” Herein, I describe my findings within the context of an 
evolutionary “arms-race” that occurs between L1 and its host, human cells. Chapter one 
begins with a general review of transposable element biology, and then focuses on 
human L1 biology, placing a particular emphasis on L1 evolution and the interaction of 
L1 with inhibitory host proteins. Chapter two describes the identification and 
characterization of Spliced Integrated Retrotransposed Elements (SpIREs) and 
demonstrates how splicing of L1 RNA potently inhibits retrotransposition via disruptions 
of the 5’UTR promoter sequence and/or translation of full-length ORF1p. Chapter three 
details my progress toward developing an unbiased forward genetic screen using 
CRISPR/Cas9-mediated genome editing to identify candidate cellular factors that may 
contribute to L1-reporter gene silencing. Chapter four provides a summary of my 
findings as they pertain to the hypothesis that L1 continues to amplify in the human 
genome despite the presence of a  “host-parasite arms-race” within our cells, and 
discusses areas for future study. 
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An Introduction to Transposable Elements 
Transposable elements (TEs), sometimes called “jumping genes,” are genomic 
DNA sequences that can physically move to new genomic locations within their host 
genome. TEs are present in all studied eukaryotic organisms and represent a diverse 
group of sequences that share a distinct feature, the potential for genomic mobilization 
(Craig et al., 2015; Fedoroff, 2012; Feschotte and Pritham, 2007). TEs utilize a variety 
of mechanisms to mobilize within genomes (Levin and Moran, 2011). Ultimately, the 
ability of any given TE to mobilize is dependent on the cellular environment in which it 
resides, an environment that can change over large spans of evolutionary time (millions 
of years (MY)), as well as within the lifetime of the organism (Levin and Moran, 2011).  
 Barbara McClintock’s discovery that “mutable-loci” in maize are the result of 
mobile DNA sequence activity demonstrated that the genome was not simply a static 
entity (McClintock, 1950, 1951). Classically considered “junk DNA,” TEs were assumed 
to be repeat DNA sequences that did not contribute phenotypically to the organism (i.e., 
“contributing little or no functional significance”) (Ohno, 1972). Though still sometimes 
referred to as “junk DNA,” the status of TEs was upgraded slightly by a pair of papers 
published in 1980 that referred to TEs as “selfish DNA” (Doolittle and Sapienza, 1980; 
Orgel and Crick, 1980). The two tenets of the “selfish DNA” hypothesis, as outlined by 
Orgel and Crick, are: 1) “It arises when a DNA sequence spreads by forming additional 
copies of itself within a genome,” and 2) “It makes no specific contribution to the 
phenotype.” By strict definition, this second point importantly means that, unlike protein 
coding genes, TE activity is not evolutionary selected to contribute phenotypically to the 
organism.  
Investigations into the mechanism of TE mobilization have yielded a tremendous 
amount of biological information since Barbara McClintock’s initial studies. In the 
context of human genetics, one of the most striking findings was the discovery of 
actively amplifying (i.e., retrotransposing) human Long INterspersed Element 1 (LINE-1 
or L1) sequences (Kazazian et al., 1988). Since that discovery, investigations into L1 
biology have yielded important insights into how L1s contribute to intra- and inter-
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individual human genetic variation and human disease (Beck et al., 2010; Cordaux and 
Batzer, 2009; Hancks et al., 2011; Richardson et al., 2015).  
  The remainder of this introductory chapter focuses on the two main classes of 
transposable elements [Class I (retrotransposons) and Class II (DNA Transposons)]. It 
then focuses on a review of human L1 biology, placing a particular emphasis on L1 
evolution and the interaction between L1 and its human host.  
The Human Genome is Replete with Transposable Elements 
 The protein-coding portion of the human genome constitutes a mere 1.5% 
(Consortium, 2012; Lander et al., 2001) of genomic DNA and may encode for as few as 
~19,000 genes (Ezkurdia et al., 2014) (Figure 1.1). Surprisingly, at least 45% of 
genomic DNA is derived from TEs (Lander et al., 2001). Indeed, bioinformatics analyses 
performed during the last six years suggest that as much as 70% of human genomic 
DNA may be derived from TEs (de Koning et al., 2011) (Figure 1.1). TE-derived 
sequences are separated into two classes: Class I retrotransposons mobilize via an 
RNA-intermediate using a “copy and paste” mechanism called retrotransposition. Class 
II DNA transposons generally mobilize via a DNA intermediate using a “cut and paste” 
mechanism called transposition.  
DNA Transposons 
  Class II DNA transposons are among the oldest type of recognizable 
transposable element, as they are present in prokaryotes (Kleckner, 1981), and all five 
eukaryote super groups (Feschotte and Pritham, 2007; Krupovic and Koonin, 2015). 
Although still active in many non-mammalian organisms, as a whole, DNA transposons 
have been less successful and contribute less genomic DNA content than other TEs 
(Feschotte and Pritham, 2007). DNA transposons comprise ~3% of the human genome 
(Lander et al., 2001) (Figure 1.1), but have been inactive in the lineage leading to 
humans for the past 50 MY. Indeed, it was thought that DNA transposons had become 
inactive in all mammalian lineages, as no evidence of their activity was present in 
recently sequenced genomes of other mammals (Feschotte and Pritham, 2007). Thus, it 
was surprising that the genome of the little brown bat, Myotis lucifigus, harbors active 
DNA transposons (Ray et al., 2008; Ray et al., 2007).  
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 Autonomous DNA transposons primarily move via a “cut and paste” mechanism 
(i.e., transposition) that is mediated by their encoded transposase gene (Craig et al., 
2015; Feschotte and Pritham, 2007). In the genome, DNA transposons are typically 
flanked by terminal inverted repeats (TIRs), which act as recognition sequences for 
transposase binding (Craig et al., 2015; Munoz-Lopez and Garcia-Perez, 2010) (Figure 
1.2). Transposase mediates both the excision of the DNA transposon from its initial 
genomic location as well as its integration into a new genomic target site (Craig et al., 
2015). The process of DNA transposition generally results in the generation of short 4-6 
bp target-site-duplications (TSDs) that flank the TIRs (Figure 1.2) (Craig et al., 2015; 
Munoz-Lopez and Garcia-Perez, 2010).  
 The counterparts to autonomous DNA transposons are non-autonomous DNA 
transposons. Non-autonomous DNA transposons contain TIRs, but do not encode a 
functional transposase gene (Craig et al., 2015; Munoz-Lopez and Garcia-Perez, 2010; 
Slotkin and Martienssen, 2007). Instead, non-autonomous DNA transposition is 
dependent on ‘hijacking’ (trans-complementation) the transposase protein expressed 
from an autonomous DNA transposon (Craig et al., 2015; Munoz-Lopez and Garcia-
Perez, 2010; Slotkin and Martienssen, 2007). Indeed, the TIRs are critical for the 
transposition of both autonomous, and non-autonomous DNA transposons (Craig et al., 
2015; Slotkin and Martienssen, 2007). Thus, the interaction between autonomous and 
non-autonomous TEs necessarily results in competition for recruitment of the catalytic 
transposase protein that is responsible for TE mobility. Strikingly, Barbara McClintock’s 
discovery of transposable elements in maize included both the autonomous Activator 
(Ac) DNA transposon, as well as its non-autonomous partner, Dissociation (Ds) 
(McClintock, 1950).  
By strict definition, “cut and paste” DNA transposition is non-replicative. Thus, 
DNA transposon copy number expansion in a given genome often depends upon 
genomic duplications that encompass an already resident DNA transposon (Craig et al., 
2015). Interestingly, it has been shown that, on occasion, the transposase genes of 
DNA transposons have been “co-opted” by the host for functional purposes (Slotkin and 
Martienssen, 2007). For example the V(D)J recombination proteins RAG1 and RAG2 
were likely domesticated from an ancient transposon (Huang et al., 2016; Kapitonov 
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and Jurka, 2005; Lander et al., 2001). RAG1 and RAG2 initiate V(D)J recombination 
allowing B- and T-cells generation of a diverse array of antigen binding receptors 
(Notarangelo et al., 2016). V(D)J recombination is considered to be a primary driving 
force in the evolution of adaptive immunity (Notarangelo et al., 2016). Likewise, the 
acquisition of adaptive immunity is considered to be a primary driving force in the 
evolution of jawed vertebrates (Huang et al., 2016; Notarangelo et al., 2016). Research 
suggests that the centromeric binding protein CENP-B is also a domesticated DNA 
transposon (Casola et al., 2008). CENP-B binds to a repeated centromere sequence 
and functions to organize the centromere in interphase as well as in mitotic 
chromosomes (Ando et al., 2002; Casola et al., 2008; McKinley and Cheeseman, 2016).  
Experimentalists have co-opted DNA transposons and their encoded 
transposase genes as tools for use in molecular biology. DNA transposon-based 
mutagenesis screens have been instrumental in uncovering new cancer genes and 
have been used as vector systems for gene therapy (Dupuy et al., 2006; Ivics et al., 
1997; Kawakami, 2005, 2007; Klinakis et al., 2000; Munoz-Lopez and Garcia-Perez, 
2010). For example the Sleeping Beauty (SB) DNA transposon has been engineered as 
an efficient gene delivery system in a variety of cell types (Ivics et al., 1997; Munoz-
Lopez and Garcia-Perez, 2010). The SB system relies on a two-plasmid delivery 
mechanism. One plasmid (i.e., the transposon vector) contains the DNA sequence of 
the gene of interest, flanked by TIRs, that is to be transposed into genomic DNA 
(Munoz-Lopez and Garcia-Perez, 2010). The other plasmid (i.e., the transposase 
expression vector) contains the SB transposase gene, but lacks TIRs (Munoz-Lopez 
and Garcia-Perez, 2010). The SB transposase acts in trans to bind the TIRs of the 
transposon vector to mediate its integration into a genomic DNA target site (Munoz-
Lopez and Garcia-Perez, 2010). Thus, transposase can mobilize a non-autonomous 
element to a new genomic location as long as it contains TIRs.     
Other transposon mutagenesis and/or gene delivery systems have been 
developed using a similar logic to the one outlined above. For example, the piggyBac 
DNA transposon was first identified in insects and piggyBac insertions tend to favor 
transcriptional units, thus making it ideal for gene mutagenesis studies (Cary et al., 
1989; Munoz-Lopez and Garcia-Perez, 2010). Similarly, the Tol2 DNA transposon, first 
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identified in fish, is capable of efficiently transposing over 10kb of DNA, making it ideal 
for delivering large transgenes (Kawakami, 2007; Munoz-Lopez and Garcia-Perez, 
2010).  
Recently, a DNA capture and deep sequencing technique (ATAC-Seq) was 
developed using the bacteria derived Tn5 DNA transposon (Buenrostro et al., 2013). 
The Tn5 transposase preferentially targets regions of open chromatin (Buenrostro et al., 
2013). Tn5 transposase simultaneously cuts exposed genomic DNA and ligates adapter 
sequences to those exposed DNA fragments (Buenrostro et al., 2013). The resultant 
fragments can subsequently be PCR amplified and used in deep sequencing 
experiments to identify regions of open chromatin (Buenrostro et al., 2013). In sum, 
despite their apparent inactivity in the human genome, DNA transposons have become 
important tools used to study human biology.  
Retrotransposons 
Class I transposable elements, also known as retrotransposons, account for an 
impressive ~42% of genomic DNA (Cordaux and Batzer, 2009; Lander et al., 2001) 
(Figure 1.1). Retrotransposons move via a “copy and paste” mechanism, called 
retrotransposition, where an RNA molecule(s) is the retrotransposition intermediate 
(Boeke et al., 1985; Craig et al., 2015). Retrotransposons can generally be subdivided 
into two classes: long terminal repeat (LTR) and non-LTR retrotransposons  (Figure 
1.1). Importantly, because retrotransposons utilize an RNA intermediate their mobility 
relies on reverse transcriptase (RT) activity. Autonomous retrotransposons typically 
encode their own RT, whereas non-autonomous retrotransposons must ‘hijack’ an RT-
containing protein from an autonomous retrotransposon (Richardson et al., 2015).  
LTR retrotransposons 
In humans LTR retrotransposons comprise ~8% of human genomic DNA (Figure 
1.1) (Lander et al., 2001). Autonomous LTR retrotransposons are closely related to 
retroviruses and are characterized by the presence of Long Terminal Repeats (LTRs) at 
their 5’ and 3’ termini (Figure 1.2). LTRs are regulatory sequences that play important 
roles in the expression of the retrotransposon RNA, cDNA synthesis, and cDNA 
integration (Beauregard et al., 2008; Craig et al., 2015). Endogenous retroviruses 
	   7	  
(ERVs) are the most relevant autonomous LTR retrotransposons with respect to human 
biology (Craig et al., 2015). Like retroviruses, complete ERVs encode gag, pol, and env 
genes (Craig et al., 2015) (Figure 1.2). The majority of ERVs in humans are incomplete; 
they harbor deletions or nonsense mutations in one or more of the gag, pol, and env 
genes (Craig et al., 2015; Hohn et al., 2013; Weiss, 2016).  
Non-autonomous ERVs contain LTRs, but generally do not encode functional 
genes (Craig et al., 2015; Havecker et al., 2004). Instead, non-autonomous ERV 
retrotransposition is dependent on ‘hijacking’ proteins expressed from an autonomous 
ERV in trans (Craig et al., 2015; Havecker et al., 2004). As with DNA transposons, the 
interaction between autonomous and non-autonomous ERVs necessarily results in 
competition for recruitment of catalytic proteins (Craig et al., 2015; Havecker et al., 
2004).  
ERV retrotransposition relies on gag and the multi-functional pol gene. After 
translation, the gag and pol proteins form a virus like particle (VLP) around the ERV 
mRNA (Craig et al., 2015; Gerdes et al., 2016). The pol gene contains protease, 
reverse transcriptase, integrase, and ribonuclease H activity (Craig et al., 2015; Gerdes 
et al., 2016; Nelson et al., 2003). The ERV cDNA is synthesized via pol RT activity 
within the VLP (Craig et al., 2015; Gerdes et al., 2016). The ERV integrase binds the 
LTRs of the mature ERV cDNA and mediates integration of ERV cDNA into the genome 
(Craig et al., 2015; Gerdes et al., 2016). ERV cDNA integration delivers the entire 
sequence of the newly replicated ERV and, like DNA transposition, results in short, 4-6 
bp TSDs (Craig et al., 2015; Gerdes et al., 2016).  
ERVs are not currently amplifying in the modern human genome and largely 
ceased retrotransposing in the lineage that gave rise to humans ~40 MYA (Cordonnier 
et al., 1995; Craig et al., 2015; Lander et al., 2001; Smit, 1993). There are, however, a 
handful of polymorphic human ERVs (HERV-K) insertions in the human population 
(Hohn et al., 2013; Macfarlane and Badge, 2015; Medstrand and Mager, 1998; Shin et 
al., 2013). A recent study identified an additional 36 polymorphic HERV-K insertions in 
data obtained from the thousand genomes project (Wildschutte et al., 2016). Thus, 
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these data suggest that after the human-chimpanzee divergence, some HERV-Ks 
retained activity, but have since ceased amplifying in the human genome. 
Despite their inability to retrotranspose, ERVs influence various cellular and 
genomic processes (Craig et al., 2015). Some ERVs contribute to gene regulation 
during human embryonic development (Grow et al., 2015; Lim and Knowles, 2015; 
Rebollo et al., 2012; Samuelson et al., 1996), while others contain sequences that are 
critical for the expression of certain interferon genes (Chuong et al., 2016). Thus, as 
presciently predicted by Britten and Davidson, in some instances, sequences derived 
from ERVs have become fodder for the development and acquisition of novel cis-acting 
gene regulatory circuits (Britten and Davidson, 1969; Chuong et al., 2016). Additionally, 
expression of gag and pol proteins has been associated with some human cancers 
(Bannert and Kurth, 2006; Conrad et al., 1997; Galli et al., 2005; Hohn et al., 2013). 
Finally, ERV env gene(s) were domesticated in some mammalian lineages, leading to 
the formation of present day Syncitin genes, which play critical roles in placental 
development (Dupressoir et al., 2012).  
Non-LTR retrotransposons 
Non-LTR retrotransposons are similar to LTR retrotransposons in that they 
require an RT-containing protein to mediate their retrotransposition (Luan et al., 1993; 
Moran et al., 1996). As their name implies, non-LTR retrotransposons lack long terminal 
repeat sequences; however, they are flanked by variable length TSDs that generally 
range in size from ~7-20 bp (Gilbert et al., 2005; Lander et al., 2001). Non-LTR 
retrotransposons comprise 35% of human genomic DNA and are the only active TEs in 
the human genome (Cordaux and Batzer, 2009; Lander et al., 2001) (Figure 1.1). 
Human autonomous non-LTR retrotransposons are called Long INterspersed Elements 
(LINEs) and are discussed in greater detail below.  
Non-autonomous non-LTR retrotransposons comprise ~11% of genomic DNA 
(Figure 1.1, 1.2). Human non-autonomous non-LTR retrotransposons do not encode an 
RT-containing protein and must ‘hijack’ an RT in trans from an autonomous non-LTR 
retrotransposon (Dewannieux et al., 2003). In humans, non-autonomous non-LTR 
retrotransposons include Mammalian Interspersed Repeats (MIRs) (Lander et al., 2001; 
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Smit, 1999), Short INterspersed Elements (SINEs; e.g., Alu) (Deininger et al., 1981; 
Dewannieux et al., 2003), and SINE-R/VNTR/Alu (SVA) elements (Hancks et al., 2011; 
Ostertag et al., 2003; Raiz et al., 2012b). Though not termed SINEs, other cellular 
RNAs [e.g., U6 small nuclear RNA (U6 snRNA) and U3 small nucleolar RNA (U3 
snoRNA)] can also ‘hijack’ proteins encoded by autonomous non-LTR retrotransposons 
(Buzdin et al., 2002; Garcia-Perez et al., 2007a; Gilbert et al., 2005; Wei et al., 2001). 
Similarly, retrotransposition of mRNAs can result in the formation of processed 
pseudogenes (Esnault et al., 2000; Wei et al., 2001) (Figure 1.1, 1.2). 
LINEs in the Human Genome 
The only active autonomous retrotransposon in the human genome is termed Long 
INterspersed Element-1 (LINE-1 or L1). Sequences derived from L1s account for ~17% 
of human genomic DNA and are present at greater than 500,000 copies in the haploid 
genome (Lander et al., 2001) (Figure 1.1). The vast majority of L1 sequences (>99.9%) 
have been rendered inactive via pre-mature 5’ truncation, point mutations that inactivate 
the L1-encoded proteins, or structural rearrangements (Grimaldi et al., 1984; Kazazian 
and Moran, 1998; Lander et al., 2001; Ostertag and Kazazian, 2001). The average 
human diploid genome, however, contains 80-100 retrotransposition-competent L1s 
(RC-L1) (Brouha et al., 2003; Sassaman et al., 1997). The mechanism of L1 
retrotransposition will be discussed in greater detail later in the Introduction. L1 
sequences arose and underwent a monophyletic expansion ~150 MYA, prior to the 
eutherian-marsupial split (Lander et al., 2001; Smit, 1996) (Figure 1.3). LINE-2 (L2) and 
LINE-3 (L3) elements are even more ancient and will briefly be described next.  
Evolution of LINEs 
“We are survival machines – robot vehicles blindly programmed to preserve the 
selfish molecules known as genes.” (Dawkins, 1976). 
Homo sapiens, like all organisms, are ultimately vehicles that transmit genetic 
material to the next generation. Yet within our genomes, repositories that contain all the 
information that makes us, lies a selfish genetic element that is truly a molecular robot. 
LINEs sole function is replication and propagation, preferably in germline cells, to 
ensure that new copies invade the next generation. LINEs follow a simple single rule: “If 
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they can propagate, they will.” In principle, LINEs can retrotranspose in any cell type. 
Any cellular consequences of LINE retrotransposition (i.e., generating beneficial, 
detrimental, or neutral mutations) are nothing more than downstream outcomes of the 
successful replication of a “molecular robot.” LINEs have been supremely successful at 
populating the human genome and comprise the single largest fraction of our genomes 
(Lander et al., 2001). The function of LINEs is conceptually simple, though the 
retrotransposition mechanism and resultant affects on the genome are rather complex. 
Indeed, LINEs represent a major evolutionary force that drives both genome and 
molecular evolution (Cordaux and Batzer, 2009; Kazazian, 2004; Kazazian and Moran, 
1998; Beck et al., 2011; Richardson et al., 2015).  
Ancient LINEs 
Recognizable LINEs in the human genome include L1s, L2s, and L3s. L2 and L3 
sequences comprise ~6% of the human genome (Figure 1.1). Both L2 and L3 are a part 
of the ancient chicken repeat 1 (CR1) clade of retrotransposons and are present in 
mammals, marsupials, birds, reptiles, fish, and insects (Jurka, 1998, 2000; Kapitonov 
and Jurka, 2003; Meyers, 2007). Present at less than a thousand copies in the human 
genome, all L3s are severely mutated and none are full-length (Jurka, 1998; Kapitonov 
and Jurka, 2003).  
L2 sequences are not necessarily younger than L3s, but apparently were active 
for a longer period of time in the mammalian lineage (Meyers, 2007) (Figure 1.3). L2 
amplification in the mammalian lineage occurred largely before the mammalian radiation 
(~65 MYA) (Jurka, 1998; Lander et al., 2001; Smit, 1996). In the lineage that gave rise 
to modern humans, L2 activity likely ceased ~80-100 MYA (Jurka, 1998; Lander et al., 
2001; Smit, 1996) (Figure 1.3). L2s were extremely successful, as there are ~300,000 
L2 sequences in the extant human diploid genome (Jurka, 1998; Lander et al., 2001). 
Just like present day SINEs parasitize the RT-containing protein of L1, ancient 
mammalian interspersed repeats (MIRs) apparently parasitized the RT-containing 
protein of L2 (Jurka, 1998; Lander et al., 2001; Smit, 1996). The L2 3’UTR contains a 50 
bp sequence required for L2 RT binding and subsequent L2 retrotransposition; MIRs 
also harbored that 50 bp sequence at their 3’ end (Lander et al., 2001; Smit, 1996, 
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1999). These data suggest that MIR elements were able to hijack the L2 EN and RT 
activities to mediate their retrotransposition to new genomic locations (Smit, 1996).  
LINE-1s 
Roughly 150 MYA, before the eutherian/metatherian split, L1s began amplifying 
in the genomes of early mammalian species (Lander et al., 2001; Smit, 1996) (Figure 
1.3). L1s amplified concomitantly with L2 elements for millions of years until L2s ceased 
to proliferate ~80-100 MYA (Lander et al., 2001) (Figure 1.3). The reason why L1 
activity supplanted L2 activity is not entirely clear. It is possible that MIRs evolved a 
3’UTR that was more efficient in recruiting the L2 containing RT than L2 itself. The 
ability of MIRs to effectively out compete L2s for RT binding may, in turn, have slowed 
L2 retrotransposition, allowing genetic drift and host repressive mechanisms to mutate 
full-length L2 copies, leading to their demise.  
In contrast to L2s, L1s employ a cis-preference mechanism to recruit RT. Recent 
data indicate that nascent ORF2p co-translationally binds to the L1 poly(A) tail and 
suggest ORF2p binding to the L1 poly(A) tail may inhibit further ORF2p synthesis (Ahl 
et al., 2015; Alisch et al., 2006; Doucet et al., 2015; Esnault et al., 2000; Wei et al., 
2001). Recent data also suggest that Alu elements, which are RNA polymerase III 
transcripts, associate with translating ribosomes, effectively allowing their encoded 
poly(A) tract to compete with the L1 RNA poly(A) tail for nascent ORF2p binding (Ahl et 
al., 2015; Doucet et al., 2015; Doudna and Rath, 2002). Indeed, we propose that the 
ability of L1 ORF2p to bind either the L1 poly(A) tail or Alu poly(A) tract does not 
necessarily hinder L1 retrotransposition, allowing both elements to co-amplify in current 
human genomes.  
L1s have undergone bursts of rapid expansion followed by periods of lower 
activity (Lander et al., 2001), a phenomenon known as subfamily succession (Boissinot 
et al., 2000; Boissinot et al., 2004a; Boissinot and Furano, 2005). L1 subfamily 
succession can be modeled in terms of a host-parasite arms race—periods of 
expansion would typify a scenario where L1s are amplifying at high rates, whereas 
periods of lower activity could reflect times when host repressive processes are limiting 
unabated L1 retrotransposition.  
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L1 evolution in mammalian genomes has been well studied and has allowed the 
reconstruction of consensus sequences of L1 subfamilies (Boissinot et al., 2000; 
Boissinot et al., 2004a; Boissinot and Furano, 2005; Boissinot et al., 2004b; Khan et al., 
2006; Smit et al., 1995). There are two major subdivisions of L1s: those that are present 
in all mammals (L1M) and those that are only present in primates (L1P) (Smit et al., 
1995) (Figure 1.3). Further divisions (called subfamilies) add an additional letter (e.g. 
L1MA-MD and L1PA-PB), and subsequently a number (e.g., L1PA15).  
Phylogenetic studies indicate that in the earliest primate genomes, both the L1M 
and L1P subfamilies were evolving simultaneously, but as independent lineages (Khan 
et al., 2006; Smit et al., 1995) (Figure 1.3). The major difference between various 
subfamilies amplifying within and between those groups is their respective 5’UTR 
sequence (Khan et al., 2006) (Figure 1.4). Acquisition of new 5’UTR sequences and 
mutations within 5’UTRs is likely a primary mechanism driving L1 evolution (Khan et al., 
2006) (Figure 1.4). In the lineage leading to modern humans, the L1PB1, L1PA11, and 
perhaps L1MA1 subfamilies apparently were co-amplifying until ~55 MYA (Khan et al., 
2006). After that time, it appears that L1PA11 sequences acquired a new 5’UTR 
yielding the L1PA10 subfamily (Khan et al., 2006) (Figure 1.3, 1.4). After L1PA10, L1 
evolution followed a curious path of subfamily succession where one L1 subfamily was 
predominantly active in the genome at any given time (Khan et al., 2006) (Figure 1.3, 
1.4). This evolutionary trajectory led to a monophyletic lineage of L1 amplification over 
the last 40MY (e.g., L1PA10 sequences gave rise to L1PA8 (there is no L1PA9), which 
gave rise to L1PA7, L1PA6, L1PA5….etc., ultimately leading to the L1Hs lineage, which 
is currently active in the human genome) (Figure 1.4). It is likely that numerous short-
lived L1 sequences branched out from these main subfamilies (e.g., L1PA8A), but only 
few were active for long enough periods of time to become fixed in the human genomic 
record.  
Inspecting non-human primate genomes and comparative genomic studies 
permits an estimation of the age and success of L1 subfamilies (Bannert and Kurth, 
2006; Boissinot and Furano, 2005; Khan et al., 2006; Smit, 1996, 1999; Smit et al., 
1995). L1 became wildly successful in primate genomes. The fossil record suggests the 
earliest primates appeared ~55-65 MYA, although molecular data suggests an earlier 
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date of primate emergence of ~75-85 MYA (Goodman et al., 1998; Tavare et al., 2002). 
Subfamily succession likely occurred only after the primate lineage was established 
(Boissinot and Furano, 2005; Khan et al., 2006). Primate specific L1s also underwent 
bursts of activity followed by periods of lower activity (Boissinot and Furano, 2005; 
Goodman et al., 1998; Khan et al., 2006; Tavare et al., 2002) (Figure 1.3). For example, 
the L1PA12 family (amplifying ~60MYA) is represented by just under 900 insertions in 
the human genome reference (HGR) (Khan et al., 2006) (Figure 1.3). In contrast, 
subfamilies L1PA7, 5, 4, and 3 (amplifying 30, 21, 18, 12 MYA, respectively) are each 
represented by more than 8000 copies in the HGR (Khan et al., 2006) (Figure 1.3). This 
burst of retrotransposition occurred shortly after the Old World/New World primate 
divergence and continued up to the lineage giving rise to modern humans and apes ~25 
MYA (Khan et al., 2006) (Figure 1.3).  
Since the expansion of the L1PA5, 4, and 3 subfamilies in the ape lineage, L1 
expansion appears to have slowed down (Khan et al., 2006). The L1PA2 subfamily, 
which is common to chimps and humans, amplified ~8 MYA and is represented by half 
the number of sequences as L1PA3 in the HGR (Khan et al., 2006). Since the lineage 
giving rise to modern humans diverged from the chimpanzee lineage ~6 MYA, only 
~1100 the human specific L1 (L1PA1 or L1Hs) sequences have accumulated in the 
HGR (Khan et al., 2006; Mills et al., 2006). Interestingly, the decrease in human specific 
L1 sequences is not born out in the chimpanzee lineage. The Pan trogolodytes specific 
L1 sequence (L1Pt) is at least twice as numerous in the chimpanzee reference genome 
than L1Hs in the HGR (Hormozdiari et al., 2013).  
L1 evolution is primarily driven by mutation and large-scale changes to the 5’UTR 
(Khan et al., 2006) (Figure 1.4). Of the L1PA family of elements, the longest 5’UTR is in 
L1PA12 (2460 bp); the shortest is in L1Hs (910 bp). Aside from a stretch of guanine 
nucleotides and a conserved Yin-Yang 1 (YY1) transcription factor binding-site at the 5’ 
end of the 5’UTR, there is little conservation in the 5’UTR amongst L1PA subfamilies. 
The YY1 site is critical in the positioning of L1 transcription at or near the 1st nucleotide 
of the element (Athanikar et al., 2004). The final 5’UTR substitution occurred in L1PA10 
giving rise to L1PA8 (~40MYA) (Khan et al., 2006) (Figure 1.3, 1.4). Subsequently, 
through monophyletic subfamily succession, sequences in the 5’UTR were both lost and 
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acquired, and led to an overall shortening of the 5’ UTR from 1338 bp in L1PA8, to its 
present size, ~910 bp in L1Hs (Khan et al., 2006).  
Rapid evolution of the 5’UTR could be due to two non-mutually exclusive 
processes: 1) competition between co-amplifying L1 subfamilies for limiting host factors 
essential for retrotransposition; and 2) escape from host factor repression. Host proteins 
have evolved to target L1 5’UTR sequences and repress L1 transcription. L1 sequences 
must, in turn, evolve to ‘escape’ the transcriptional repressive effects of these host 
proteins. The evolutionary relationship of host repression followed by L1 response 
exemplifies a “Red Queen” scenario, where active L1s must retrotranspose new full-
length L1 copies as quickly as possible to evade the repressive effects of host proteins 
and genetic drift host (Carroll et al., 2004; Vanvalen, 1973).  
A beautiful example of a “Red Queen” scenario was recently demonstrated in a 
study from the Haussler lab. Cell culture based experiments demonstrated that a zinc-
finger protein, ZNF93, inhibits L1 expression and retrotransposition, but in a subfamily 
specific manner (Jacobs et al., 2014). The ZNF93 protein binds to a 129 bp sequence 
within the 5’UTR of L1PA3 subfamily members, leading to transcriptional repression 
(Jacobs et al., 2014). The loss of the ZNF93 binding from the 5’UTR of L1PA2 subfamily 
members allowed them to escape ZNF93-mediated transcriptional repression and 
undergo subsequent amplification in the lineage leading to humans (Jacobs et al., 
2014). 
Additional observations suggest that other repressive factors may have led to the 
extinction of older L1 subfamilies. For example, recent studies demonstrated that the 
zinc-finger protein, KAP1, binds to the 5’UTR and represses transcription of older L1s 
(L1PA6-L1PA2), but not the currently active L1Hs (Castro-Diaz et al., 2014). 
In sum, using anthropomorphic reasoning, the evolutionary “objective” of L1 is 
simple: it retrotransposes throughout the genome as much as the host can tolerate. The 
host, in turn, evolves restriction factors that inhibit unabated L1 retrotransposition. L1 
then subsequently evolves to escape those restrictive factors—and the cycle continues. 
Thus, L1 amplification meets the definition of a successful selfish genetic element that, 
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in most mammalian genomes, has not succumbed to repressive processes during the 
last 150 MY.  
Structure of an Active Human LINE-1 
Active human L1s are ~6 kilobases (6 kb) in length (Dombroski et al., 1991; Scott 
et al., 1987) and contain a 5’UTR that harbors both sense (Swergold, 1990) and anti-
sense (Speek, 2001) RNA polymerase II promoters (Figure 1.2B). An open reading 
frame (ORF0) with unknown function resides in the anti-sense orientation within the 
5’UTR (Denli et al., 2015). Following the 5’UTR are two open reading frames (ORF1 
and ORF2) that are separated by a 63 base pair (bp) inter-ORF spacer that contains 
two in-frame stop codons (Alisch et al., 2006; Dombroski et al., 1991). L1 ends with a 
3’UTR positioned between the ORF2 stop codon and a variable-length poly adenosine 
tract (Dombroski et al., 1991; Grimaldi et al., 1984; Scott et al., 1987). Genomic L1s are 
flanked by variable-length (~7-20 bp) TSDs (Gilbert et al., 2005; Gilbert et al., 2002; 
Richardson et al., 2015; Symer et al., 2002). 
5’UTR 
The L1 5’UTR is ~910bp and contains an internal RNA polymerase II promoter(s) 
that direct the transcription of both sense (Athanikar et al., 2004; Becker et al., 1993; 
Swergold, 1990) and anti-sense (Speek, 2001) L1 RNAs. The centrally located anti-
sense promoter is weaker than the sense promoter, but has been shown to drive 
transcription of adjacent genes residing upstream of a genomic L1 in a tissue-specific 
manner (Macia et al., 2011; Matlik et al., 2006; Nigumann et al., 2002; Speek, 2001). 
Experimental evidence suggests that anti-sense driven promoter transcripts may 
bind to sense L1 promoter transcripts to create double stranded RNAs that are 
subsequently processed into siRNAs by Dicer to repress L1 retrotransposition (Yang 
and Kazazian, 2006). It has also been suggested that the microprocessor (Drosha-
DGCR8) binds to and catalytically processes anti-sense transcripts emanating from 
5’UTR; however, the role of these processed transcripts in L1 retrotransposition, if any, 
remains unclear (Heras et al., 2013). Some studies have suggested that the 
aforementioned processes may represent self-regulatory mechanism that acts as a 
“rheostat” to dampen L1 retrotransposition (Yang and Kazazian, 2006). However, these 
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findings violate a key tenet of a selfish genetic element; it is more likely that the L1 anti-
sense promoter somehow benefits L1 expression. Indeed, more than 10% of human 
protein coding genes contains both sense and anti-sense promoters (Bratthauer and 
Fanning, 1993; Core et al., 2012; Thayer et al., 1993; Trinklein et al., 2004). Some 
evidence from yeast suggests that anti-sense transcription from gene promoters is 
associated with alterations in local chromatin that may facilitate sense transcription 
(Murray et al., 2015). However, the authors of Murray et al., 2015, observed only a 
slight increase in promoter activity when compared to promoters that lack anti-sense 
transcription. Rigorous dissection of the L1 anti-sense promoter is necessary to 
determine any effect it may have on L1 transcription and retrotransposition.  
At least five defined transcription factor binding sites reside within the L1 5’UTR. The 
YY1 transcription factor binds at +13 and directs transcriptional initiation at or near the 
first nucleotide of the L1 5’UTR (Athanikar et al., 2004; Becker et al., 1993). Two 
RUNX3 transcription factor-binding sites have been identified (Yang et al., 2003). One 
of these, at +90, strongly enhances sense L1 transcription and retrotransposition in a 
cell cultured based assay (Yang et al., 2003). The other RUNX3 site, at +510, may 
regulate anti-sense promoter activity (Yang et al., 2003). Two SRY-like sites at +472 
and +572 are responsive to SOX11 and SOX3 overexpression in cell culture 
retrotransposition assays and drive L1 promoter activity (Tchenio et al., 2000). 
Conversely, studies in transgenic mice neuronal cells suggest SOX2 may repress L1 
transcription (Muotri et al., 2005). 
ORF1 
The first L1 open reading frame (ORF1) immediately follows the 5’UTR.  ORF1 
encodes a ~40 kiloDalton (kDa) protein, ORF1p, containing three defined domains 
(Hohjoh and Singer, 1996, 1997b; Holmes et al., 1992; Martin, 1991) (Figure 1.2). The 
amino terminus of ORF1p consists of a coiled-coil domain that is required for ORF1p 
trimerization (Khazina et al., 2011; Khazina and Weichenrieder, 2009; Martin et al., 
2003). Mutations disrupting ORF1p trimerization disrupt L1 retrotransposition (Basame 
et al., 2006; Doucet et al., 2010; Khazina et al., 2011; Khazina and Weichenrieder, 
2009).  
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An RNA Recognition Motif (RRM) is centrally located in ORF1p (Khazina et al., 
2011; Khazina and Weichenrieder, 2009), which is followed by a carboxy-terminal 
domain (CTD) that is rich in positively charged amino acids (Moran et al., 1996). ORF1p 
has been demonstrated to bind to L1 RNA forming a ribonucleoprotein particle (RNP) 
(Doucet et al., 2010; Hohjoh and Singer, 1996, 1997b; Kulpa and Moran, 2005; Martin, 
1991). Evidence suggests that the RRM and carboxyl-terminal domains interact and are 
critical for ORF1p nucleic acid binding (Hohjoh and Singer, 1996, 1997b; Holmes et al., 
1992; Januszyk et al., 2007; Khazina et al., 2011; Khazina and Weichenrieder, 2009; 
Martin, 1991). The RRM and CTD domains may also be important for ORF1p nucleic 
acid chaperone activity (Khazina and Weichenrieder, 2009; Martin and Bushman, 
2001). ORF1p has been demonstrated to bind both ssDNA, and with less affinity dsDNA 
(Callahan et al., 2012; Khazina and Weichenrieder, 2009; Martin and Bushman, 2001; 
Martin et al., 2005). ORF1p chaperone activity is hypothesized to facilitate L1 
integration into the genome (Martin and Bushman, 2001). Additionally, three short 
blocks of conserved amino acids in the CTD were demonstrated to be crucial for L1 
retrotransposition in a cell-culture based assay (Moran et al., 1996). 
ORF2 
The second ORF encodes a ~150 kDa, ORF2p, which mediates L1 cDNA 
insertion into the genome (Figure 1.2) (Doucet et al., 2010; Ergun et al., 2004; Feng et 
al., 1996; Goodier et al., 2010; Moran et al., 1996). ORF2p contains at least three 
functional domains. The N-terminal endonuclease (EN) domain was originally identified 
in a Trypanosom cruzi non-LTR retrotransposon L1Tc, (Martin et al., 1995) and 
resembles an apurinic/apyrimidinic endonuclease (APE) (Feng et al., 1996). The L1 EN 
domain creates a single-strand endonucleolytic nick in both super-coiled and relaxed 
DNA (Feng et al., 1996), but unlike traditional APEs (Mol et al., 1995), does not appear 
to have a preference for cleaving DNA at abasic sites. The L1 EN domain makes a 
single-strand endonucleolytic cleavage at a degenerate consensus sequence [e.g., 5’-
TTTT/A-3’ where the (/) represents the location of the scissile phosphate] (Feng et al., 
1996). The consequence of endonuclease activity is the liberation of a free 5’-
monophosphate and 3’-hydroxyl group (Feng et al., 1996).  
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The reverse transcriptase (RT) domain of ORF2p follows 3’ of the EN domain. 
The core RT domain is homologous across all sequences that encode an RT, including 
group II introns, telomerase, LTR-retrotransposons, and retroviruses (Craig et al., 2015; 
Eickbush, 1997; Eickbush et al., 1997; Hattori et al., 1986; Malik et al., 1999; Xiong and 
Eickbush, 1990). Experiments in yeast expressing Ty1/ORF2 fusion proteins first 
demonstrated L1 ORF2p contained RT activity (Dombroski et al., 1994; Mathias et al., 
1991). Later work indicated that the RT domain of ORF2p mediates both RNA- and 
DNA-dependent DNA polymerization (Cost et al., 2002; Piskareva et al., 2003; 
Piskareva and Schmatchenko, 2006). Like ORF1p, ORF2p is present in 
ribonucleoprotein particles (RNPs) (Doucet et al., 2010; Kulpa and Moran, 2005, 2006). 
In vitro studies have demonstrated that RNP-associated ORF2p RT activity could utilize 
L1 RNA as a template for reverse transcription (Doucet et al., 2010; Kulpa and Moran, 
2005, 2006).  
The final domain of ORF2p is a cysteine-rich (C) domain (Fanning and Singer, 
1987; Moran et al., 1996). The function of the C domain is unclear, but mutations in the 
C domain reduce RT activity, ORF2p localization to RNPs, and retrotransposition of L1 
RNAs in human cells (Doucet et al., 2010; Moran et al., 1996) and RT activity in yeast 
(Clements and Singer, 1998). Recent experiments performed in a cell culture based 
retrotransposition assay suggest that a ccarboxyl-terminal tyrosine (amino acid 1180) 
residue is dispensable for L1 retrotransposition, but may aid in ORF2p-mediated 
retrotransposition of Alu RNAs (Christian et al., 2017). Additional experimentation is 
required to further elucidate the function of the C domain. 
3’UTR 
L1s end with a ~200 bp 3’UTR situated between the ORF2 stop codon and a 
variable length poly(A) sequence at the L1 3’ terminus (Dombroski et al., 1991; Grimaldi 
and Singer, 1983; Grimaldi et al., 1984). A poly-guanosine tract present proximal to the 
beginning of the 3’UTR is a general feature of mammalian 3’UTRs and may form a 
stable G-quadruplex (Howell and Usdin, 1997; Sahakyan et al., 2017; Usdin and 
Furano, 1989). Despite this conservation, the 3’UTR is dispensable for L1 
retrotransposition, at least in cultured human cells (Moran et al., 1999; Moran et al., 
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1996). Though the function of the guanosine tract remains unclear, its conservation 
suggests that it may play a role in some aspect of L1 RNA biology. The 3’UTR ends in a 
weak poly(A) signal that is often bypassed in favor of adjacent poly(A) signals present in 
downstream genomic DNA (Holmes et al., 1994; Moran et al., 1999; Moran et al., 1996). 
Read through transcripts that bypass the canonical L1 poly(A) signal allows 3’ genomic 
sequences to be appended to the L1 RNA; retrotransposition of these RNAs results in 
L1-mediated 3’ transductions (Holmes et al., 1994; Moran et al., 1999; Moran et al., 
1996).  
LINE-1 Retrotransposition Cycle 
 Continued success of L1 requires the faithful retrotransposition of a full-length 
RNA. Genomic L1s are generally 5’ truncated or contain internal deletions and/or 
inversions (Grimaldi et al., 1984; Lander et al., 2001). However, ~1/3 of endogenous 
L1Hs sequences are full-length (Lander et al., 2001). Similarly, L1 insertions recovered 
from engineered retrotransposition events in HeLa cells demonstrated that 6/100 were 
full-length insertions and an additional four contained ~6 kb of L1 sequence that was 
either internally rearranged or contained short 5’ deletions (Gilbert et al., 2005). Despite 
the low percentage of full-length insertions, L1 genomic retrotransposition has been 
extremely successful over evolutionary time.  
 A round of L1 retrotransposition begins with the transcription of a genomic, 
retrotransposition-competent L1 (RC-L1) (Figure 1.5). RNA polymerase II initiates 
transcription at or near the first nucleotide of the 5’UTR (Athanikar et al., 2004; Becker 
et al., 1993; Swergold, 1990). The bicistronic, polyaddenylated L1 RNA is exported to 
the cytoplasm where ORF1 is translated in a cap-dependent manner (Dmitriev et al., 
2007; Leibold et al., 1990; McMillan and Singer, 1993) (Figure 1.5). Translation initiation 
of the second open reading frame (ORF2) is incompletely understood. It has been 
suggested that ORF2p translation may involve an unconventional ribosomal 
termination-reinitiation mechanism (Alisch et al., 2006; Dmitriev et al., 2007; McMillan 
and Singer, 1993). Notably, ORF2 translation can initiate in an AUG-independent 
manner and ORF2 is efficiently translated regardless of the composition of the upstream 
ORF (Alisch et al., 2006). One study suggests that mouse ORF2 could also be 
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translated via ribosome termination-reinitiation (Alisch et al., 2006). Another study 
suggests that mouse ORF2 is translated with the aid of an internal ribosome entry site 
(IRES) at the end of ORF1p (Li et al., 2006), although deletion of this sequence in 
human L1 does not prevent ORF2 translation (Alisch et al., 2006).  Additional 
experimentation is necessary to determine if an IRES is important for mouse L1 
retrotransposition. Importantly both ORF1p and ORF2p are translated independently as 
no fusion ORF1/2p proteins have been identified (Alisch et al., 2006; Leibold et al., 
1990). 
 Following translation, both ORF1p (Hohjoh and Singer, 1996, 1997a, b) and 
ORF2p (Kulpa and Moran, 2005, 2006) bind L1 RNA by a mechanism known as cis-
preference (Doucet et al., 2015; Esnault et al., 2000; Kulpa and Moran, 2006; Wei et al., 
2001) forming a ribonucleoprotein particle (RNP). RNP formation is necessary, but not 
sufficient, for LINE-1 retrotransposition (Kulpa and Moran, 2005) (Figure 1.5). In 
addition to biochemical assays, immunofluorescence of epitope-tagged L1 proteins 
demonstrated an intimate cytoplasmic co-localization of L1 RNA, ORF1p, and ORF2p 
(Doucet et al., 2010; Goodier et al., 2010). Recent work has shown that the poly(A) tail 
of L1 RNA is crucial for retrotransposition and likely acts to recruit ORF2p to L1 mRNA 
(Doucet et al., 2015). The L1 RNP likely consists of other cellular proteins and RNAs in 
addition to ORF1p, ORF2p, and L1 RNA (Goodier et al., 2013; Moldovan and Moran, 
2015; Taylor et al., 2013). Determining what other constituents distinguish functional vs. 
nonfunctional RNPs, will be crucial to better understanding the mechanism of L1 
retrotransposition.   
 Following RNP formation, components of the L1 RNP enter back into the nucleus 
by a process that does not strictly require cell division (Kubo et al., 2006) (Figure 1.5). 
L1 integration occurs by a mechanism termed target-site primed reverse transcription 
(TPRT) and minimally requires ORF2p and L1 RNA (Cost et al., 2002; Feng et al., 
1996; Kulpa and Moran, 2006; Luan et al., 1993) (Figure 1.5). TPRT initiates with a 
single-strand endonucleolytic nick at a genomic target DNA sequence mediated by 
ORF2p EN (Cost et al., 2002; Feng et al., 1996; Morrish et al., 2002, Luan et al., 1993). 
The single-strand nick occurs in a thymidine-rich sequence (e.g., 5’-TTTT/A-3’) where 
the (/) denotes the siscile phosphate (Cost and Boeke, 1998; Feng et al., 1996; Morrish 
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et al., 2002). The result of the endonucleolytic nick is exposure of a reactive 3’ hydroxyl 
group, which ORF2p RT activity uses as a primer to initiate minus (-) strand L1 cDNA 
synthesis (Cost and Boeke, 1998; Feng et al., 1996) (Figure 1.5). It is unclear how 
second strand cDNA synthesis is completed. Top (+) strand cleavage likely occurs 
downstream of the initial nick, but whether this is performed by ORF2p or another 
cellular enzyme requires elucidation. By analogy to the R2 retrotransposon of Bombyx 
mori, it is likely that ORF2p cleaves the top strand and polymerizes second strand L1 
cDNA (Christensen and Eickbush, 2005; Luan et al., 1993). The completion of TPRT 
results in the insertion of a new L1 cDNA molecule flanked by variable length/sequence 
target site duplications (TSDs) (Figure 1.5).  
Despite cis-preference, other cellular RNAs are occasionally mobilized by 
associating with L1 ORF1p and/or ORF2p. In a process termed trans-complementation, 
RNAs ‘hijack’ L1 proteins that mediate their retrotransposition (Ahl et al., 2015; Doucet 
et al., 2015; Wei et al., 2001)  (Figure 1.5). The Small INterspersed Element (SINE) 
family, including Alu (Deininger et al., 1981; Dewannieux et al., 2003) and SINE-
R/VNTR/Alu (SVA) elements (Hancks et al., 2011; Ostertag et al., 2003; Raiz et al., 
2012b), can parasitize the L1 encoded protein(s) (Ahl et al., 2015; Doucet et al., 2015). 
Indeed, Alus have been more retrotranspositionally successful than L1s, amplifying to 
over one million copies in the human genome (Lander et al., 2001).  
The active human Alu is derived from the 7SL RNA component of the signal 
recognition particle (SRP) (Bennett et al., 2008; Kriegs et al., 2007; Okada et al., 1997; 
Ullu and Weiner, 1985; Weichenrieder et al., 2000). Alu retrotransposition requires L1 
ORF2p (Bennett et al., 2008; Dewannieux et al., 2003) and a poly(A) tract (Dewannieux 
et al., 2003; Dewannieux and Heidmann, 2005). Experiments have demonstrated that 
Alu RNA binds to the signal recognition particle (SRP) 9/14 heterodimer (Weichenrieder 
et al., 2000) forming an Alu RNP that can interact with the ribosome (Ahl et al., 2015). It 
has been postulated that active translation of L1 RNAs prevents Alu from efficiently 
interacting with the ribosome, whereas stalled or slowed ribosomes are permissive for 
Alu RNP interaction (Ahl et al., 2015). The Alu RNP-ribosome interaction may arrest the 
L1 translating ribosome, which could favor Alu RNA ‘hijacking’ of L1 ORF2p (Ahl et al., 
2015; Doucet et al., 2015; Doudna and Rath, 2002). The other active human SINE, 
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SVA, is much less abundant, present at less than 3,000 copies in the human genome 
(Ostertag et al., 2003; Wang et al., 2005) and unlike Alu, SVAs may require both 
ORF1p and ORF2p for their retrotransposition (Hancks et al., 2011; Raiz et al., 2012a). 
In addition to SINEs, L1 ORF2p can mobilize cellular mRNAs leading to the 
formation of processed pseudogenes, which lack introns (Esnault et al., 2000; Wei et 
al., 2001) (Figure 1.2). Additionally, small uracil-rich nuclear RNAs (U6 snRNA) (Buzdin 
et al., 2002; Garcia-Perez et al., 2007a; Gilbert et al., 2005) and small nucleolar RNAs 
(U3 snoRNA) (Weber, 2006) can be mobilized in trans by L1 ORF2p. The panoply of 
RNAs that are mobilized by the L1-encoded protein(s) is exceptional. ORF2p enzymatic 
activity, through the mobilization of L1 or other RNAs, has singularly been responsible 
for over one-third, or one billion base pairs, of sequence in the human genome (Figure 
1.1) (Cordaux and Batzer, 2009; Lander et al., 2001).   
Effects of LINE-1 Retrotransposition  
L1 biologists frequently get asked the question, “What do L1s do?” L1 function is 
simple; they selfishly create copies and spread throughout the genome. However, the 
effect of L1 amplification and insertion varies widely in scale and impact on genomic 
integrity (Beck et al., 2011; Richardson et al., 2015). As repeat sequences, genomic L1s 
can serve as scaffolds for non-allelic homologous recombination resulting in reciprocal 
chromosomal insertions and deletions. L1 insertion via TPRT can also mediate 
alterations of native genomic DNA. L1-mediated insertions have been implicated in 
causing diseases, including cancer, while also serving as drivers of genomic evolution 
by providing fodder for the evolution of gene regulatory systems (Chuong et al., 2017) 
and de novo gene creation (Moran et al., 1999; Nisole et al., 2004; Sayah et al., 2004). 
LINE-1 in disease 
A major breakthrough in understanding the effects of L1 retrotransposition on the 
human genome occurred in 1988, when Haig Kazazian discovered de novo L1 
insertions in the Factor VIII gene of two unrelated boys afflicted with hemophilia A 
(Kazazian et al., 1988). Until that observation, L1s were thought to be inactive. 
Currently, 124 documented cases of L1-mediated retrotransposition events have 
resulted in human disease (Hancks and Kazazian, 2016). Of these, 76 are the result of 
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Alu insertions, 30 are due to L1 insertions, 13 are due to SVA insertions, four are due to 
poly(A) insertions, and one is due to a processed pseudogene insertion (Hancks and 
Kazazian, 2016). Furthermore, it has been suggested that 1/250 genetic diseases are 
the result of an L1-mediated retrotransposition event (Wimmer et al., 2011).  
The effects of de novo retrotransposition-mediated mutagenesis are diverse. 
Both of the L1 insertions first identified in the Factor VIII gene inserted into exon 14 
(Kazazian et al., 1988). Six L1 retrotransposition events into the DMD gene resulted in 
five cases of Duchenne Muscular Dystrophy and one case of X-linked Dilated 
Cardiomyopathy (Hancks and Kazazian, 2016). Of those events, four retrotransposed 
into exons resulting in exon skipping and/or the creation of pre-mature stop codons 
(Awano et al., 2010; Holmes et al., 1994; Musova et al., 2006; Narita et al., 1993), 
whereas one retrotransposed into the 5’UTR likely affecting DMD transcription (Yoshida 
et al., 1998). The effect of the remaining insertion remains unknown. Intronic L1 
retrotransposition events resulting in exon skipping have also been observed in the 
FKTN gene resulting in Fukuyama congenital muscular dystrophy (Kondo-Iida et al., 
1999) and the SLCO1B3 gene resulting in Rotor syndrome (Kagawa et al., 2015). 
Finally, a L1 insertion resulted in a ~47 kb deletion within the PDHX gene resulting in 
Pyruvate Dehydrogenase Complex deficiency (Mine et al., 2007).  
L1 mediated retrotransposition has also been implicated in cancer. The major 
question remains, “Does L1 mediated retrotransposition directly drive the cancer 
phenotype?” Currently, there are only a handful of examples that suggest L1 
retrotransposition resulted in cancer. Somatic L1 retrotransposition into the exons of the 
APC gene (Miki et al., 1992; Scott et al., 2016), the PTEN gene (Helman et al., 2014), 
and within an intron of the RB1 gene, resulting in cryptic splicing (Rodriguez-Martin et 
al., 2016), were all shown to drive cancer progression. Notably, APC, PTEN, and RB1 
are tumor suppressor genes. L1 mediated gene disruption could act as either the first, 
or second, ‘hit’ of a tumor suppressor gene to drive cancer progression (Knudson, 
1971). Recently, a report demonstrated that an SVA insertion in the CASP8 gene is 
associated with basal cell carcinoma and breast cancer, but curiously confers protection 
against prostate cancer (Stacey et al., 2016). Finally, another report suggests an L1 
retrotransposition event into the ST18 gene disrupted a transcriptional repressor, 
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leading to ST18 oncogenic activation in a patient with hepatocellular carcinoma (Shukla 
et al., 2013). 
Many laboratories have reported de novo L1 insertions in somatic tumor tissues 
(Doucet-O'Hare et al., 2015; Ewing et al., 2015; Helman et al., 2014; Iskow et al., 2010; 
Lee et al., 2012; Solyom et al., 2012; Tubio et al., 2014). The Kazazian laboratory has 
demonstrated that de novo L1 insertions can be found clonally in tumor tissues, while 
other insertions are found in tumor as well as surrounding healthy tissues (Doucet-
O'Hare et al., 2015; Ewing et al., 2015). Recent evidence suggests that overexpression 
of L1 ORF2p may lead to genomic damage, which could, in principle, contribute to 
tumorigenesis (Gasior et al., 2007; Sciamanna et al., 2013; Sciamanna et al., 2014). 
The result of increased L1 retrotransposition in some tumors is unclear and continued 
efforts are necessary to determine the potency of retrotransposition-mediated 
mutagenesis and cancer progression. 
L1 retrotransposition-mediated structural variation  
L1-mediated retrotransposition events can contribute to various target-site 
alterations. Cell culture assays demonstrated that two bp to >71 kb of genomic DNA can 
be deleted upon retrotransposition (Gilbert et al., 2005; Gilbert et al., 2002; Symer et al., 
2002). Genomic deletions that occur during TPRT often manifest as intrachromosomal 
deletions and could be formed by DNA recombination mechanisms that include non-
homologous end joining, single-strand annealing, or synthesis dependent strand 
annealing (Gilbert et al., 2005; Gilbert et al., 2002; Symer et al., 2002).  
L1 retrotransposition can also result in addition of genomic DNA sequence at the 
genomic target-site via a process called transduction.  L1-mediated 5’ and 3’ transduced 
sequences alone account for ~1% of genomic DNA (Goodier et al., 2000; Pickeral et al., 
2000). A 5’ transduction occurs if a promoter upstream of the L1 5’UTR initiates 
transcription, resulting in an L1 RNA containing sequences transcribed from upstream 
genomic DNA (Evrony et al., 2012; Lander et al., 2001; Symer et al., 2002; Wei et al., 
2001). L1-mediated 5’ transductions are rare, but have been observed in the human 
genome reference sequence, in experiments conducted in human cells, and within brain 
neurons (Evrony et al., 2012; Lander et al., 2001; Symer et al., 2002; Wei et al., 2001).  
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L1-mediated 3’ transductions occur when the canonical poly(A) sequence of L1 is 
bypassed and a downstream poly(A) sequence is utilized for transcription termination 
(Holmes et al., 1994; Moran et al., 1999; Moran et al., 1996). L1-mediated 3’ 
transduction events are common due to the weak poly(A) signal present in the L1 
sequence (Holmes et al., 1994; Moran et al., 1999; Moran et al., 1996) and are 
associated with ~20% percent of genomic L1s (Goodier et al., 2000; Beck et al., 2010; 
Kidd et al., 2010; Pickeral et al., 2000; Tubio et al., 2014). Transduced sequences also 
serve as useful molecular tags to identify actively retrotransposing L1s (Goodier et al., 
2000; Badge et al., 2003; Beck et al., 2010; Brouha et al., 2002; Holmes et al., 1994; 
Macfarlane et al., 2013; Tica et al., 2016; Tubio et al., 2014). 
Post-insertion structural variation 
The plethora of L1 and Alu sequences in the human genome provides ample 
fodder for chromosomal alterations. For example, an intrachromosomal deletion 
between an L1 and Alu sequence, potentially by non-homologous end joining, resulted 
in ~430kb deletion within the Dystrophin gene (Suminaga et al., 2000). Additionally, 
non-allelic homologous recombination (NAHR) events between homeologous L1s or 
homeologous Alus has been demonstrated to lead to genomic deletions (Bailey et al., 
2003; Fitch et al., 1991; Han et al., 2008; Han et al., 2005; Shen et al., 1981; Startek et 
al., 2015). NAHR between L1s has resulted in genomic deletions in the β-subunit of 
phosphorylase kinase (Burwinkel and Kilimann, 1998), deletion of the collagen genes 
COL4A5 and COL4A6 (Burwinkel and Kilimann, 1998), and a deletion encompassing 
the EVC, EVC2, C4orf6, and STK32B genes (Temtamy et al., 2008). Similarly, NAHR 
between Alus resulted in a ~5 kb deletion of exons within the Low-density Lipoprotein 
Receptor gene (Lehrman et al., 1985) as well as numerous other interchromosomal 
deletions associated with disease (Konkel and Batzer, 2010). Finally, reports suggest 
that accumulation of L1 sequences surrounding Abp gene families in mice and rats 
drives rapid gene duplication via NAHR (Janousek et al., 2013; Janousek et al., 2016).  
Retrotransposition-mediated evolution of new genes  
In principle, L1 sequences can be co-opted for use in regulatory control of genes. 
An L1 5’UTR located upstream of the Apolipoprotein A (Apo A) gene was likely co-opted 
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as an enhancer to augment expression of Apo A (Yang et al., 1998). Additionally, L1 is 
replete with poly(A) signals (Perepelitsa-Belancio and Deininger, 2003). If an L1 
retrotransposes within a gene, a cryptic L1 poly(A) sequence(s) could be utilized for pre-
mature polyadenylation of the transcript, resulting in a 3’ truncated genic mRNA (Han et 
al., 2004; Perepelitsa-Belancio and Deininger, 2003).  
L1-mediated retrotransposition of pseudogenes are responsible for the creation 
of two independent TRIM/Cyp gene fusion events in two different primate species. Owl 
monkeys contain a fusion protein that resulted from a processed Cyclophilin A (CypA) 
pseudogene retrotransposing into an intron of the Trim5 gene (Nisole et al., 2004; 
Sayah et al., 2004). In addition, macaques harbor a TRIMCyp fusion resulting from 
retrotransposition of the CypA gene into the 3’UTR of the macaque TRIM5 gene (Liao et 
al., 2007; Virgen et al., 2008). TRIMCyp fusion genes are potent anti-virals against 
some lentiviruses (Malfavon-Borja et al., 2013). Another proposed mechanism of novel 
gene creation is L1-mediated exon shuffling (Moran et al., 1999). This mechanism could 
occur either by 3’ transduction of genomic sequences to new locations (Moran et al., 
1999) or by mobilizing processed pseudogenes in trans as mentioned above for the 
TRIMCyp fusions. The identification of three human AMAC gene duplications mediated 
by SVA 3’ transductions suggested that 3’ transductions could result in the formation of 
new genes (Xing et al., 2006) 
Host Defense to LINE-1 Retrotransposition 
Addressed above are the effects of L1 retrotransposition on genomic integrity. L1 
retrotransposition is inherently mutagenic; thus, it stands to reason that the cell has 
evolved numerous mechanisms to inhibit L1 retrotransposition. Indeed, at virtually every 
stage of the retrotransposition cycle, the host has developed mechanisms to inhibit 
unabated L1 retrotransposition (Figure 1.6) (Goodier, 2016).  
DNA methylation and other transcriptional regulators 
DNA methylation is frequently associated with gene silencing (Jones, 2012). 
Though DNA methylation affects numerous genes, the majority of methylated residues 
in the genome reside within TE sequences (Goll and Bestor, 2005; Yoder et al., 1997). 
Altered methylation of the L1 promoter was first identified in cancer cell lines (Thayer et 
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al., 1993). Additional investigation suggested that the 5’UTR of some younger, L1Hs 
subfamily members was de-methylated in some cancers (Alves et al., 1996) and 
resulted in increased expression of ORF1p (Bratthauer and Fanning, 1993; Thayer et 
al., 1993) (Figure 1.6). Subsequent in vitro and in vivo experimental evidence 
demonstrated methylation of the L1 CpG island within the human L1 5’UTR (Hata and 
Sakaki, 1997). Additional investigation in tumor cell lines revealed a correlation between 
L1 hypomethylation and increased L1 expression and retrotransposition (Iskow et al., 
2010; Suter et al., 2004; Tubio et al., 2014). In brain tissue (Coufal et al., 2009), and in 
some hESC and iPSC derived cells lines (Klawitter et al., 2016; Wissing et al., 2012), a 
correlation between L1 5’UTR hypomethylation and L1 expression were also observed. 
More recently, proteins hypothesized to be involved in L1 and non-LTR DNA 
methylation have been reported. Loss of DNA-Methyltransferase Like 3 L protein, 
DNMT3L, in knockout mice led to male meiotic catastrophe and sterility (Bourc'his and 
Bestor, 2004). Additionally, the testes of these mice expressed increased L1 and the 
LTR-retrotransposon, IAP, RNA (Bourc'his and Bestor, 2004). Identification and 
knockout of the catalytic methyltransferase, DNMT3C, resulted in a male germline 
phenotype similar to DNMT3L knockout mice (Barau et al., 2016).  A triple knockdown 
of the de novo methyltransferases (DNMT3A and DNMT3B) as well as a maintenance 
methylase, DNMT1, in hESCs resulted in increased expression of young L1s (Castro-
Diaz et al., 2014). Overexpression of the Methyl CpG binding protein 2 (MECP2) in 
HeLa cells repressed retrotransposition of an engineered L1 (Yu et al., 2001). MECP2 
knockout in mice and rats exhibited increased L1 retrotransposition in neuronal tissue 
(Muotri et al., 2010) as well as in cell lines derived from patients with Rett Syndrome, a 
neuron development disorder typically caused by MECP2 mutations (Muotri et al., 
2010). In sum, these data suggest that methylation represses L1 transcription in both 
germ and somatic cells. 
Evidence suggests histone modifications also are implicated in repressing L1 
activity (Figure 1.6). One study, using a human embryonic carcinoma cell line, 
demonstrated that a reporter cassette delivered by an engineered L1 construct is 
subject to transcriptional silencing either during or shortly after integration (Garcia-Perez 
et al., 2010). Addition of pan-histone deacetylase inhibitors activated expression of the 
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integrated L1 reporter cassette, suggesting that histone deacetylases may target newly 
integrated L1s to restrict their expression (Garcia-Perez et al., 2010).  
Alu sequences in HeLa cells were demonstrated to bind the histone 
methyltransferase, Suppressor of Variegation 39 H1, SUV39H1 (Varshney et al., 2015). 
After treatment of HeLa cells with a pan H3K9 inhibitor, SUV39H1 occupancy at Alus 
was diminished and a concomitant increase of Alu RNA was detected (Varshney et al., 
2015). Recent evidence suggests knockout of the H3K9 di-methyltransferase, G9A, and 
MILl in mouse testis lead to increased expression of endogenous L1 and ORF1p (Di 
Giacomo et al., 2014). The authors hypothesize that piRNAs and histone methylation 
actively co-repress endogenous L1s in mouse germ cells (Di Giacomo et al., 2014). 
Though there is growing evidence that histone modifications may repress genomic L1 
expression, a concerted effort is required to discern what role histone modifications may 
play in modulating L1 expression and retrotransposition.  
 Zinc finger (ZNF) transcription factors have also been shown to negatively 
regulate L1 transcription (Figure 1.6). Krüppel-associated box (KRAB) motif ZNF 
transcription factors (KZNF) represent a fast evolving set of transcription factors present 
only in tetrapods (Birtle and Ponting, 2006). The expansion KZNFs, in part, is likely a 
response to mobile element activity and it appears some KZNFs specifically inhibit 
different L1 subfamily members (Birtle and Ponting, 2006; Thomas and Schneider, 
2011). For example, in hESCs, knockdown of TRIM28 (KAP1), a KZNF protein, resulted 
in increased L1 RNA expression, but only in older (L1PA7-L1PA3) subfamilies (Castro-
Diaz et al., 2014). Similarly in hESCs, the KZNF protein, ZNF93, only repressed L1 
expression in the older L1PA6-L1PA3 (Jacobs et al., 2014). These data highlight the 
evolutionary “arms-race” occurring within our cells and it may be that a KZNF protein(s) 
has not yet evolved a response to the active L1Hs subfamily. 
Small RNA based interference 
 Small RNA based interference (RNAi) mechanisms that regulate gene 
expression are relatively recent discoveries (Fire et al., 1998). Several lines of evidence 
suggest L1 retrotransposition may also be regulated by RNAi based mechanisms. RNAi 
relies on short RNA sequences that are loaded onto Argonaute proteins that form an 
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RNA-induced silencing complex (RISC). RISC and enzymatic proteins associated with 
the piRNA pathway can subsequently target complementary RNAs for degradation 
and/or translation inhibition (Wilson and Doudna, 2013).  
 The P-element induced wimpy testis (PIWI) proteins are Argonaute family 
members specific to the germline and were first identified in fruit fly (Cox et al., 2000). 
PIWI proteins bind with PIWI-interacting RNAs (piRNAs) that are ~ 28-31 nucleotides in 
length (Ishizu et al., 2011; Siomi et al., 2011). The piRNA induced silencing complex 
(piRISC) can both degrade TE mRNA as well as target TE genomic loci to silence 
transcription (Aravin et al., 2007; Ishizu et al., 2011; Siomi et al., 2011) (Figure 1.6). 
Recent observations in fruit fly suggest components of the piRNA pathway recruit 
proteins that actively enforce transcriptional silencing (Yu et al., 2015). 
In mouse testis, loss of the mouse PIWI protein, MILI (Piwi-Like RNA-Mediated 
Gene Silencing 2), results in an increase of endogenous L1 and IAP expression (Aravin 
et al., 2007), and a concomitant de-methylation of L1 promoter sequences (Aravin et al., 
2008; Aravin et al., 2007) (Aravin et al., 2007) (Figure 1.6). Ablation of MILI in mouse 
testis leads to spermatogenic arrest and an increase in the expression of L1 ORF1p (Di 
Giacomo et al., 2013). Recent reports suggest cooperation between piRNA-, DNA 
methylation-, and histone methylation-mediated repression of endogenous L1 
expression in mouse spermatogonia (Di Giacomo et al., 2013; Di Giacomo et al., 2014).  
Small interfering RNAs (siRNAs) are ~21 nucleotides in length and represent 
another class of small RNAs (Wilson and Doudna, 2013). Dicer-dependent siRNAs 
have been demonstrated to silence plant, invertebrate, and perhaps mouse transposons 
(Castel and Martienssen, 2013). In mice, there is evidence that siRNAs in oocytes may 
be derived from L1 and LTR-retrotransposons (Watanabe et al., 2008). Additionally, 
siRNAs originating from antisense transcription of the L1 5’UTR are postulated to target 
L1 transcripts in human cultured cells (Yang and Kazazian, 2006). Intriguingly, L1 hypo-
methylation and increased L1 expression was observed in a breast cancer cell line upon 
depletion of Dicer (Chen et al., 2012). Additional experimentation is required to 
understand how RNAi mechanistically modulates L1 retrotransposition in humans; 
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however, accumulated evidence suggest a possible role for small RNA mediated L1 
repression. 
Splicing and Pre-mature polyadenylation 
 Post-transcriptional processing events including, splicing and/or polyadenylation, 
are canonical cellular processes that occur on almost every protein coding RNA. As 
splicing results in the removal of RNA sequence, it was surprising to find that some L1 
RNAs undergo splicing (Belancio, 2011; Belancio et al., 2006; Belancio et al., 2008) 
(Figure 1.6 and Chapter 2). A subset of the potential splice donor (SD), and splice 
acceptor (SA) sites in L1 RNA can sometimes be activated (Belancio et al., 2006; 
Belancio et al., 2008). Loss of any sequence within the L1 is hypothesized to be 
detrimental to L1 mobilization (Chapter 2), and surprisingly it appears that some of 
these SD and SA sequences are highly conserved in L1 (Chapter 2).  
 The 3’ end of L1 RNAs harbor a weak poly(A) signal, but L1 RNAs also contain 
numerous pre-mature poly(A) signals throughout the body of L1 RNA (Han et al., 2004; 
Perepelitsa-Belancio and Deininger, 2003). Pre-mature polyadenylation is hypothesized 
to be detrimental to L1 retrotransposition (Perepelitsa-Belancio and Deininger, 2003). 
Mouse and human L1s transfected into mouse NIH 3T3 cells were subject to pre-
mature polyadenylation as observed by Northern blot (Perepelitsa-Belancio and 
Deininger, 2003). However, NIH 3T3 cells transfected with human L1s containing 
mutations that ablated poly(A) signals resulted in an increase in full-length L1 RNAs, 
and a decrease in pre-maturely polyaddenylated RNAs (Perepelitsa-Belancio and 
Deininger, 2003). There are no instances of pre-maturely retrotransposed 
polyadenylated L1s in the human genome; however, premature polyadenylated L1s 
were identified in expressed sequence tags (ESTs) databases (Perepelitsa-Belancio 
and Deininger, 2003).  
Cytoplasmic binding proteins 
Studies have demonstrated that cytoplasmic proteins associate with the L1 RNP 
(Dai et al., 2012; Goodier et al., 2013; Goodier et al., 2015; Goodier et al., 2007; 
Moldovan and Moran, 2015; Taylor et al., 2013) (Figure 1.6). The functions of these 
proteins are varied and have different effects on L1 RNP biogenesis and L1 
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retrotransposition. Processing bodies (PBs) and stress granules (SGs) are cytoplasmic 
aggregations of proteins and mRNAs that affect mRNA decay and protein translation 
(Decker and Parker, 2012). PBs are present in unstressed cells; however, their quantity 
is increased in response to stress (Decker and Parker, 2012; Kedersha et al., 2005). 
SGs are primarily induced from various types of cellular stress (Decker and Parker, 
2012; Kedersha et al., 2005) and are thought to sequester mRNAs until a decision is 
made to translate, sequester, or shuttle mRNAs to PBs for degradation (Kedersha et al., 
2005). 
 Components of the L1 RNP have been demonstrated to associate with SG 
markers using immunofluorescence, immunoprecipitation followed by tandem mass 
spectrometry, and western blot experiments (Dai et al., 2012; Goodier, 2016; Goodier et 
al., 2013; Goodier et al., 2015; Goodier et al., 2007; Moldovan and Moran, 2015; Taylor 
et al., 2013). The zinc-finger antiviral protein (ZAP) associates both with stress granules 
and the L1 RNP (Goodier, 2016; Goodier et al., 2015; Moldovan and Moran, 2015) and 
when overexpressed decreases L1 retrotransposition in cell culture based assays 
(Goodier et al., 2015; Moldovan and Moran, 2015). The mechanism of action remains 
unclear, but ZAP could either inhibit L1 mRNA translation or initiate destruction of the 
mRNA molecule (Moldovan and Moran, 2015).  
A component of PBs and SGs, 5’-3’ exonuclease XRN1, degrades mRNAs and 
was loosely associated with L1 ORF1p in immunofluorescence experiments (Goodier et 
al., 2007). Largely, L1 proteins and RNA are not directly associated with PBs; however, 
it has been suggested that the L1 RNP may first associate with stress granules, and 
then interact with PBs to facilitate degradation (Goodier et al., 2007). It has also been 
suggested that autophagosomes can target PBs or SGs containing L1 RNP 
components. Experiments using siRNA-mediated knockdown of the Autophagy Protein 
5 (ATG5) in human cells resulted in an increase of endogenous L1 and Alu RNA as well 
as increased L1 retrotransposition in a cell culture assay (Guo et al., 2014). Additional 
experimentation is necessary to determine the role of SGs and PBs in disrupting the L1 
retrotransposition cycle (Goodier et al., 2013; Goodier et al., 2015; Goodier et al., 2007; 
Moldovan and Moran, 2015).  
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Antiviral proteins and integration inhibition 
 Antiviral proteins usually targeting specific viral components to inhibit viral 
replication (Goff, 2004). Given that L1 is an ancient endogenous parasite, it is not 
surprising that some proteins that inhibit various infectious viruses also inhibit L1 
retrotransposition (Burton et al., 1986; Goodier, 2016; Lander et al., 2001; Moldovan 
and Moran, 2015; Sawyer et al., 2004) (Figure 1.6). For example, overexpression of the 
Moloney Leukemia Virus 10 protein (MOV10), an RNA helicase, inhibits L1 and Alu 
retrotransposition (Goodier et al., 2012, 2013; Moldovan and Moran, 2015) and 
retrovirus replication (Wang et al., 2010) in cell culture assays. The mechanism of 
MOV10 is unknown but it may bind L1 RNA and inhibit translation and/or ORF2p RT 
activity (Goodier et al., 2012, 2013; Moldovan and Moran, 2015).  
 SAM domain and HD domain-containing protein 1 (SAMHD1) has been shown to 
repress HIV-1 infection and L1 retrotransposition through different mechanisms. In 
immune cells infected by HIV-1, SAMHD1 restricts retroviral replication by depleting 
cellular levels of dNTPs as well as by acting as an RNase to destroy the viral RNA 
(Ballana and Este, 2015; White et al., 2014). Contrastingly, overexpression of SAMHD1 
leads to sequestration of the L1 RNP in SGs (Hu et al., 2015). Evidence suggests 
SAMHD1 overexpression may inhibit L1 retrotransposition by both depleting cellular 
levels of dNTPs, and/or by somehow disrupting ORF2p RT activity (Zhao et al., 2013). 
Thus, it seems clear that some proteins evolved to inhibit L1 and viral replication 
through different mechanisms, perhaps suggesting that the protein arose to combat one 
particle, and subsequently evolved an additional function to combat both particles.  
A family of cytidine deaminases has been shown to restrict HIV-1 infection as 
well as L1 and Alu retrotransposition. Apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like 3 (APOBEC3, A3) has undergone six duplications in the primate 
lineage yielding seven members (A3A, A3B, A3C, A3D/E, A3F, A3G, A3H) (Koito and 
Ikeda, 2013; Lindic et al., 2013; Sawyer et al., 2004). A3 proteins generally function by 
deaminating single-strand DNA substrates, or perhaps RNA, leading to cytidine to 
uridine transition mutations (Chiu and Greene, 2008) or by directly blocking RT activity 
(Chiu and Greene, 2008; Koito and Ikeda, 2013). The overexpression of A3A (Bogerd et 
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al., 2006; Muckenfuss et al., 2006; Richardson et al., 2015; Richardson et al., 2014; 
Stenglein and Harris, 2006), A3B (Bogerd et al., 2006; Muckenfuss et al., 2006; 
Stenglein and Harris, 2006), A3C (Muckenfuss et al., 2006), and A3F (Muckenfuss et 
al., 2006; Stenglein and Harris, 2006) proteins are able to restrict L1 retrotransposition 
in a cell culture model. A3G blocks replication of HIV-1 (Sheehy et al., 2002) and 
overexpression inhibits Alu retrotransposition, but not L1 retrotransposition (Hulme et 
al., 2007).  
The mechanism of APOBEC inhibition of L1 and Alu retrotransposition is varied. 
A3B and A3C catalytic mutants are able to inhibit L1 retrotransposition; thus, they may 
act as a physical barrier to RT (Bogerd et al., 2006). Similarly, the Alu specific A3G 
protein also likely does not require deaminase activity suggesting its mechanism of 
repression is sequestration of Alu RNA into high molecular weight cellular complexes. 
(Chiu et al., 2006). In contrast, it has recently been demonstrated that A3A restricts L1 
retrotransposition, in part, by deaminating transiently exposed single-strand L1 cDNA 
exposed during TPRT, which could subsequently lead to cDNA cleavage and L1 5’ 
truncation (Richardson et al., 2014). Alternatively, A3A could deaminate exposed single 
stranded genomic DNA that would ultimately lead to the loss of the entire L1 cDNA 
(Richardson et al., 2014).  
Locations of LINE-1 Retrotransposition 
Efficient L1 propagation requires that it retrotranspose in either the germline or 
very early in embryogenesis. It is unclear how frequently offspring harbor a new L1 
insertion, but it has been hypothesized that one out of 20 to one out of 200 human live 
births contain a de novo L1 insertion (Cordaux and Batzer, 2009).  
 Experimental evidence of retrotransposition in the germ line has been observed 
in mice. A transgenic mouse containing a tagged L1 expression construct expressing an 
EGFP indicator cassette was shown to retrotranspose in both male testis and female 
ovaries (Ostertag et al., 2002). Additionally, two offspring from these transgenic mice 
exhibited a de novo retrotransposition event and importantly did not contain the 
transgene from the parent (Ostertag et al., 2002). These results suggest that 
retrotransposition occurred in the male germ line prior to meiosis II, and was not the 
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result of retrotransposition early in offspring embryogenesis (Athanikar et al., 2002). In 
human testis, expression of both ORF1p and ORF2p has been observed (Ergun et al., 
2004) and evidence suggests human oocytes express endogenous L1 RNA and 
support retrotransposition of an engineered L1 (Georgiou et al., 2009). 
 Retrotransposition can occur in early embryogenesis. Depending on when the 
retrotransposition event occurs, the new insertion can contribute only to somatic cells, 
only to germ cells, or to both somatic and germ cells; the latter two cases representing 
heritable insertions (Richardson et al., 2015). Cell culture experiments using both 
hESCs (Garcia-Perez et al., 2007b) and ECs (Garcia-Perez et al., 2010; Skowronski et 
al., 1988; Skowronski and Singer, 1985) demonstrated that endogenous L1 RNA and 
proteins are highly expressed in these cells and that these cell types support 
retrotransposition of an engineered L1 (Garcia-Perez et al., 2007b; Garcia-Perez et al., 
2010). Additionally, de novo retrotransposition events can occur in both human induced 
pluripotent stem cells (hiPSCs) and hESCs (Klawitter et al., 2016; Wissing et al., 2011). 
These experiments show that in principle, L1 can retrotranspose early in human 
embryonic development.  
  A direct example of endogenous L1 retrotransposition in the early embryo was 
gleaned from a male patient with X-linked choriodermia. He harbored an L1 insertion in 
the CMH gene (van den Hurk et al., 2003). The mother of the patient was a somatic 
mosaic for the L1 insertion, suggesting that the insertion into the CMH gene occurred 
early enough during her development to give rise to both somatic and germline cells 
(van den Hurk et al., 2007). Of the patients’ two sisters, only one had the L1 insertion 
into the CMH gene, even though they both shared the same maternal haplotype block, 
further supporting the notion that this L1 insertion occurred in the mother, early in her 
embryonic development (van den Hurk et al., 2007). 
 It was originally assumed that most somatic tissues were unable to support 
retrotransposition, as these represent ‘dead ends’ for L1 inheritance. This notion was 
radically overturned when it was found that an engineered L1 retrotransposed in 
cultured rat neuronal precursor cells (NPCs), as well as in various brain tissues of 
transgenic mice expressing an engineered L1 (Muotri et al., 2005). Additional data 
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suggested human neural progenitor cells (NPCs) from fetal brain, as well as NPC 
derived hESCs supported retrotransposition of an engineered L1 (Coufal et al., 2009). 
Quantitative PCR (qPCR) analysis of genomic L1 insertions supported the notion that 
neuronal tissues harbor more endogenous retrotransposition events than heart or liver 
tissues from the same individuals (Coufal et al., 2009).  
 Next generation sequencing (NGS) of L1, SVA, and Alu enriched libraries 
revealed de novo insertions from all three retrotransposons occurred in the brain, but 
were not present in the germline from the same individuals (Baillie et al., 2011). Single 
neuron sequencing of hippocampal neurons from four individuals suggests that, at least 
in this tissue, each neuron harbors ~13 somatic insertions when compared to matched 
liver samples (Upton et al., 2015). Single cell analysis of cortical neurons shows that, at 
least in this tissue, somatic retrotransposition occurs at a frequency of ~1 insertion per 
neuron (Evrony et al., 2012; Evrony et al., 2015). Despite potential cell-type differences 
in L1 retrotransposition activity, it is clear that retrotransposition occurs somatically in 
the human brain. Given the number of neurons in the human brain, it is intriguing to 
consider the possibility that there may be hundreds of millions of somatic 
retrotransposition events in a single brain. Future studies are needed to elucidate the 
frequency of retrotransposition in the human brain and the effect it may have on 
neuronal biology. 
Conclusion   
Despite Barbara McClintock’s astute and pioneering observations (McClintock, 
1950, 1951), it is unlikely even she could predict the scope in which mobile genetic 
elements affect humans. Her first suspicion that genomes are not static, but are in fact 
constantly changing and mutable entities, set the stage for more than 60 years of 
research and discovery. 
 Though the majorities of TEs are molecular fossils and are incapable of mobility, 
they still affect the genome by serving as fodder for cooption of sequences for gene 
regulation, mediating gene birth, and acting as arbiters of genetic variation. Yet, each 
individual cell harbors nearly 100 potentially active L1s, and even more Alu elements, 
which continue to diversify our genomes. Their existence is measured in the hundreds 
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of millions of years, and their reverse transcriptase domain may harken back to the 
transition from the RNA to the DNA world. Indeed, reverse transcriptase likely was 
instrumental in constructing the genetic code for life. There is a monumental amount of 
work yet to be done and the most exciting aspects L1 and Alu biology remain to be 
uncovered.  
 Future work should focus on TE role in disease and cancer progression. Though 
they may rarely be responsible for activating the cancer phenotype, it is very likely that 
their activity can drive cancer progression. TEs could be utilized as a model to identify 
antiviral proteins as a safer alternative than screening proteins using HIV. TEs continue 
to be an invaluable tool in understanding the genetic flow in populations and in 
genotyping individuals. Finally, mounting evidence suggests TE mobilization may play a 
role in neuronal plasticity and perhaps contribute to neuronal disease phenotypes. New 
technologies in gene editing and deep sequencing are going to be instrumental in 
investigating the budding field of neuronal TE biology. 
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Figure 1.1: Sequence composition of the human genome.  
Completion of the human genome uncovered that Transposable Elements (TEs) (blue 
and dark blue) comprise nearly 50% of genomic DNA whereas protein coding genes 
(red) comprise only ~1.5% of genomic DNA (Lander et al., 2001). Retrotransposons 
alone constitute ~42% of genomic DNA (blue). Of the retrotransposons, non-LTR 
retrotransposons are the most abundant.  Ancient, inactive LINE sequences (in 
mustard) represent ~6% of genomic DNA. Autonomous LINE-1 (green) sequences 
constitute ~17% of genomic DNA and their non-autonomous counterpart, SINE (light 
green) represent ~11% of genomic DNA. Autonomous and non-autonomous LTR-
retrotransposons comprise ~8% (in orange). The least abundant TE, DNA transposons 
(dark blue) comprise twice the fraction of the human genome that protein-coding genes 
do.  
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Figure 1.2: Diagrams of transposon and transposon-derived sequences in the 
human genome.  
Representative Transposable Elements (TEs) in the human genome. A) A full-length 
Long Terminal Repeat (LTR) HERV-K is depicted. LTR retrotransposons range from 6-8 
kilobases (kb) in length. They encode a gag protein (mustard rectangle), followed by a 
pol protein (navy blue rectangle), and end with an env protein (orange rectangle). LTR 
retrotransposon coding sequences are flanked by long terminal repeats (grey boxes). 
The 5’ LTR contains polII promoter activity (black arrow) and the 3’ LTR harbors a 
polyadenylation sequence (P(A)). The entire element is flanked by ~4-6 base pair (bp) 
target site duplications (black arrows flanking element. (B-D Non-LTR 
Retrotransposons) B) The autonomous Non-LTR retrotransposon LINE-1 is depicted. 
LINE-1s are ~6 kb and begin with a 5’UTR (grey rectangle) with sense and antisense 
polII promoter activity (forward and backward facing arrows respectively). Following the 
5’UTR is Open Reading Frame 1 (ORF1, maize rectangle), a short intergenic spacer 
(white box), and Open Reading Frame 2 (ORF2, blue rectangle). The sequence ends 
with a 3’UTR (dark grey rectangle) and a polyadenosine tail (AN). The entire element is 
flanked by 7-20 bp target site duplications (black arrows flanking element) C) The non-
autonomous non-LTR retrotransposon Alu is depicted. Alu elements are ~280 bp. Alus 
do not encode proteins and are derived from 7SL RNA. A poly-adenosine rich tract 
(dark green rectangle in center) separates the left and right 7SL-derived monomers 
(green rectangle). The left monomer contains an A and B box (vertical black lines) that 
contains polIII promoter activity (black arrow). Alu elements end in a polyadenosine tail 
(AN). The entire element is flanked by 7-20 bp target site duplications (black arrows 
flanking element). D) Processed pseudogenes are not transposons, but are processed 
(spliced and polyadenylated) mRNAs derived from protein coding genes that have been 
mobilized by LINE-1 proteins. Adjacent purple rectangles are spliced exons and grey 
rectangles at either end are the 5’ and 3’ untranslated regions. As they are derived from 
genes their length is variable. Processed pseudogenes end in a polyadenylated tail (AN) 
and are flanked by 7-20 bp target site duplications (black arrows flanking processed 
pseudogene.    E) DNA transposons are 2-3 kb and encode a transposase gene (blue 
rectangle) which is flanked by terminal inverted repeats (black triangle in white box). 
Terminal inverted repeats can have promoter activity (black arrow). The entire element 
is flanked by 4-6 bp target site duplications (black arrows flanking element). (See main 
text for references) 
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Figure 1.3: Timeline of LINE-1 evolution in the context of global evolutionary 
events. 
The top of the figure lists selected evolutionary events in the mammalian lineage. The 
depicted timeline is measured in million years ago (MYA). Arrows and short descriptions 
of events are placed in relation to when they occurred. Below the timeline is a cluster of 
six long rectangles. The rectangles indicate the three major LINE families. LINE-3 (L3) 
is shown on the top and is indicated with a black to grey rectangle that ends in a slope. 
The slope depicts the gradual decrease of genomic amplification. Note that even though 
these elements ceased amplifying, fossilized copies are still present in mammalian 
genomes. LINE-2 (L2) is depicted by a red orange bar that fades to a yellow slope. 
Beneath L2 is a cluster of four rectangles indicated with a black bracket. These are all 
members of the LINE-1 family. L1M and L1PB subfamilies are shown as light blue 
rectangles that fade to  white and ending with a slope. The second to the bottom 
rectangle (solid blue) depicts the L1PA subfamily. Note linear subfamily succession is 
indicated by white sloping lines and L1 subfamily label (e.g., PA8) The final dark blue 
rectangle depicts the emergence of the human specific LINE-1 (L1Hs). It is a part of the 
L1PA subfamily and is separated on this diagram for clarity. Beneath the long 
rectangles is another timeline on the same scale as the top timeline. This timeline 
depicts the approximate timing of events that occurred during LINE-1 evolution. Arrows 
and short descriptions of events are placed in relation to when they occurred. Below the 
time line are two red boxes that indicate increased rates of LINE-1 amplification. Finally 
two brackets indicate when, during evolution, multiple LINE-1 subfamilies were 
amplifying and evolving simultaneously (green bracket, radiating evolution), and when 
linear evolution of LINE-1 occurs (orange bracket, linear evolution). 
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Figure 1.4: Evolution of LINE-1 5’UTR sequences 
The evolution of 5’UTR sequences is depicted. The arrow depicts evolutionary time with 
more ancient elements placed at the bottom. The green bar to the right of the arrow 
indicates the period of time when LINE-1s underwent radiating evolution and the orange 
bar indicates linear evolution (See Figure 1.3 and text for more details). Note that the 
ORF1 and ORF2 reading frames are kept constant in this diagram, however they too 
underwent changes over evolutionary history. The bottom LINE-1 depicts a hypothetical 
5’UTR (dark grey rectangle with two dark brown lines). This progenitor 5’UTR gave rise 
to the M (light grey rectangle with two dark brown lines) family of 5’UTRs as well as a 
precursor(s) to the PB and PA  (dark grey rectangle with single dark brown line) 
subfamily of elements. The PA and PB precursor 5’UTR gave rise to the PB (grey 
rectangle with tan line) subfamily and PA (grey rectangle with light brown line) 
subfamilies of 5’UTRs. The M and PA and PB subfamilies amplified concomitantly until 
only the PA subfamily was dominant. Members of the PA subfamily were also 
amplifying concomitantly until ~45 million years ago a single lineage (PA8, light grey 
5’UTR) was the sole amplifying member. Since then, only a single subfamily has 
amplified at any given time. Note: the 5’UTR has tended to shorten over time. The 
5’UTR depicted at the top of the diagram is the human specific L1Hs 5’UTR. (See text 
for references) 
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Figure 1.5: The LINE-1 retrotransposition cycle. 
LINE-1 is transcribed (wavy line; black depicts 5’ and 3’ UTRs, maize depicts ORF1, 
blue depicts ORF2, backwards “G” depicts 5’methyl guanosine, and AN depicts 
polyadenylation) from a genomic location (dark brown rectangle on red chromosome) 
and exported to the cytoplasm.   Both ORFs are translated and the proteins (maize 
circles depict ORF1p, blue oval depicts ORF2p) bind back to the L1 mRNA from which 
they were translated (termed cis-preference). A cellular mRNA or SINE element (green 
wavy line) can ‘hijack’ an ORF2p molecule and use it for its own retrotransposition. 
Components of the resulting ribonucleoprotein particle (RNP) are imported into the 
nucleus where ORF2p mediates insertion into a new genomic location (dark green 
rectangle on green chromosome) by a process termed target-site primed reverse 
transcription (TPRT; shown as a blow up, black lines indicated top and bottom strand of 
genomic DNA). ORF2p EN domain initiates TPRT with a single-stranded 
endonucleolytic nick at a thymidine-rich sequence (e.g., 5’-TTTT/A-3’), where the (/) 
denotes the siscile phosphate (Cost et al., 2002; Feng et al., 1996; Morrish et al., 2002, 
Luan et al., 1993) The result of the endonucleolytic nick is exposure of a reactive 3’ 
hydroxyl group, which ORF2p RT activity uses as a primer to initiate minus (-) strand L1 
cDNA synthesis (Cost and Boeke, 1998; Feng et al., 1996) (Figure 1.5). Completion of 
second strand cDNA requires elucidation. (See text for more details) 
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Figure 1.6: Mechanisms that inhibit LINE-1 retrotransposition. 
The schematic shows a single round of LINE-1 retrotransposition (See Figure 1.5). Red 
boxes contain mechanisms or proteins that inhibit retrotransposition. The repressor bars 
emanating from each box indicate where in the retrotransposition cycle they act. Note 
that the piRNA/siRNA box has an activating red arrow pointing to the box containing 
DNA methylation. The activity of piRNAs can also influence genomic methylation of 
LINE-1s (see text).  
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Abstract 
Long INterspersed Element-1 retrotransposons (LINE-1s or L1s) contain an internal 
RNA polymerase II promoter within their 5’ untranslated region (UTR) and encode two 
proteins (ORF1p and ORF2p) required for their mobilization (i.e., retrotransposition). 
The evolutionary success of L1 relies on the reiterative retrotransposition of full-length 
L1 sequences. Previous studies identified functional splice donor, splice acceptor, and 
polyadenylation sequences in L1 RNA and provided evidence that spliced L1 RNAs can 
retrotranspose. Here, we report that the retrotransposition of intra-5’UTR or 
5’UTR/ORF1 spliced L1 transcripts leads to the generation of Spliced Integrated 
Retrotransposed Elements (SpIREs) and describe a new Intra-5’UTR SpIRE that is 10 
times more abundant than previously identified SpIREs. Intra-5’UTR SpIREs lack cis-
acting transcription factor binding sites and exhibit reduced promoter activity. In addition 
to lacking cis-acting sequences 5’UTR/ORF1 SpIREs produce non-functional ORF1p 
variants. We show that these deletions render SpIREs retrotransposition-defective and 
conclude that splicing negatively affects L1 retrotransposition. Surprisingly, two percent 
of annotated full-length L1s from the L1PA1-L1PA6 subfamilies are actually SpIREs, 
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demonstrating that L1 splicing has occurred for at least ~27 million years. Finally, we 
describe how sequence changes in the 5’UTR can result in new, deleterious splicing 
events, representing another layer of negative selective pressure on L1 evolution.  
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Introduction 
Long INterspersed Element-1 (LINE-1 or L1) retrotransposon sequences comprise 
approximately 17% of human genomic DNA (Lander et al. 2001). Over 99.9% of human 
L1s cannot retrotranspose due to 5’ truncations, internal DNA rearrangements, or point 
mutations that inactivate the L1-encoded proteins (Grimaldi et al. 1984; Kazazian and 
Moran 1998; Lander et al. 2001). However, the average diploid genome harbors 
approximately 80-100 full-length retrotransposition-competent (RC-L1s) L1s (Brouha et 
al. 2003), and a small number of these, called highly active or ‘hot’ L1s, can 
retrotranspose efficiently in cultured cells (Sassaman et al. 1997; Brouha et al. 2003; 
Beck et al. 2010; Macfarlane et al. 2013). Active L1 retrotransposition affects both intra- 
and inter-individual human genetic variation (Kazazian et al. 1988; Holmes et al. 1994; 
Beck et al. 2010; Beck et al. 2011; Wimmer et al. 2011; Hancks and Kazazian 2016). 
Indeed, L1-mediated retrotransposition events are responsible for approximately 1/250 
disease-producing mutations in man (Kazazian et al. 1988; Wimmer et al. 2011; Hancks 
and Kazazian 2016) 
Human RC-L1s are approximately six-kilobases (kb) in length (Scott et al. 1987; 
Dombroski et al. 1991). They contain a 5’UTR that harbors both sense (Swergold 1990) 
and anti-sense (Speek 2001) RNA polymerase II promoters, as well as an anti-sense 
open reading frame (ORF-0) (Denli et al. 2015) of unknown function. The 5’UTR is 
followed by two open reading frames (ORF1 and ORF2), which are separated by a 63 
base pair (bp) inter-ORF spacer (Dombroski et al. 1991; Alisch et al. 2006). L1s end 
with a 3’UTR containing a conserved polypurine motif, an RNA polymerase II 
polyadenylation signal, followed by a variable length polyadenosine (poly(A)) tract (Scott 
et al. 1987; Usdin and Furano 1989; Moran et al. 1999; Perepelitsa-Belancio and 
Deininger 2003).  
ORF1 encodes an ~40 kiloDalton (kDa) protein (ORF1p) that contains an amino-
terminal coiled-coil domain required for ORF1p trimerization (Martin et al. 2003; Khazina 
et al. 2011; Naufer et al. 2016), a centrally located, non-canonical RNA recognition motif 
(RRM) domain (Khazina and Weichenrieder 2009; Khazina et al. 2011), and a carboxyl-
terminal domain that harbors conserved basic amino acid residues (Moran et al. 1996; 
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Januszyk et al. 2007). The RRM and carboxyl-terminal domains are critical for ORF1p 
nucleic acid binding (Martin 1991; Holmes et al. 1992; Hohjoh and Singer 1996; Hohjoh 
and Singer 1997; Januszyk et al. 2007; Khazina and Weichenrieder 2009). ORF1p also 
exhibits nucleic acid chaperone activity, which is postulated to play a role in L1 
integration (Martin and Bushman 2001; Khazina and Weichenrieder 2009).  
ORF2 encodes an ~150 kDa protein (ORF2p) (Ergun et al. 2004; Doucet et al. 2010; 
Goodier et al. 2010) that contains conserved apurinic/apyrimidinic endonuclease-like 
(EN) (Martin et al. 1995; Feng et al. 1996) and reverse transcriptase (RT) domains 
(Hattori et al. 1986; Mathias et al. 1991; Moran et al. 1996), as well as a conserved 
cysteine-rich (C) domain (Fanning and Singer 1987; Moran et al. 1996). Biochemical 
activities contained within both ORF1p and ORF2p are required for L1 retrotransposition 
in cultured human cells (Moran et al. 1996). 
A round of human RC-L1 retrotransposition begins with the internal sense-strand 
promoter initiating transcription at or near the first nucleotide of the 5’UTR (Athanikar et 
al. 2004; Dmitriev et al. 2007; Richardson et al. 2015). The resultant mRNA is exported 
to the cytoplasm where it undergoes translation (Leibold et al. 1990; McMillan and 
Singer 1993; Alisch et al. 2006; Dmitriev et al. 2007). Following translation, ORF1p and 
ORF2p preferentially bind to their encoding mRNA in cis to form a ribonucleoprotein 
(RNP) particle (Martin 1991; Hohjoh and Singer 1996; Wei et al. 2001; Kulpa and Moran 
2005; Kulpa and Moran 2006; Doucet et al. 2015). Nascent ORF2p recruitment in cis is 
likely mediated by the L1 poly(A) tail (Ahl et al. 2015; Doucet et al. 2015). Components 
of the L1 RNP then gain access to the nucleus by a mechanism that does not require 
nuclear envelope breakdown (Kubo et al. 2006). L1 integration occurs by target-site 
primed reverse transcription (TPRT) (Luan et al. 1993; Feng et al. 1996; Cost et al. 
2002; Kulpa and Moran 2006). The L1 EN makes a single-strand endonucleolytic nick at 
a thymidine-rich sequence (e.g., 5’-TTTT/A-3’, 5’-TTTC/A-3’, etc.) to liberate a 3’ 
hydroxyl group that is used as a primer by the ORF2p RT to initiate the reverse 
transcription of L1 mRNA (Feng et al. 1996; Cost et al. 2002; Morrish et al. 2002). How 
TPRT is completed requires elucidation. However, as demonstrated for the related R2 
retrotransposon from Bombyx mori, (Christensen et al. 2005), it is possible that L1 
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ORF2p participates in both second-strand genomic DNA cleavage and second-strand 
L1 cDNA synthesis.  
 Although the L1-encoded proteins preferentially retrotranspose their encoding 
mRNA (Esnault et al. 2000; Wei et al. 2000; Kulpa and Moran 2006), L1 ORF1p and/or 
ORF2p also can act in trans (trans-complementation) to mobilize RNAs encoded by 
non-autonomous Short INterspersed Elements (SINEs; e.g., Alu RNA (Deininger et al. 
1981; Dewannieux et al. 2003) and SINE-R/VNTR/Alu (SVA) RNA (Ostertag et al. 2003; 
Hancks et al. 2011; Raiz et al. 2012) and, more rarely, cellular mRNAs, which leads to 
processed pseudogene formation (Esnault et al. 2000; Wei et al. 2001; Buzdin et al. 
2002; Gilbert et al. 2005; Garcia-Perez et al. 2007). 
The evolutionary success of L1 requires the faithful retrotransposition of full-length 
L1 mRNAs and their amplification in subsequent generations. Previous studies have 
revealed the presence of functional splice donor (SD), splice acceptor (SA), and 
premature polyadenylation signals in primary full-length RC-L1 transcripts (Perepelitsa-
Belancio and Deininger 2003; Belancio et al. 2006; Belancio et al. 2008; Belancio et al. 
2010). Paradoxically, the use of these sites during post-transcriptional processing leads 
to the production of truncated and/or internally deleted L1 mRNAs (Perepelitsa-Belancio 
and Deininger 2003; Belancio et al. 2006; Belancio et al. 2008; Belancio et al. 2010), 
which could adversely affect L1 retrotransposition. Thus, it is somewhat surprising that 
cis-acting sequences that could negatively affect L1 retrotransposition have been 
maintained and not subject to negative selection  
Here, we address how the retrotransposition of spliced L1 RNAs leads to the 
generation of Spliced Integrated Retrotransposed Elements (SpIREs). We describe two 
classes of SpIREs: those that splice within the 5’UTR (intra-5’UTR SpIREs) and those 
that splice from within the 5’UTR and into the ORF1 sequence (5’UTR/ORF1 SpIREs). 
By combining genetic, genomic, molecular biological, biochemical, and computational 
approaches, our data demonstrate that SpIREs are evolutionary “dead-ends” that likely 
are unable to undergo efficient retrotransposition in subsequent generations. 
Additionally, our data suggest a mechanism for how some apparently deleterious cis-
acting splicing sequences are retained in the currently amplifying L1 lineage.  
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Results 
A previously identified polymorphic L1 likely resulted from the retrotransposition of a 
spliced L1 transcript 
We previously identified a polymorphic L1 in the human population (accession 
#AC225317) that contains a 524 nucleotide deletion within its 5’UTR (Beck et al. 2010). 
Upon closer inspection, we determined that this deletion may have resulted from the 
retrotransposition of a spliced L1 transcript that used a previously identified splice donor 
(SD: G98U99) (Belancio et al. 2006) and an unreported splice acceptor (SA: A620G621) 
within the 5’UTR of a full-length L1 (numbering based on L1.3, accession # L19088) 
(Figures 2.1A and 2.1B). The structure of this element resembled previous L1s 
characterized by Belancio and colleagues, lending support to the hypothesis that 
spliced L1 transcripts occasionally could undergo retrotransposition in the human 
genome (Belancio et al. 2006; Belancio et al. 2008). We named these L1s SpIREs 
(Spliced Integrated Retrotransposed Elements). The three SpIREs investigated here 
(Figures 2.1B, 2.1C, and 2.1D) all use the same splice donor (SD: G98U99), but pair with 
different splice acceptor sequences that reside within either the L1 5’UTR (SA: A620G621 
or SA: A788G789) or L1 ORF1 (SA: A974G975).  
SpIREs are present in the human genome 
To determine the copy number of SpIRE G98U99/A620G621 sequences (now named 
SpIRE97/622) present in the human genome reference sequence (HGR), we conducted 
BLAT (https://genome.ucsc.edu/index.html) (Kent 2002) searches using a 100 
nucleotide in silico probe that spanned the intra-5’UTR splice junction present in 
SpIRE97/622 (nucleotides 47-97 and 622-672 of L1.3). We screened build 37 of the HGR 
(GRCh37/hg19) for L1 sequences using Repeat Masker  (Jurka et al. 2005).  
The HGR contains an annotated record of L1s that have accumulated over 
evolutionary time. Thus, querying the genome allows a determination of how SpIREs 
contribute to the L1 genomic repertoire. We identified 116 SpIRE97/622 sequences that 
spanned the youngest L1PA1 (also known as L1Hs, currently amplifying in the human 
population) to L1PA6 subfamilies (which amplified approximately 27 million years ago 
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(MYA)), but none in older L1 subfamilies (Figure 2.6A) (Khan et al. 2006; Song and 
Boissinot 2007). Thus, 116/6609 or ~1.8% of previously determined full-length L1s in 
the L1PA1-L1PA6 subfamilies are SpIRE97/622 sequences (Figure 2.6).  
Almost half of the SpIRE97/622 sequences we identified belong to the L1PA3 
subfamily (53 sequences, comprising ~3.4% of annotated full-length L1s in that 
subfamily) (Figure 2.6A; Data Set 1, Table 2.1). The L1PA1 subfamily harbors 6 
SpIRE97/622  (comprising 2.0% of annotated full length L1s in that subfamily) and the 
L1PA6 subfamily contains only one SpIRE97/622 (comprising 0.1% of annotated full-
length L1s in that subfamily) (Figure 2.6; Data Set 1; Table 2.1). Seven SpIRE97/622 
sequences could not be unambiguously assigned to a specific L1 subfamily and are 
classified as either L1PA2-L1PA3 or L1PA4-L1PA6 sequences (Figure 2.6A; Data Set 
1; Table 2.1) (Smit et al. 1995).  
Given the above data, we used BLAT to search the HGR for additional L1s 
containing G98U99/A788G789 and G98U99/A974G975 splicing events (now named SpIRE97/790 
and SpIRE97/976 respectively) (Belancio et al. 2006; Belancio et al. 2008). These 
searches confirmed the presence of four previously identified SpIRE97/790 sequences in 
the L1PA1-L1PA2 subfamilies (Figure 2.6A, Data Set 1, Table 2.1). We added an 
additional SpIRE97/976 sequence to the ten previously identified (Figure 2.6C; Data 1; 
Table 2.1) (Belancio et al. 2006; Belancio et al. 2008). In total, these three classes of 
SpIREs comprise a small, but significant (131/6609 or ~2%), percentage of annotated 
full-length L1s from the L1PA1-L1PA6 subfamilies. The newly identified SpIRE97/622 
represents the majority (116/131 or ~89%) of those sequences.  
SpIREs contain L1 structural hallmarks 
Sequence characterization of the 131 SpIRE97/622, SpIRE97/790, and SpIRE97/976 
sequences revealed SpIREs are general flanked by target site duplications that ranged 
from 6-32 bp, end in a 3’ poly(A) tract, and integrated into an L1 EN consensus 
cleavage site (5’-TTTT/A-3’ and variants of that sequence) (Data Set 1; Table 2.1). The 
majority (119/131) of SpIRES generally did not contain additional structural alterations 
(e.g., internal deletions). However, three SpIREs contained additional internal deletions, 
one contained an inversion/deletion, and eight appeared to be truncated at there 3’ 
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ends. Four of the eight 3’ truncated SpIREs retrotransposed into an older L1 generating 
chimeric L1s (Kriegs et al. 2007) that were easily identifiable in the genome browser 
(Data Set 1; Table 2.1). For the remaining four 3’ truncated elements we were unable to 
determine the reason for the apparent truncation (see Methods). 
Consistent with previous studies, approximately one-third of the SpIREs (46/131) are 
present within the introns of RefSeq (https://www.ncbi.nlm.nih.gov/refseq/) (Pruitt et al. 
2007) annotated genes and the majority (29/46 or ~63%) are present in the opposite 
transcriptional orientation of the annotated gene (Table 2.1) (Smit 1999; Gilbert et al. 
2002; Symer et al. 2002; Gilbert et al. 2005; Boissinot et al. 2006; Chen et al. 2006b). 
Two SpIREs (~1.5%) have a 5’ transductions of 130 and 560 bp (Lander et al. 2001; 
Chen et al. 2006a; Evrony et al. 2012), whereas 11/131 (~8.4%) contained 3’ 
transductions that range in length from 61 to 1036 bp (Moran et al. 1999; Goodier et al. 
2000; Pickeral et al. 2000; Macfarlane et al. 2013). Despite identifying SpIREs 
containing transduction events, we were unable to uncover evidence that any SpIRE 
acted as a progenitor element that gave rise to a new SpIRE (Table 2.1).  
Intra-5’UTR splicing reduces L1 promoter activity 
Since the formation of SpIRE97/622 resulted in the deletion of five of six known 
transcription factor binding sites within the L1 5’UTR (Hohjoh et al. 1990; Minakami et 
al. 1992; Becker et al. 1993; Yang et al. 1998; Tchenio et al. 2000; Yang et al. 2003; 
Athanikar et al. 2004) (Figure 2.1A), we hypothesized the SpIRE97/622 5’UTR would have 
reduced promoter activity. To test this, we created L1/firefly luciferase expression 
vectors by subcloning the wild type (WT) and SpIRE97/622 5’UTR sequences upstream of 
a promoterless firefly (Photinus pyralis) luciferase expression vector (pGL4.11), creating 
pPLWTLUC and pPL97/622LUC respectively (Figure 2.2A). We then characterized the 
expression from these 5’UTRs in functional assays. 
We first conducted northern blot analyses using polyadenylated mRNAs isolated 
from untransfected (UTF) HeLa-JVM cells and HeLa-JVM cells transfected with the 
different luciferase expression vectors (Figure 2.2). An RNA probe complementary to 
the first 100 ribonucleotides of the L1 5’UTR (Figure 2.2A; purple line) detected a strong 
signal at the expected size of roughly 2.7 kb in mRNAs derived from HeLa-JVM cells 
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transfected with pPLWTLUC. We did not detect signals in mRNAs derived from 
untransfected HeLa-JVM cells or HeLa-JVM cells transfected with pPL97/622LUC, or 
pGL4.11 (Figure 2.2B, first panel). Similar results were obtained using RNA probes 
complementary to either ribonucleotides 103-330 of the L1 5’UTR (Figure 2A, red line; 
Figure 2.2B, second panel) or the 3’ end of luciferase mRNA (Figure 2.2A, blue line; 
Figure 2.2B, third panel). Control experiments verified the integrity and quality of the 
mRNAs (Figure 2.2B, actin probe). These data are consistent with previously published 
findings, which demonstrated that L1 transcription faithfully begins at or near the first 
nucleotide of the L1 5’UTR (Athanikar et al. 2004).  
We were able to detect the predicted 2.2 kb transcript emanating from pPL97/622LUC 
upon the prolonged exposure of the Northern blots using probes complementary to 
either the first 100 ribonucleotides of the L1 5’UTR or the 3’ end of the luciferase gene, 
but not using a probe complementary to ribonucleotides 103-330 of the L1 5’UTR 
(Figure 2.7), suggesting that SpIRE97/622 5’UTR retained weak promoter activity. Since 
the splicing events that gave rise to SpIRE97/790 and SpIRE97/976 led to larger deletions of 
the 5’UTR when compared to SpIRE97/622, we reasoned that they would lead to a 
similar, if not greater, reduction in transcriptional activity; thus, they were not tested in 
this assay. 
To corroborate the northern blot analyses, we conducted dual luciferase expression 
assays on whole cell lysates derived from HeLa-JVM cells co-transfected with firefly 
luciferase-based vectors (pPLWTLUC, pPL97/622LUC, or pGL4.11) and a constitutively 
expressed Renilla luciferase (Renilla reniformis) plasmid (pRL-TK; see Methods). 
Consistent with the northern blot data, HeLa-JVM cells transfected with pPLWTLUC 
exhibited ~267-fold increase of normalized firefly luciferase activity over those 
transfected with the promoterless pGL4.11 vector (Figure 2.2C). By comparison, HeLa-
JVM cells transfected with pPL97/622LUC exhibited only ~7-fold increase of normalized 
firefly luciferase activity over those transfected with the promoterless pGL4.11 vector 
(Figure 2.2C). Together, the above data suggest that the splicing event leading to the 
generation of SpIRE97/622 severely compromises its promoter activity. 
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Mutating the 5’ splice donor site results in decreased L1 promoter activity 
Given that splicing reduces transcriptional activity we wanted to determine why the 
G98U99 splice donor might be conserved. Previous studies revealed that a RUNX3 
binding site within the 5’UTR is important for maximal L1 promoter activity (Yang, Zhang 
et al. 2003). Interestingly, the splice donor site used to generate the three classes of 
SpIREs reported here is contained within a core RUNX3 binding site in L1 DNA that is 
conserved from the L1PA1-PA10 subfamilies (Figure 2.1A; SD: G98U99; Figure 2.6) 
(Khan et al. 2006). Thus, we hypothesized that this SD is retained to maintain an active 
RUNX3 site. To test this hypothesis we mutated the splice donor sequence in the WT 
5’UTR (U99C, creating pPLSDmLUC) (Krawczak et al. 1992) and asked if this mutation 
affects 5’UTR promoter activity. Northern blot analyses using the previously described 
riboprobes detected a signal at ~2.7kb in mRNAs derived from HeLa-JVM cells 
transfected with pPLSDmLUC. Notably, there is markedly less of this transcript when 
compared to cells transfected with pPLWTLUC  (Figure 2.2B; ~18% of pPLWTLUC). By 
comparison, mutating the splice acceptor site within the 5’UTR did not drastically affect 
promoter activity (Figure 2.2B; pPLSAmLUC; A620C). Thus, our data suggest retention of 
the complete RUNX3 site is critical for L1 promoter activity and are consistent with 
previous findings (Yang et al. 2003).  
Reverse Transcription PCR (RT-PCR) shows that intra-5’UTR splicing is a rare event 
We next wanted to identify spliced L1 mRNAs that might give rise to SpIREs. To this 
end we conducted qualitative RT-PCR experiments using poly(A) mRNAs isolated from 
HeLa-JVM cells transfected with a series of L1/firefly luciferase expression vectors 
(Figure 2.2D; see Methods). The REV-LUC oligonucleotide (Figure 2D, purple line) was 
used to initiate L1/firefly luciferase first strand cDNA synthesis; the cDNA products then 
were PCR amplified using FWD-5’UTR (Figure 2.2D, red line) and REV-LUC 
oligonucleotide primers. The resultant cDNAs were cloned and characterized by Sanger 
DNA sequencing. Control experiments conducted in the absence of reverse 
transcriptase (Figure 2.2D, bottom gel) revealed that the characterized products were 
derived from the PCR amplification of cDNAs (Figure 2.2D, top gel). 
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We detected the predicted L1/firefly luciferase cDNA products from HeLa-JVM cells 
transfected with pPLWTLUC, pPLSDmLUC, and pPLSAmLUC (Figure 2.2D, top gel, yellow 
“*” in lanes 1, 3, and 4), as well as the shorter predicted L1/firefly luciferase cDNA 
product from HeLa-JVM cells transfected with pPL97/622LUC (Figure 2.2D, yellow “#” in 
lane 2). However, consistent with the northern blot experiments (Figure 2.2B), we could 
not detect the SpIRE97/622 L1/firefly luciferase cDNA product from mRNAs derived from 
HeLa-JVM cells transfected with pPLWTLUC (Figure 2.2D). Instead, we detected a minor 
L1/firefly luciferase cDNA product that corresponds to the SpIRE97/790 splicing event 
from cells transfected with pPLWTLUC and pPLSAmLUC (Figure 2.2D, top gel, yellow “+”, 
lanes 1 and 4; Figure 2.1C) (Belancio et al. 2006). Importantly, this product was not 
detected in untransfected HeLa-JVM cells or in HeLa-JVM cells transfected with either 
pGL4.11 or pPLSDmLUC. Thus, in agreement with our northern blot data, it appears that 
full-length L1/firefly luciferase mRNAs represent the major RNA species in these assays 
and that intra-5’UTR splicing is a relatively rare event. 
Intra-5’UTR splicing does not dramatically affect L1 mRNA translation  
Given that spliced L1 RNAs can integrate suggests that L1 translation is intact. We 
next tested whether intra-5’UTR splicing affects L1 mRNA translation. To accomplish 
this goal, we transfected HeLa-JVM cells with a WT L1 (pJM101/L1.3), an L1 that lacks 
the 5’UTR (pJM102/L1.3), or an L1 that contains an intra-5’UTR splicing event (pPL97-
622/L1.3) (Sassaman et al. 1997; Morrish et al. 2002). A cytomegalovirus early (CMV) 
promoter augments the expression of each L1 and a hygromycin resistance gene on the 
pCEP4 plasmid ensures selection of transfected cells.  
Western blot analyses were conducted using whole cell lysates (WCLs) derived from 
hygromycin-resistant HeLa-JVM cells transfected with the above constructs nine days 
post-transfection. An ORF1p polyclonal antibody (α-N-ORF1p; directed against amino 
acids +31 to +49 in L1.3(Moldovan and Moran 2015) (UniProtKB accession #Q9UN81)) 
detected an ~40 kDa product in cells transfected with pJM101/L1.3, pJM102/L1.3, and 
pPL97-622/L1.3, but not in untransfected cells (Figure 2.3B). HeLa-JVM cells transfected 
with pPL97-622/L1.3 exhibited a slight reduction in the steady state level of ORF1p when 
compared to HeLa-JVM cells transfected with pJM101/L1.3 or pJM102/L1.3 (Figure 
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2.3B). Since a CMV promoter augmented L1 transcription, it is unlikely that this 
reduction is due to reduced L1 expression, although it remains possible that the slight 
reduction in ORF1p is due to an alteration of the sequence or secondary structure of the 
5’UTR in pPL97-622/L1.3 mRNA. 
5’UTR/ORF1 splicing leads to N-terminal truncated ORF1p  
The 5’UTR/ORF1 splicing event generates a deletion that lacks the first 66 
nucleotides of ORF1, which includes the canonical ORF1p methionine start codon 
(Figure 2.3C, black AUG, 37 kDa). Thus, we hypothesized that ORF1p synthesis might 
initiate from one of two in-frame methionine codons (AUG) that are located in weak 
Kozak consensus sequences either 102 or 270 ribonucleotides downstream from the 
canonical AUG start codon (Figure 2.3C) (Kozak 1984). If the downstream methionine 
codons are used for translation initiation we expected truncated ORF1 proteins of ~33 
kDa and ~27 kDa respectively. 
Western blot analyses were conducted as above using WCLs derived from 
hygromycin-resistant HeLa-JVM cells transfected with pJM101/L1.3, pPL97-976/L1.3, or 
pCEP/GFP (Alisch et al. 2006). As predicted, the α-N-ORF1p and α-C-ORF1p 
antibodies detected an ~40 kDa protein in WCLs derived from HeLa-JVM cells 
transfected with pJM101/L1.3, but did not detect a protein in WCLs derived from HeLa-
JVM cells transfected with the pCEP/GFP control (Figure 2.3C). The α-N-ORF1p 
antibody also detected an ~33kDa protein in WCLs derived from HeLa-JVM cells 
transfected with pPL97-976/L1.3, whereas the α-C-ORF1p antibody detected ~33kDa and 
~27kDa proteins in the same extracts (Figure 2.33C). Similar results were obtained 
when RNP extracts were used in western blot experiments (Figure 2.8A). To confirm 
that these products were ORF1p derived we added a T7-gene10 epitope tag to ORF1 in 
pPL97-976/L1.3. Western blots using a α−T7 antibody recapitulated our ORF1p antibody 
results (Figure 2.8B).  Thus, the 5’UTR/ORF1 splicing event leads to the generation of 
an mRNA that if translated results in amino-terminal truncated derivatives of ORF1p.  
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Intra-5’UTR splicing drastically decreases L1 retrotransposition efficiency 
Our data indicate that the intra-5’UTR splicing event that leads to the generation of 
SpIRE97/622 contains a defective promoter and, if transcribed, produces slightly less 
ORF1p than a WT L1. Thus, we hypothesized that an intra-5’UTR spliced L1 mRNA 
would be capable of undergoing an initial round of L1 retrotransposition. However, the 
resultant full-length retrotransposition events would contain a defective promoter, 
compromising subsequent retrotransposition.  
To test the above hypothesis, we examined whether RNAs derived from the L1 
expression constructs with or without an exogenous CMV, could retrotranspose using a 
cultured cell retrotransposition assay (Moran et al. 1996). The 3’UTR of each of these 
constructs contains a retrotransposition indicator cassette (mneoI). The mneoI cassette 
consists of an antisense copy of a neomycin transferase gene whose coding sequence 
is interrupted by an intron that resides in the same transcriptional orientation as the L1 
(Freeman et al. 1994; Moran et al. 1996). This arrangement ensures that a functional 
neomycin transferase gene only will be activated upon L1 retrotransposition (Freeman 
et al. 1994; Moran et al. 1996). Retrotransposition efficiency then can be quantified by 
counting the resultant numbers of G418-resistant foci (Moran et al. 1996; Wei et al. 
2000). 
Consistent with previous reports, RNAs derived from RC-L1s that either lack 
(pJM101/L1.3∆CMV, grey bar) or contain an exogenous CMV promoter (pJM101/L1.3 
and pJM102/L1.3, black bar) could undergo efficient retrotransposition (Figure 4A), 
whereas RNAs derived from a retrotransposition-deficient L1 containing a missense 
mutation (D702A) that disrupts ORF2p RT activity (pJM105/L1.3) could not undergo 
retrotransposition (Figure 2.4A) (Wei et al. 2001). By comparison, the pPL97-622/L1.3 
expression construct produced RNAs that could undergo efficient retrotransposition only 
when a CMV promoter augmented L1 expression (Figure 2.4A, black bar, ~70% the 
activity of pJM101/L1.3), but not when L1 expression was driven from the 5’UTR 
harboring the intra-5’UTR splicing event (Figure 2.4A, grey bar, ~7.1% the activity of 
pJM101/L1.3). Consistent with this conclusion, we also showed that an L1 lacking 
promoter sequences (JM102/L1.3∆CMV) could not retrotranspose in cultured cells 
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(Figure 2.4A) (Wei et al. 2001). These data suggest that the intra-5’UTR splicing event 
present in SpIRE97/622 severely compromises L1 5’UTR promoter activity and, by proxy, 
L1 retrotransposition. 
5’UTR/ORF1 SpIREs rely on ORF1p supplied in trans for mobilization 
The retrotransposition of an mRNA derived from a 5’UTR/ORF1 splicing event would 
generate a SpIRE (e.g., SpIRE97/976) that contains a defective promoter and, if 
transcribed and translated, would produce amino-terminal truncated versions of ORF1p. 
If the truncated version(s) of ORF1p were non-functional, we reasoned that the 
5’UTR/ORF1 splicing event would lead to an L1 mRNA that is compromised for an initial 
round of retrotransposition in cis. Indeed, RNAs derived from pPL97-976/L1.3 could not 
retrotranspose despite expression being driven by the CMV promoter (Figure 2.4B). 
We next hypothesized that a source of wild-type ORF1p would be required to act in 
trans to promote the retrotransposition of L1 mRNAs containing a 5’UTR/ORF1 splicing 
event. To test this hypothesis, we co-transfected pPL97-976/L1.3 with a series of 
retrotransposition “driver” plasmids that lack the mneoI retrotransposition indicator 
cassette and either express or do not express WT ORF1p (Wei et al. 2001; Alisch et al. 
2006). The co-transfection of pPL97-976/L1.3 with “driver” plasmids that express WT 
ORF1p (pJBM561 (a monocistronic ORF1p expression vector)), pJM101/L1.3NN, or 
pJM105/L1.3NN), promoted a low level of pPL97-976/L1.3 mRNA retrotransposition in 
trans (Figure 2.4C; columns 1, 2, and 3, respectively). By comparison the co-
transfection of pPL97-976/L1.3 with “driver” plasmids that do not express ORF1p (pO2NN 
(a monocistronic ORF2p expression vector) or pCEP4) did not promote pPL97-976/L1.3 
mRNA retrotransposition (Figure 2.4C; columns 4 and 5, respectively) (Alisch et al. 
2006). Thus, the expression of ORF1p, but not ORF2p, can promote low levels of 
retrotransposition of pPL97-976/L1.3 mRNA in trans. 
Discussion 
The continued evolutionary success of L1 requires the reiterative retrotransposition 
of full-length L1 RNAs. Previous studies have provided compelling evidence that L1 
ORF1p and L1 ORF2p exhibit cis-preference and preferentially bind to their encoding 
mRNA to promote its retrotransposition (Figure 2.5A) (Martin 1991; Hohjoh and Singer 
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1996; Wei et al. 2001; Kulpa and Moran 2005; Kulpa and Moran 2006; Doucet et al. 
2015). Thus, it was surprising when Belancio and colleagues identified a small number 
of L1 retrotransposition events in the HGR that apparently were derived from spliced L1 
RNAs (Belancio et al. 2006; Belancio et al. 2008). Here, we confirmed and extended 
those findings and report a novel class of retrotransposed L1s that are derived from an 
L1 RNA containing an intra-5’UTR splicing event (SpIRE97/622; Figure 1). SpIRE97/622 is 
10 times more prevalent than SpIREs previously identified, present at 116 copies in the 
HGR, and comprises ~1.8% of the full-length L1 retrotransposition events in the L1PA1-
PA6 subfamilies accumulated during the past ~27 million years (MY)(Figure 2.6).  
The retrotransposition of spliced L1 RNAs leads to the generation of SpIREs that are 
compromised for subsequent rounds of retrotransposition. L1 RNAs that contain intra-
5’UTR splicing events can produce ORF1p and ORF2p and undergo an initial round of 
retrotransposition in cis (Figure 2.4A). However, the resultant SpIREs lack cis-acting 
sequences required for efficient L1 transcription (Figure 2) (Tchenio et al. 2000; Yang et 
al. 2003; Athanikar et al. 2004); thus, they are compromised for subsequent rounds of 
retrotransposition (Figure 2.4A; Figure 2.5B). By comparison, L1 RNAs containing 
5’UTR/ORF1 splicing produce non-functional, amino-terminal truncated versions of 
ORF1p (Figure 2.3C; Figure 2.8A, B). As a result, these RNAs are retrotransposition-
defective in cis and must rely on exogenous sources of ORF1p to promote their 
retrotransposition in trans (Figure 2.4B, C; Figure 2.5C). In the rare cases where trans-
complementation occurs, the resultant 5’UTR/ORF1 SpIREs will lack cis-acting 
sequences required for efficient L1 transcription and, if transcribed, produce non-
functional versions of ORF1p, making it highly unlikely that they will undergo 
subsequent rounds of retrotransposition (Figure 2.5C).  
The above data strongly indicate that SpIREs represent evolutionary ‘dead ends’ in 
the L1 amplification process. It is possible that a small number of SpIREs could give rise 
to new L1 retrotransposition events. For example, the insertion of SpIRE97/622 
downstream of a cellular promoter could, in principle, enhance its expression and 
subsequent retrotransposition. However, any resultant retrotransposition events would 
contain a defective promoter and would still be compromised for subsequent rounds of 
	   86	  
retrotransposition. Indeed, the examination of 3’ transduction sequences associated 
with SpIREs did not uncover any examples where one SpIRE served as a progenitor for 
a subsequent retrotransposition event. Thus, we conclude that splicing negatively 
affects L1 retrotransposition.  
The three classes of SpIREs examined in our study each use a common splice 
donor site (SD: G98U99), but different splice acceptor sites (SA: A620G621, SA: A788G789, 
or SA: A974G975)(Belancio et al. 2006; Belancio et al. 2008). These findings raise the 
following question: if splicing adversely affects L1 retrotransposition, why is the G98U99 
splice donor site retained in L1 RNA? The G98U99 splice donor site has been conserved 
in the L1PA1-L1PA10 subfamilies for at least 46 MY (Figure 2.6B) (Khan et al. 2006) 
and resides within a core binding site for the RUNX3 transcription factor (Yang et al. 
2003). Indeed, previous studies indicated that RUNX3 is required for efficient L1 
transcription (Yang et al. 2003) and we found that mutating the splice donor sequence 
leads to an ~5-fold reduction in L1 promoter activity (Figure 2B). Together, these finding 
strongly suggest that the importance of the RUNX3 binding site in L1 expression far 
outweighs the cost of harboring the splice donor site (SD: G98U99) in the L1 5’UTR. 
Despite the evolutionary conservation of the G98U99 splice donor, northern blotting 
and RT-PCR experiments revealed that the vast majority of L1 transcripts do not 
undergo splicing (Figures 2.2B and 2.2D). SpIREs only are formed when L1 RNAs 
containing rare splicing events undergo retrotransposition. The reason(s) why G98U99 is 
not efficiently utilized as a functional splice donor site require elucidation. However, it is 
possible that the G98U99 sequence is sequestered into a secondary structure in L1 RNA 
that restricts its access to U1 snRNA (reviewed in (Hastings and Krainer 2001; Buratti 
and Baralle 2004)). Indeed, such a scenario provides a plausible mechanism for how L1 
can tolerate a functional splice donor sequence in its mRNA and could, in part, explain 
why SpIREs only represent ~2% of full-length L1 retrotransposition events that occurred 
during the past ~27 MY.  
The notion that sequences within the L1 5’UTR are subject to selective pressure has 
precedent. A recent study demonstrated that a Krüppel-associated Box-containing Zinc-
Finger Protein (ZNF93) could bind sequences within the 5’UTR of full-length L1s from 
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the L1PA3 subfamily to repress their expression (Jacobs et al. 2014).  By comparison 
the 5’UTRs of full-length L1s from the L1PA2 and currently amplifying L1PA1 
subfamilies harbor a 129-bp deletion that eliminates the ZNF93 binding site, allowing 
them to escape ZNF93-mediated repression (Jacobs et al. 2014).  
Our RT-PCR experiments using transfected L1/firefly luciferase expression vectors 
only uncovered evidence of rare SpIRE97/790 splicing events. Intriguingly, we only 
identified genomic SpIRE97/790 retrotransposition events in the L1PA2 and L1PA1 
subfamilies despite the fact that the SA: A788G789 sequence has been conserved from 
the L1Hs to L1PA15B subfamilies for ~70 MY (Figure 2.6B) (Khan et al. 2006). We 
propose that the 129bp deletion may have allowed the SpIRE97/790 splice acceptor 
(A916G917 in L1PA3) to come into closer proximity (A786G787 in L1PA2) with a putative 
splicing branch point sequence in L1PA1-PA2 RNAs (ACCTCAC761-767 in L1PA2) 
(Figure 2.9). If so, the 129-bp deletion present not only allowed L1PA2 and L1Hs 
5’UTRs to escape ZNF93 mediated repression, but also may have altered the intra-
5’UTR splicing dynamics, leading to new, low-level splicing events that can lead to the 
generation of new SpIREs (Figure 2.9).  
In sum, our data strongly indicate that L1 mRNA splicing is detrimental to L1 
retrotransposition and further strengthen the hypothesis that ORF1p and ORF2p 
predominantly retrotranspose their encoding full-length L1 RNAs to new genomic 
locations in cis. In addition, we demonstrated that, despite harboring evolutionarily 
conserved functional splice donor and splice acceptor sites within their 5’UTR, the vast 
majority of L1 transcripts evade splicing. These data provide insights into the 
evolutionary dynamics of the L1 5’UTR and raise the intriguing possibility that host 
factors that promote L1 splicing or alter L1 splicing profiles may represent a mechanism 
by which the cell can restrict the expression of full-length L1 RNA and unabated L1 
retrotransposition. 
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Materials and Methods 
 
E. coli and the Propagation of Plasmids 
All plasmids were propagated in DH5α E. coli (genotype: F- φ80lacZ∆M15 
∆(lacZYA-argF) U169 recA1 endA1 hsdR17 (rk-, mk+) phoA supE44 λ- thi-1 gyrA96 
relA1) (Invitrogen, Carlsbad, CA). Competent cells were generated as described 
previously (Inoue et al. 1990). Plasmids were prepared using the Plasmid Midi Kit 
(Qiagen, Germany) according to the protocol provided by the manufacturer.  
Cell Lines and Cell Culture Conditions 
HeLa-JVM cells were cultured in high glucose Dulbecco's Modified Eagle Medium 
(DMEM) lacking pyruvate (Invitrogen). DMEM was supplemented with 10% fetal bovine 
calf serum (FBS) and 1X penicillin/streptomycin/glutamine to create DMEM-complete 
medium as described previously (Moran et al. 1996). HeLa-JVM cells were grown in a 
humidified tissue culture incubator (Thermo Scientific, Waltham MA) at 37oC in the 
presence of 7% CO2.  
BLAT Searches and SpIRE Sequence Curation 
BLAT (https://genome.ucsc.edu/cgi-bin/hgBlat?command=start) was used to screen 
build 37 (GRCh37/hg19) of the UCSC genome browser (https://genome.ucsc.edu) with 
the repeat masker track “on” using 100 bp in silico probes that spanned (50 bases 
upstream and downstream) the splice junctions of SpIRE97/622, SpIRE97/790 and 
SpIRE97/976. The in silico probes were designed using the L1.3 sequence (Accession 
#L19088) as a template. Putative SpIREs shared >95% sequence identity to the in silico 
probes.  
 Putative SpIREs were downloaded from the UCSC genome browser and manually 
curated with the aid of repeat masker (http://repeatmasker.org). Each sequence was 
inspected to ensure it contained a splicing event and represented a bona fide SpIRE. 
For four events that were prematurely 3’ truncated, we analyzed 4kb of genomic DNA 
flanking the 3’ end of the SpIRE to determine if it shared >95% sequence identity with 
L1.3 using the Serial Cloner alignment tool (http://serialbasics.free.fr/Home/Home.html). 
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We were unable to identify any L1 sequence in the flanking DNA; thus we cannot 
determine the reason for the apparent 3’ truncation in these four SpIREs. Structural 
hallmarks of L1 integration events that occur by canonical TPRT (i.e., the presence of 
target site duplications, a 3’ poly(A) tract, L1-mediated sequence transductions, and the 
L1 integration site) were determined manually by analyzing sequences flanking the 5’ 
and 3’ ends of each SpIRE (Goodier et al. 2000; Szak et al. 2002; Gilbert et al. 2005). 
Sequences are named based on the class of SpIRE (SpIRE97/622, SpIRE97/790, or 
SpIRE97/976) and a corresponding number for easy referral between Tabale 2.1 and data 
set 1 (for example; SpIRE97/622-1 is the first of the analyzed 116 SpIRE97/622 sequences). 
Determining the conservation of splice donor and splice acceptor sites 
Khan et al. 2006 provided full-length L1 consensus sequences of L1PA1(L1Hs) 
through L1PA16 and assembled an alignment of the respective 5’UTRs (Khan et al. 
2006). We manually inspected these alignments to determine the oldest L1 subfamily 
that contained the 5’UTR splice donor/splice acceptor sequences utilized in generating 
the reported SpIREs. We next determined the conservation of the ORF1 splice acceptor 
sequence (SA: A974G975) by aligning full-length L1 consensus sequences using the 
ClustalW alignment function (Thompson et al. 2002; Khan et al. 2006) from the 
MegAlign	   (http://www.dnastar.com/t-megalign.aspx) software. As with the 5’UTR, we 
manually inspected the resulting alignment to determine the oldest L1 subfamily that 
contained the ORF1 splice acceptor sequence (SA: A974G975).    
Identification of putative branch point sequences 
To identify putative branch point sequences, we downloaded full-length 5’UTR 
sequences as described above (Khan et al. 2006), and submitted them for analysis 
using the Human Splicing Finder v3.0 online prediction program 
(http://www.umd.be/HSF3/HSF.html) (Desmet et al. 2009). The resultant analyses 
identify potential SD, SA, and branch point sequences and assigns consensus value 
scores for each motif (Desmet et al. 2009). Motif scores greater than 80 represent 
“strong” splice sites; sequences with scores less than 80 represent “weaker” splice 
sites. The 5’UTR sequence of each L1 subfamily was uploaded and analyzed by the 
general ‘Analyze a sequence’ function. We then matched predicted branch points with 
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the known splice acceptor SA: A786G787 (L1PA2) using the criteria from Gao et al. 2008, 
where 100% of branch points are at positions −50 to −5 relative to the last nucleotide of 
the intron (in this case, the -1 position is G789). Using this procedure, we identified the 
strong branch point (A761C762C763T764C765A766C767) with a score of 95.75 that is 20  bp 
upstream of the SA: A786G787 in the L1PA2 subfamily. This putative branch point 
sequence is 147 bp upstream of the conserved SA: A916G917 in the L1PA3 family (See 
Figure 2.9).  
L1 Expression Constructs 
 
The following L1 constructs contain a derivative of a retrotransposition-competent L1 
(L1.3, accession number L19088 (Dombroski et al. 1993; Sassaman et al. 1997)) 
cloned into the pCEP4 plasmid backbone (Life Technologies) unless indicated 
otherwise. Cloning strategies used to create these constructs are available upon 
request. 
 pJM101/L1.3: contains a full-length version of L1.3 in the pCEP4 backbone. The 3’UTR 
of L1.3 contains the mneoI retrotransposition indicator cassette (Dombroski et al. 1993; 
Moran et al. 1996; Sassaman et al. 1997). 
pJM101/L1.3∆CMV: is identical to pJM101/L1.3, but the CMV promoter was deleted 
from the pCEP4 plasmid (Dombroski et al. 1993; Moran et al. 1996; Sassaman et al. 
1997). 
pJM101/L1.3NN: is a derivative of pJM101/L1.3 that lacks the mneoI retrotransposition 
indicator cassette (Wei et al. 2001). 
pDK101/L1.3: is a derivative of pJM101/L1.3 that expresses a version of ORF1p that 
contains a T7 gene10 epitope tag on its carboxyl-terminus (Kulpa and Moran 2005). 
pJM105/L1.3: is identical to pJM101/L1.3, but contains a D702A missense mutation in 
the ORF2p RT active site (Wei et al. 2001). 
pJM105NN: is a derivative of pJM105/L1.3 that lacks the mneoI retrotransposition 
indicator cassette (Wei et al. 2001). 
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pJM102/L1.3: is a derivative of pJM101/L1.3 that lacks the L1 5’UTR (Morrish et al. 
2002). 
pJM102/L1.3∆CMV: is identical to pJM102/L1.3, but the CMV promoter was deleted 
from the pCEP4 plasmid (Wei et al. 2001). 
pPL97-622/L1.3: is a derivative of pJM101/L1.3 that contains a 524 intra-5’UTR deletion 
(L1.3 nucleotides 98-621) present in SpIRE97/622 (Beck et al. 2010).  
pPL97-622 /L1.3∆CMV: is identical to pPL97-622/L1.3, but the CMV promoter was deleted 
from the pCEP4 plasmid. 
pPL97-976/L1.3: is a derivative of pJM101/L1.3 that contains an 878 bp 5’UTR/ORF1 
deletion (L1.3 nucleotides 98-975) present in SpIRE97/976. 
pPL97-976/L1.3-T7: is a derivative of pPL97-976/L1.3 that expresses a version of ORF1p 
that contains a T7 gene10 epitope tag on its carboxyl-terminus. 
pORF2/L1.3NN: is a monocistronic L1 ORF2 expression plasmid that lacks the mneoI 
retrotransposition indicator cassette (Alisch et al. 2006). 
pJBM561: is a monocistronic L1 ORF1 expression plasmid that lacks the mneoI 
retrotransposition indicator cassette. Plasmid created by Dr. John B. Moldovan. 
pCEP/GFP: is a pCEP4-based plasmid that expresses a humanized Renilla green 
fluorescent protein (hrGFP) from phrGFP-C (Stratagene).  A CMV promoter drives the 
expression of the hrGFP gene (Alisch et al. 2006).  
Luciferase Expression Constructs 
The following plasmids are based on the pGL4.11 promoterless firefly luciferase 
expression vector (Promega, Madison, WI). Oligonucleotides and cloning strategies 
used to create these constructs are available upon request. 
pPLWTLUC: is a derivative of pGL4.11 that contains the wild type L1.3 5’UTR upstream 
of the firefly luciferase reporter gene. 
pPL97-622LUC: is a derivative of pGL4.11 that contains the pPL97-622/L1.3 5’UTR deletion 
derivative upstream of the firefly luciferase reporter gene. 
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pPLSDmLUC: is a derivative of pPLWTLUC that contains a U99C splice donor mutation in 
the L1.3 5’UTR upstream of the firefly luciferase reporter gene. 
pPLSAmLUC: is a derivative of pPLWTLUC that contains an A620C splice acceptor 
mutation in the L1.3 5’UTR upstream of the firefly luciferase reporter gene. 
pGL3-Control: is an expression plasmid where the SV40 promoter drives firefly 
luciferase transcription (Promega). 
pRL-TK: is an expression plasmid where the HSV-TK promoter drives Renilla luciferase 
transcription (Promega). 
RNA isolation  
Briefly, 8X106 HeLa-JVM cells were seeded into a T-175 Falcon tissue culture flask 
(BD Biosciences, San Jose, CA). On the following day, transfections were conducted 
using the FuGene HD transfection reagent (Promega, Madison, WI). The transfection 
reactions contained 1 mL of Opti-MEM® (Life Technologies), 120µl of the FuGene HD 
transfection reagent, and 20µg of plasmid DNA per flask. The tissue culture medium 
was changed 24 hours post-transfection. The cells were collected 48 hours post-
transfection. Briefly, cells were washed in ice-cold 1X phosphate buffered saline (PBS) 
(Life Technologies). The cells then were scraped from the tissue culture flasks, 
transferred to a 15 mL conical tube (BD Biosciences), and centrifuged at 3000 x g for 5 
minutes at 4oC. Cell pellets were frozen at -20oC overnight. The frozen pellets were 
thawed and total RNA was prepared using the TRIzol reagent following the protocol 
provided by the manufacturer (Life Technologies). Poly(A) RNAs then were isolated 
from the total RNAs using a Oligotex mRNA Midi Kit (Qiagen), suspended in 
UltraPure™ DNase/RNase-Free distilled water (Thermo Fisher Scientific, Waltham, 
MA), and quantified using a NanoDrop 1000 spectrophotometer (Thermo Fisher 
Scientific). 
Northern Blots 
Northern blot experiments were conducted using the NorthernMax-Gly Kit (Thermo 
Fisher Scientific) following the protocol provided by the manufacturer. Briefly, aliquots of 
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poly(A) RNAs (2 µg) were incubated for 30 minutes at 50oC in Glyoxal Load Dye 
(containing DMSO and ethidium bromide) and then were separated on a 1.2% agarose 
gel. The RNAs were transferred by capillary action to a Hybond-N nylon membrane (GE 
Healthcare, Marlborough, MA) for four hours, and cross-linked to the membrane using 
the Optimum Crosslink setting of a Stratalinker (Stratagene, LaJolla, CA). Membranes 
were then baked at 80oC for 15 minutes. Membranes were prehybridized for 
approximately four hours at 68°C in NorthernMax® Prehybridization/Hybridization Buffer 
(Thermo Fisher Scientific) and then were incubated overnight at 68°C with a strand 
specific RNA probe (final concentration of probe ~ 3×106 cpm/ml). The following day, 
the membranes were washed once with low stringency wash solution (2x saline sodium 
citrate (SSC), 0.1% sodium dodecylsulfate (SDS)) and then twice with high stringency 
wash solution (0.1x SSC, 0.1% SDS). The washed membranes were placed in a film 
cassette (Thermo Fisher Scientific, Autoradiography Cassette FBCA 57) and exposed 
to Amersham Hyperfilm ECL (GE Healthcare) overnight at -80oC. Films were developed 
using a JP-33 X-Ray Processor (JPI America Inc., New York, NY). 
Preparation of Northern Blot Probes 
Strand-specific αP32-UTP radiolabeled riboprobes were generated using the 
MAXIscript T3 system (Thermo Fisher Scientific). Briefly, oligonucleotide primers were 
used to PCR amplify portions of the L1.3 5’UTR (Moldovan and Moran 2015)(L1.3 
nucleotides 1-100 or L1.3 nucleotides 103-330) or the 3’ end of the luciferase gene (see 
below). The resultant PCR products were separated on a 1% agarose gel and were 
purified using QIAQuik gel extraction (Qiagen). Notably, a T3 RNA polymerase 
promoter sequence was included on the reverse primer used to generate the antisense 
riboprobe (underlined below). The labeling reaction was carried out at 37oC using the 
following reaction conditions: 500ng of gel purified DNA template, 2 µL of transcription 
buffer supplied by the manufacturer, 1 µL each of unlabeled 10 mM ATP, CTP, GTP, 5 
µL of αP32-UTP (10 mCi/mL), and 2 µL of T3 RNA polymerase. The reaction 
components then were mixed and brought to a total volume of 20µL using nuclease-free 
water in a 1.5 mL Eppendorf tube, which was incubated at 37oC for 10 minutes in a 
heating block. Unincorporated nucleotides were subsequently depleted using the 
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Ambion® NucAway™ Spin Columns (Thermo Fisher Scientific) following the protocol 
provided by the manufacturer. To generate a control β-actin riboprobe, the pTRI-β-actin-
125-Human Antisense Control Template (Applied Biosystems) was used in T3 labeling 
reactions. Biological triplicates of each northern blot exhibited similar results.  
Oligonucleotide sequences used to generate northern blot probes: 
L1.3 5’UTR 1-100 Sense: 5'-GGAGCCAAGATGGCCGAATAGGAACAGCT-3'  
L1.3 5’UTR 1-100 AS: 5'-AATTAACCCTCAAAGGGACCTCAGATGGAAATGCAG-3'  
L1.3 5’UTR 103-336 Sense: 5’-GGGTTCATCTCACTAGGGAGTG-3’ 
L1.3 5’UTR 103-336 AS: 5’-AATTAACCCTCACTAAAGGGTATAGTCTCGTGGTGCGCCG-3’ 
Quantification of Northern Blots 
Northern blot bands were quantified using the ImageJ software 
(https://imagej.nih.gov/ij/ software) (Schneider et al. 2012). The intensity of the bands in 
the pPLWTLUC and pPLSDmLUC lanes were determined and normalized to the actin 
loading control. Three independent northern blots were subject to quantification. We 
then computed that average intensity of the bands and calculated a standard deviation. 
As reported in the text, the steady state level of pPLSDmLUC RNA is ~18% the level of 
pPLWTLUC RNA with a standard deviation of +/-3.1%. 
Dual Luciferase Assays 
Luciferase assays were performed using the Dual-Luciferase® Reporter Assay 
System (Promega, Madison, WI) following the manufacturers protocol. Briefly, 2X104 
HeLa cells were plated into each well of a 6-well plate (BD Biosciences). Approximately 
24 hours later each well was transfected using a transfection mixture of 100µl Opti-
MEM® (Life Technologies), 3 µl of FuGENE6 transfection reagent (Promega), and 1 µg 
plasmid DNA (0.5 µg of a firefly luciferase test plasmid and 0.5 µg of an internal control 
Renilla luciferase expression). Each transfection was performed as a technical duplicate 
(i.e., in two wells of a 6-well tissue culture plate). Approximately 24 hours post-
transfection, the transfected cells were washed once with ice-cold 1X PBS and the cells 
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in each well were subjected to lysis for 15 minutes at room temperature using 500µl of 
the 1X Passive Lysis Buffer supplied by the manufacturer. Following homogenization of 
the lysate by manual pipetting, 60µl of the lysate from each well of the 6-well tissue 
culture plate was distributed equally in 3-wells of a 96-well white opaque, optically 
transparent top plate (BD Biosciences), allowing six luminescence readings for each 
transfection condition (six technical replicates – 3 readings per well of a 6-well plate). 
The 96-well plate then was subject to luciferase detection using a GloMax®-Multi 
Detection System (Promega) following the protocol provided by the manufacturer. 
Luminescence readings from the six technical replicates were averaged to give a single 
normalized luminescence reading (NLR). This assay then was performed in biological 
triplicate, yielding three independent NLRs. The resultant data were subsequently 
analyzed using a Student’s one-tailed t-test. Error bars indicate the standard deviation. 
Luminescence readings from lysis buffer alone and from lysates derived from 
untransfected cells were included used as negative controls.  
Reverse Transcription (RT)-PCR 
Poly(A) selected mRNA from transfected HeLa-JVM cells in a T-175 tissue culture 
flask were collected as previously described for northern blots. The resultant RNAs 
were subjected to targeted reverse transcriptase-PCR (RT-PCR) using SuperScript® III 
One-Step RT-PCR System with Platinum® Taq DNA Polymerase (Thermo Fisher 
Scientific) following the protocol provided by the manufacturer. The REVLUC primer 
was used to synthesize first strand cDNA.  The FWD5’UTR and REVLUC primers then 
were used to amplify the resultant cDNAs (see sequences below). The RT-PCR 
products were separated on a 1.2% agarose gel, excised from the gel using QIAQuik 
gel extraction (Qiagen), and were cloned using the TOPO TA Cloning Kit (Thermo 
Fisher Scientific). Sanger DNA sequencing performed at the University of Michigan 
DNA Sequencing Core verified the cDNA sequences in the resultant plasmids. 
Biological triplicates of this experiment yielded similar results.  
Oligonucleotide sequences used in the RT-PCR experiments: 
FWD5’UTR: 5’-GGAACAGCTCCGGTCTACAGCTCCC-3’ 
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REVLUC: 5’-CCCTTCTTAATGTTTTTGGCATCTTCC-3’ 
Protein collection 
The plating and transfection of HeLa-JVM cells in T-175 tissue culture flasks was 
performed as detailed above in the RNA isolation section except that HeLa-JVM cells 
were subjected to selection in DMEM-complete medium supplemented with 200µg/ml of 
hygromycin B (Thermo Fisher Scientific) 48 hours post-transfection and the selection 
medium was changed every other day for seven days. The hygromycin resistant HeLa-
JVM cells were harvested nine days post-transfection as described in the RNA isolation 
section.  The cell pellets were frozen overnight. The following day, pellets were lysed for 
15 minutes on ice by incubation in 0.5 mL of lysis buffer: 10% glycerol, 20 mM Tris-HCl 
pH 7.5, 150 mM NaCl, 0.1% NP-40 (IGPAL) (Sigma-Aldrich, St. Louis, MO), and 1X 
Complete Mini EDTA-free Protease Inhibitor Cocktail (Roche Applied Science, 
Germany). The resultant protein lysates then were centrifuged at 15,000 x g for 30 
minutes to clear the lysate. The resultant supernatant (approximately 0.4mls) was 
designated as the whole cell lysate (WCL). Alternatively, the supernatant fraction was 
subject to RNP collection as previously described (Kulpa and Moran 2005). Briefly, 
200µl of the WCL was layered onto a sucrose solution cushion (6 mL of 17% sucrose, 
bottom layer, followed by 4 mL of 8.5% sucrose, top layer, overlaid by 200 µl of the 
WCL) and ultracentrifuged at 178,000 x g for two hours at 4oC. Following 
ultracentrifugation the supernatant was aspirated and the resultant RNP pellet was 
suspended in 100 µl of water supplemented with 1X Complete Mini EDTA-free Protease 
Inhibitor Cocktail (Roche Applied Science). Bradford assays (Bio-Rad Laboratories, 
Hercules, CA) were used to determine protein concentrations. WCLs generally yielded 
15-19 µg/µl of protein. RNP preparations yielded 6-10 µg/µl of protein. The protein 
samples were stored at -80oC. 
Western blots 
Protein samples were collected as described above and then were incubated with a 
2X solution of NuPAGE reducing buffer (containing 1.75-3.25% lithium dodecyl sulfate 
and 50 mM dithiothreitol (DTT)) (ThermoFisher Scientific). An aliquot (20 µg) of the 
reduced proteins were incubated at 100oC for 10 minutes and then were separated by 
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electrophoresis on 10% precast mini-PROTEAN® TGX gels (Bio-Rad Laboratories, 
Hercules, CA) run at 200V for 1 hour in 1X Tris/Glycine/SDS (25 mM Tris-HCL, 192 mM 
glycine, 0.1% SDS, pH 8.3) buffer (Bio-Rad Laboratories). Transfer was performed 
using the Trans-Blot® Turbo™ Mini PVDF Transfer Packs (BioRad Laboratories) with 
the Trans-Blot® Turbo™ Transfer System (BioRad Laboratories) at 25V for 7 minutes. 
The resultant membranes then were cut at the 75 kDa marker using the Precision Plus 
Protein™ Kaleidoscope™ marker (Bio-Rad Laboratories) as a guide.  The membranes 
then were incubated at room temperature in blocking solution (containing 1X PBS and 
5% dry low-fat milk) (Kroger, Cincinnati, OH). The eIF3 antibody (Santa Cruz 
Biotechnology Inc. (SC-28858)) was used at a 1:1,000 dilution to probe membranes 
containing to detect eIF3 at 110 kDa as a loading control.  The α-N-ORF1p (Moldovan 
and Moran 2015) antibody (directed against ORF1p amino acids 31-49; 
EQSWMENDFDELREEGFRR), α-C-ORF1p (directed against ORF2p amino acids 319-
338; EALNMERNNRYQPLQNHAKM), and anti-T7 (Merck Millipore 69048 T7•Tag® 
Antibody HRP Conjugate) antibodies were used at 1:10,000, 1:2,000 and 1:5,000 
dilutions, respectively to probe membranes for ORF1p. Antibody hybridizations were 
carried out overnight at 4oC in blocking solution. The blots were washed three times 
with 1X PBS, 0.1% Tween-20 (Sigma Aldrich) and then were incubated with a 1:5,000 
dilution of secondary Amersham ECL HRP Conjugated Donkey anti-rabbit IgG 
Antibodies (GE Healthcare Life Sciences) for 60 minutes at room temperature blocking 
solution. The membranes were washed three times with 1X PBS, 0.1% Tween-20 
(Sigma Aldrich). The signals then were visualized using the SuperSignal™ West Pico 
Chemiluminescent Substrate reagent (ThermoFisher Scientific) according to the 
protocol provided by the manufacturer.  The membranes exposed to Amersham 
Hyperfilm ECL (GE Healtchare) for a time that spanned five seconds to five minutes and 
were developed using a JP-33 X-Ray Processor (JPI America Inc.). 
L1 Retrotransposition Assay 
The cultured cell retrotransposition assay was conducted as described previously 
(Moran et al. 1996; Wei et al. 2001; Kopera et al. 2016). Briefly, 2×103 HeLa-JVM 
cells/well were plated in 6-well tissue culture dishes (BD Biosciences). Approximately 24 
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hours post-plating, transfections were performed using a mixture containing 100 µl Opti-
MEM® (Life Technologies), 3 µl FuGENE6 (Promega) transfection reagent, and 1 µg L1 
plasmid DNA per well of a 6-well plate. Approximately 24 hours post-transfection, the 
media was replaced with DMEM-complete medium to stop the transfection. Three days 
post-transfection, the tissue culture medium was replaced and the cells were grown in 
DMEM-complete medium supplemented with 400 µg/mL of G418 (Life Technologies) to 
select for retrotransposition events. After approximately 12 days of G418 selection, the 
resultant G418-resistant foci were washed with ice cold 1X Phosphate-Buffered Saline 
(PBS), fixed to the tissue culture plate by treating them for 10 minutes at room 
temperature in a 1X PBS solution containing 2% paraformaldehyde (Sigma Aldrich) and 
0.4% glutaraldehyde (Sigma Aldrich), and stained with a 0.1% crystal violet solution for 
30 minutes at room temperature to visualize the G418-resistant foci. As a transfection 
control, parallel 6-well tissue culture dishes of HeLa-JVM cells were co-transfected with 
0.5 µg of an L1 expression plasmid and 0.5 µg of a pCEP/GFP expression plasmid 
(Stratagene). Three days post-transfection, the transfected HeLa-JVM cells were 
subjected to fluorescence detection on an Accuri C6 Flow Cytometer (BD Biosciences) 
to determine the transfection efficiencies (i.e., the percentage of GFP-positive cells) for 
each experiment (Kopera et al. 2016). 
The trans-complementation retrotransposition assay was modified slightly from a 
previously described protocol (Wei et al. 2001). Briefly, 2X105 HeLa-JVM cells were 
plated into 60 mm dishes (BD Biosciences). Approximately 24 hours post-plating, 
transfections were performed using a mixture containing 93 µl of Opti-MEM® (Life 
Technologies), 6 µl of FuGeneHD (Promega), and 2µg plasmid DNA (i.e., 1 µg of the L1 
“reporter” plasmid and 1 µg of the L1 “driver” plasmid). Subsequent steps of the 
retrotransposition assay were carried out as described above. As a transfection control, 
parallel 60mm tissue culture dishes of HeLa-JVM cells were co-transfected with 0.5µg 
of an L1 “reporter” plasmid, 0.5 µg of an L1 “driver” plasmid, and 1 µg of a pCEP/GFP 
expression plasmid (Stratagene). Three days post-transfection, the transfected HeLa-
JVM cells were subjected to fluorescence detection on an Accuri C6 Flow Cytometer 
(BD Biosciences) to determine the transfection efficiencies (i.e., the percentage of GFP-
positive cells) for each experiment (Kopera et al. 2016). The transfection efficiencies 
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were used to control for variability and normalize the retrotransposition efficiencies in 
individual transfections. At least three biological replicates were performed for each 
retrotransposition assay. Error bars on all retrotransposition assays represent standard 
deviation of technical triplicates from the indicated experiment.  
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Figure 2.1: LINE-1 RNA contains potential splice donor and splice acceptor sites. 
A) Schematic of a full-length retrotransposition competent L1: Top: the 5’ and 3’ UTRs 
(grey rectangles), ORF1 (yellow rectangle), and ORF2 (blue rectangle) are indicated in 
the cartoon. The 3’UTR ends in a poly(A) tract (AN). The L1 is flanked by target-site 
duplications (black arrow heads) in genomic DNA (black helical lines). Bottom: a 
magnified schematic of the 5’UTR and 5’ end of ORF1. The functional splice donor (SD, 
red) and splice acceptor (SA, green) sequences used to generate SpIREs are indicated 
above the gray rectangle. The position of the SD and SA sequences relative to L1.3 are 
indicated with superscript numbers. The relative positions of cis-acting transcription 
factor binding sequences are indicated in the 5’UTR. B-D) Schematics of the splicing 
events generating SpIRE97/622, SpIRE97/790, and SpIRE97/976: The SD (bold red 
underlined GT nucleotides) and SA (bold green underlined AG nucleotides) demark the 
intron boundaries used to generate each class of SpIRE. 
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Figure 2.2: Intra-5’UTR splicing drastically reduces L1 promoter activity. A) 
Schematic of the luciferase constructs and the relative position of northern blot probes: 
The L1.3 5’UTR (grey bar) was used to drive the transcription of the promoterless firefly 
luciferase reporter gene (green bar) present in plasmid pGL4.11. The following plasmids 
were created: pPLWTLUC contains the full length L1.3 5’UTR; pPL97-622LUC contains the 
SpIRE97/622 5’UTR; pPLSDmLUC contains a U99C splice donor mutation (red asterisk) in 
the L1.3 5’UTR; pPLSAmLUC contains an A620C splice acceptor mutation (blue asterisk) 
in the L1.3 5’UTR. The relative positions of complementary riboprobes used in the 
Northern blot experiments (ribonucleotides 1-100 (purple line), ribonucleotides 103-330 
(red line), and the 3’ end of the luciferase gene (blue line)) are indicated below the 
schematic. B) Representative northern blots: The black arrowhead indicates the 
predicted size of full-length L1/luciferase RNA (~2.7 kb). Construct names are indicated 
above the gel lanes; UTF=untransfected HeLa-JVM cells. The probe used in the 
northern blot experiment is indicated below the autoradiograph. Actin served as an RNA 
loading control (2.1 kb). Molecular weight standards using Millenium™ RNA Markers 
(ThermoFisher Scientific) (kb) are indicated to the left of the autoradiograph panels. C) 
Results from the luciferase assays: The x-axis indicates the name of the luciferase 
expression plasmid. The y-axis indicates the relative firefly luciferase units normalized 
to a co-transfected Renilla luciferase control. These data represent the averages of 
three biological replicates. Each biological replicate contained six technical replicates. 
Error bars indicate the standard deviation.  P-values were determined using a Student’s 
one-tailed t-test. D) Results from RT-PCR Assays: Top: the relative positions of the 
oligonucleotide primers used to reverse transcribe (REV-LUC) and then amplify (FWD-
5’UTR and REV-LUC) the L1/firefly luciferase cDNA products. Middle: a 1.2% agarose 
gel depicting the results from a representative qualitative RT-PCR experiment. DNA 
size markers (1 kb Plus DNA Ladder (Life Technologies)) are shown at the right and left 
of the gel. Construct names are indicated above the gel; UTF=untransfected HeLa-JVM 
cells, H20=water control. The inset to the right of the gel indicates the major (* and #) 
and minor (+) cDNA products detected in the experiments. Bottom: a 1.2% agarose gel 
depicting the results from a representative experiment conducted without the addition of 
reverse transcriptase. DNA from pPL97/622LUC served as a positive control for PCR 
amplification. The final lane contains reverse transcriptase but no mRNA (-mRNA). RT-
PCR assays were conducted at least 3 independent times.  
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Figure 2.2: Intra-5’UTR splicing drastically reduces L1 promoter activity. 
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Figure 2.3: ORF1p expression from intra-5’UTR and 5’UTR/ORF1 SpIREs. A) 
Schematics of the engineered L1 constructs: The L1 5’ and 3’ UTRs (grey rectangles), 
ORF1 (yellow rectangle), and ORF2 (blue rectangle) are indicated in the cartoon. The 
CMV promoter (white arrowhead, left of 5’UTR), mneoI retrotransposition indicator 
cassette (green rectangle=neo gene sequences; black “v” line=intron), and relative 
positions of the SpIRE97/622 and SpIRE97/976 deletions (red triangles) are indicated in the 
figure. B) Representative ORF1p western blots: Molecular weight standards (Precision 
Plus Protein™ Kaleidoscope™(Bio-Rad)) are indicated (kDa) to the left of the gel. The 
black arrowhead indicates the predicted size of full-length ORF1p (~40 kD). Construct 
names are indicated above the gel; UTF=untransfected cells. The antibodies used in the 
western blot experiments are indicated to the right of the gel.  The eIF3 (110 kDa) 
western blot served as a lysate loading control. Western blots were performed three 
times yielding similar results. C) Schematic of ORF1 and representative western blots 
from SpIRE97/976: Top: the relative positions of the splice acceptor sequence at 
nucleotide 976 (SA, green), the canonical ORF1 initiator methionine (AUG, black, 37 
kDa), the two in-frame putative initiator methionine codons (AUG, red, 33 kDa; AUG, 
blue, 27 kDa), and the N- and C-terminal epitopes recognized by the ORF1p antibody 
(Ab) are indicated in the figure. Bottom: Molecular weight standards (Precision Plus 
Protein™ Kaleidoscope™(Bio-Rad)) are indicated (kDa) to the left of the gels. The 
predicted sizes of full-length ORF1p (black arrowhead), and the N-terminal truncated 
ORF1p variants (orange and blue arrows, respectively) are highlighted on the gel. 
Construct names are indicated above the gel; pCEP/GFP=negative control. The 
antibodies used in the western blot experiments are indicated to the left (α-N-ORF1p) 
and right (α-C-ORF1p) of the gel images, respectively.  The eIF3 (110 kDa) western 
blots served as lysate loading controls. The unlabeled band at ~25 kDa in the α-C-
ORF1p experiment is a cross-reacting product. Western blots were performed three 
times yielding similar results.  
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Figure 2.3: ORF1p expression from intra-5’UTR and 5’UTR/ORF1 SpIREs. 
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Figure 2.4: Intra-5’UTR and 5’UTR/ORF1 SpIREs are retrotransposition-defective. 
A) Results from the SpIRE97/622 retrotransposition assay: The x-axis indicates the 
construct names. The y-axis indicates the relative retrotransposition efficiency (%). The 
CMV promoter either augments L1 expression (+CMV, black bars) or is absent from the 
L1 expression construct (ΔCMV, gray bars). The relative retrotransposition efficiencies 
are normalized to pJM101/L1.3 (set at 100%). The pJM105/L1.3 plasmid served as a 
negative control. The images and data are from one representative experiment. Error 
bars represent the standard deviations of technical triplicates for the depicted assay. 
Each assay was repeated three times yielding similar results. B) Results from the 
SpIRE97/976 retrotransposition assay: The x-axis indicates the construct names. The y-
axis indicates the relative retrotransposition efficiency (%). A CMV promoter augments 
L1 expression (+CMV, black bars). The relative retrotransposition efficiencies are 
normalized to pJM101/L1.3 (set at 100%). The pJM105/L1.3 plasmid served as a 
negative control. The images and data are from one representative experiment. Error 
bars represent the standard deviations of technical triplicates for the depicted assay. 
Each assay was repeated three times yielding similar results. C) Results from the 
SpIRE97/976 trans-complementation assay: The x-axis indicates the “reporter” (top text) 
and the “driver” (bottom text) construct names. The y-axis indicates the relative trans-
complementation efficiency (%). The results of each assay were normalized to the 
pPL97-976/L1.3 “reporter” plasmid + pJBM561 “driver plasmid” co-transfection 
experiment, which was set at 100%. The image at the bottom right hand side of the 
figure represents the efficiency of pJM101/L1.3 retrotransposition in cis. The pPL97-
976/L1.3 “reporter” plasmid + pCEP4 “driver plasmid” co-transfection experiment served 
as a negative control. The images and data are from one representative experiment.  
Each assay was repeated four times.  Error bars represent standard deviations of 
technical triplicates for the depicted experiment. 
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Figure 2.4: Intra-5’UTR and 5’UTR/ORF1 SpIREs are retrotransposition-defective. 
A.
B.
C.
%
 R
et
ro
tr
an
sp
os
iti
on
%
 R
et
ro
tr
an
sp
os
iti
on
0 
20 
40
60 
80 
100 
120 
pPL97-976/L1.3
+
pJBM561
pPL97-976/L1.3
+
pJM101NN
pPL97-976/L1.3
+
pJM105NN
pPL97-976/L1.3
+
pO2NN
pPL97-976/L1.3
+
pCEP4
JM101/L1.3
(cis-preference)
%
 R
et
ro
tr
an
sp
os
iti
on
0 
20 
40 
60 
80 
100 
120 
pJM101/L1.3 pJM102/L1.3 pPL97/622/L1.3 pJM105/L1.3 
+CMV
-CMV
0 
20 
40 
60 
80 
100 
120 
pJM101/L1.3 pPL97/976/L1.3 pJM105/L1.3 
+CMV
pPL97/ /L1.3 
	   109	  
Figure 2.5: A working model for how SpIREs are generated. A) Canonical L1 
Retrotransposition: An L1 is transcribed from a genomic location (red chromosome). 
Translation of the mRNA (multi-colored wavy line) occurs in the cytoplasm and ORF1p 
(yellow circles) and ORF2p (blue oval) bind back onto their respective mRNA (cis-
preference) to form an RNP. The L1 RNP then enters the nucleus and a de novo L1 
insertion occurs at a new genomic location (green chromosome) by TPRT. This 
insertion, if full-length, could act as a source element, giving rise to new insertions 
(green arrow) at a new genomic location (grey chromosome). B) Retrotransposition of 
intra-5’UTR spliced L1 isoform: A full-length L1 element is transcribed from its genomic 
location (red chromosome) and undergoes intra-5’UTR splicing. Translation of the 
mRNA (multi-colored wavy line) occurs in the cytoplasm and ORF1p (yellow circles) and 
ORF2p (blue oval) bind back onto their respective mRNA (cis-preference) to form an 
RNP. The L1 RNP then enters the nucleus and L1 RNAs subject to intra-5’UTR splicing 
can undergo a single round of retrotransposition (green chromosome) by TPRT. 
However, since the intra-5’UTR splicing event deletes sequences required for L1 
promoter activity, the resultant insertion is unlikely to undergo subsequent rounds of 
retrotransposition in future generations (dashed green arrow). C.) Retrotransposition of 
5’UTR/ORF1 spliced L1 isoform: An L1 is transcribed from its genomic location (red 
chromosome) and is subject to 5’UTR/ORF1 splicing. Translation of the mRNA (multi-
colored wavy line) occurs in the cytoplasm; however, since translation occurs at 
downstream AUG codons, ORF1p (yellow circles) is non-functional, the 5’UTR/ORF1 
spliced L1 mRNA relies on a wild type source of ORF1p to be supplied from another L1 
in trans. In the rare instance that trans-complementation occurs (dotted arrow), it is 
highly unlikely that the resultant SpIRE will generate RNAs that can undergo 
retrotransposition in future generations (dashed thin green arrow). 
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Figure 2.5: A working model for how SpIREs are generated. 
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Figure 2.6: SpIREs in the human genome reference sequence (Supporting Figure 
2.1). A) SpIREs are present in the HGR at varying copy numbers: The class of SpIRE 
(SpIRE97/622, SpIRE97/790 and SpIRE97/976) is indicated at the top of each table.  Column 1 
indicates the L1 subfamily. Column 2 indicates the number of SpIREs present in each 
subfamily.  Column 3 indicates the number of full-length L1s in each subfamily. Column 
4 indicates the percentage (%) of SpIREs in each subfamily compared to full-length L1s. 
B) Evolutionary conservation of L1 splice sites: The panels shows the conservation of 
the splice donor site in the L1 5’ UTR (column 1, SD, red box), as well as splice 
acceptor sites in the L1 5’UTR (columns 2 and 3, SA, green box) and ORF1 (column 4, 
SA, green box). Consensus sequences and alignment of those sequences that span the 
L1PA1(L1Hs)-L1PA16 subfamilies were downloaded (Khan et al. 2006) and manually 
inspected to determine conservation of splicing sequences (See methods).  
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Figure 2.6: SpIREs in the human genome reference sequence (Supporting Figure 
2.1). 
A.
B. SA-5’UTR621/622 SA-ORF1974/975SD-5’UTR98/99 SA-5’UTR788/789
SpIRE97/790
Family # Spliced Full Length Spliced/FL 
( %) 
1 296 0.33 
PA2 3 1088 0.27 
PA1(L1Hs) 
Family # Spliced Full Length Spliced/FL 
(%) 
0 296 0 
PA2 2 1088 0.18 
PA3 4 1548 0.26 
PA4 5 1452 0.34 
SpIRE97/976
PA1(L1Hs) 
Family # Spliced Full Length Spliced/FL 
(%) 
PA1(L1Hs) 6 296 2.0 
PA2 10 1088 0.9 
PA3 53 1548 3.4 
PA4 22 1452 1.6 
PA5 17 1136 1.5 
PA6 1 1089 0.1 
SpIRE97/622
PA2 - PA3  5
PA4 - PA6 2 
* 
* 
* 
* 
	   113	  
Figure 2.7: Intra-5’UTR splicing drastically reduces L1 promoter activity 
(Supporting Figure 2.2). A longer exposure of the northern blots depicted in Figure 2B. 
Molecular weight standards (kb) are indicated to the left of the autoradiograph panels. 
The predicted sizes of the full-length 2.7 kb L1/Luciferase RNA from pPLWTLUC and 
pPLSAmLUC (black arrowhead) and 2.2 kb L1/Luciferase RNA from pPL97-622LUC (red 
arrowhead) are indicated at the right side of the autoradiographs. Construct names are 
indicated above the gel; UTF=untransfected cells. The probe used in the northern blot 
experiment is indicated below the autoradiograph. 
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Figure 2.7: Intra-5’UTR splicing drastically reduces L1 promoter activity 
(Supporting Figure 2.2): 
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Figure 2.8: ORF1p expression from 5’UTR/ORF1 SpIREs (Supporting Figure 2.3). 
A) Amino terminal truncated ORF1 proteins are detected in RNPs preparations: 
Molecular weight standards (Precision Plus Protein™ Kaleidoscope™(Bio-Rad)) are 
indicated (kDa) to the left of the gels. The predicted sizes of full-length ORF1p (black 
arrowhead), and the N-terminal truncated ORF1p variants (orange and blue arrows) are 
highlighted in the gel. Construct names are indicated above the gel; 
pCEP/GFP=negative control. The antibodies used in the western blot experiments are 
indicated to the left (α-N-ORF1p) and right (α-C-ORF1p) of the gel images.  The eIF3 
(110 kDa) western blots served as loading controls. Western blots were performed three 
times yielding similar results. B) Amino terminal truncated ORF1 proteins are detected 
in WCL and RNPs preparations using an antibody to a carboxyl-terminal T7gene10 
epitope tag: Molecular weight standards (Precision Plus Protein™ Kaleidoscope™ (Bio-
Rad)) are indicated by the “M” lanes (kDa). The predicted sizes of full-length ORF1p 
(black arrowhead), and the N-terminal truncated ORF1p variants (orange and blue 
arrows) detected by the anti-T7 gene10 antibody (α-T7) in WCLs (left) and RNP 
preparations (right) are highlighted on the gel. Construct names are indicated above the 
gel. The eIF3 (110 kDa) western blots served as loading controls. The untagged 
pJM101/L1.3 and pCEP/GFP samples served as negative controls. The bands at ~30 
and ~45 kDa indicates a cross-reacting protein. Western blots were performed three 
times yielding similar results.   
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Figure 2.8: ORF1p expression from 5’UTR/ORF1 SpIREs (Supporting Figure 2.3). 
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Figure 2.9: Sequence changes within the L1 5’UTR may alter L1 RNA splicing 
profiles. A) Schematic of the L1PA2 and L1PA3 5’UTRs: Top, the relative positions of 
the splice donor (SD, red lettering), splice acceptor (SA, green lettering), and putative 
branch point sequence (ACCTCAC, black lettering) in the PA2 5’UTR that led to the 
formation of the SpIRE97/790 are indicated in the schematic. Superscript numbers 
indicate the first and last nucleotide of the indicated sequence. Note nucleotide 
positions in the L1PA2 and L1PA3 differ slightly from those in L1PA1. Superscript 
numbers indicate the position of the splice sites in that subfamily. Numbers below the 
branch point (underlined A) (95.75) and SA (84.95) indicate the predicted strength of 
those sequences for utilization in a splicing reaction as determined using Human 
Splicing Finder v.3.0 (http://www.umd.be/HSF3/) (Desmet et al. 2009). Bottom, the 
relative positions of the splice donor (SD, red lettering), splice acceptor (SA, black 
lettering), and putative branch point sequence (ACCTCAC, black lettering) in the L1PA3 
5’UTR are indicated in the schematic. Superscript numbers indicate the first and last 
nucleotide of the indicated sequence. Numbers above the branch point (95.75) and SA 
(79.66) indicate the predicted strength of those sequences for utilization in a splicing 
reaction as determined using Human Splicing Finder v.3.0 (http://www.umd.be/HSF3/) 
(Desmet et al. 2009). Notably, the PA3 5’UTR contains a 129 bp insertion that was lost 
in the transition from L1PA3 to L1PA2 subfamilies (gray triangle).  The deletion results 
in moving the SA closer to the branch point in the PA2 5’UTR, leading to a higher 
predicted strength score (84.95 in PA2 compared to 79.66 in PA3) as determined using 
the Human Splicing Finder v.3.0 program (see above). B) Table of SD, SA, and branch 
point sequence scores. Consensus value scores were determined using Human 
Splicing Finder v.3.0 (http://www.umd.be/HSF3/)(Desmet et al. 2009). The score of the 
SD does not change from L1PA3 to L1PA1 as its sequence is identical and its position 
changes nominally. In contrast, the consensus value score of the SA increases from 
L1PA3 (79.66) to L1PA2 (84.95) (see methods). The table also shows the score of the 
strongest potential branch within 50 bp upstream of the SA (see methods).  
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Figure 2.9: Sequence changes within the L1 5’UTR may alter L1 RNA splicing 
profiles. 
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Table 2.1: Additional information for each SpIRE. Column 1 indicates the clone 
number. Column 2 indicates the L1 subfamily. Column 3 indicates the chromosomal 
location. Column 4 indicates the length (bp). Column 5 indicates whether the insertion 
resides within a gene and the name of that gene. Column 6 indicates the transcriptional 
orientation of the insertion within the gene (same orientation=”same”, opposite 
orientation=”Opp.”. Column 7 indicates the starting location of the insertion in the HGR. 
Column 8 indicates the calculated L1 EN cleavage sequence of the insertion. Column 9 
indicates the calculated size of the target site duplication. Column 10 indicates whether 
the insertion contains an L1-mediated sequence transduction. Column 11 indicates 
other structural features associated with the insertion. Column 12 indicates additional 
major deletions within the SpIRE. Column 13 described the type of deletion.  
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Table 2.1: Additional information for each SpIRE. 
N
am
e - Clone num
ber
L1 Subfam
ily
Chrom
osom
e
Length
G
ene
O
rientation
Location Start
Consensus Site
TSD
 Length
Transduction
Extra
Additional deletions
Type of deletion
SpIRE(97/622)-9
PA1(L1H
s)
1
3398
104464623
TATT/G
7
Yes
3' 391 untem
p
3' truncation (3925-end)
In transposon
SpIRE(97/622)-38
PA1(L1H
s)
4
5653
167187141
AG
TA/A
13
N
o
5' 3 m
ism
atch
SpIRE(97/622)-52
PA1(L1H
s)
6
2398
27911128
TTTA/A
16
N
o
5' 2 m
ism
atch, 1 m
issing
del (1390-3692; 5225-end)
Inversion/deletion
SpIRE(97/622)-62
PA1(L1H
s)
7
3822
62521121
N
O
N
E
N
O
N
E
N
o
3' truncation (4349-end)
3' truncation
SpIRE(97/622)-90
PA1(L1H
s)
12
5484
10502541
CTTT/C
18
N
o
5' 1 m
ism
atch
SpIRE(97/622)-104
PA1(L1H
s)
15
5507
UACA
O
pp.
71022057
TTTT/C
12
N
o
5' 2 m
ism
atch
SpIRE(97/622)-6
PA2
1
5505
206506662
CATT/C
16
N
o
SpIRE(97/622)-28
PA2
3
5344
SYN
2
O
pp.
12074791
AATT/C
14
N
o
5' one untem
p
SpIRE(97/622)-35
PA2
4
5500
RAP1G
D
S
Sam
e
99241583
G
AAT/C
11
N
o
SpIRE(97/622)-64
PA2
7
5500
D
G
KB
O
pp.
14744105
TTTT/G
32
N
o
 5' one m
ism
atch
SpIRE(97/622)-70
PA2
8
5500
C8orf34
Sam
e
69274647
TTTC/C
13
N
o
5' 20 untem
p
SpIRE(97/622)-72
PA2
8
5141
129724828
CTTT/G
7
Yes
 5' 130 untem
p
del(4381-4751)
Internal deletion
SpIRE(97/622)-75
PA2
10
5486
7105433
CTTT/G
16
N
o
5' 2 untem
p
SpIRE(97/622)-78
PA2
10
5505
7179414
TTTT/A
17
N
o
5' 23 untem
p
SpIRE(97/622)-79
PA2
10
5501
44983702
ATTT/A
15
N
o
SpIRE(97/622)-105
PA2
15
5509
51465698
TATT/A
7
N
o
SpIRE(97/622)-1
PA3
X
5507
100795847
TCCT/A
19
N
o
5' one untem
p
SpIRE(97/622)-2
PA3
X
5514
68683795
ATTT/C
15
N
o
5' one untem
p
SpIRE(97/622)-4
PA3
X
5500
112689223
TTTA/A
16
N
o
SpIRE(97/622)-8
PA3
1
5613
C1orf146
O
pp.
92703286
TATA/T
11
N
o
SpIRE(97/622)-10
PA3
1
5644
101148126
TTTT/G
14
N
o
 5'  one m
ism
atch
SpIRE(97/622)-11
PA3
1
5494
RH
O
U
Sam
e
228843077
TTTA/T
16
N
o
5' 12 untem
p
SpIRE(97/622)-12
PA3
1
5497
BC054887
Sam
e
71681513
TCTT/A
14
N
o
SpIRE(97/622)-13
PA3
1
5676
37673543
TCTT/A
13
Yes
3' 705 untem
p
SpIRE(97/622)-14
PA3
1
5496
81411743
CTTT/A
16
N
o
5' 4 untem
p
SpIRE(97/622)-18
PA3
2
5499
193902734
TTCA/G
17
N
o
SpIRE(97/622)-19
PA3
2
5482
162392723
TTTT/A
17
N
o
 5' one m
ism
atch
SpIRE(97/622)-20
PA3
2
5655
1321311384
TTTA/A
13
N
o
5' A untem
p
SpIRE(97/622)-23
PA3
2
5628
LRRTM
4
O
pp
77132008
TTTC/A
17
N
o
SpIRE(97/622)-25
PA3
2
5503
97106840
TCTT/A
15
N
o
 5 one' m
ism
atch, 3 untem
p
SpIRE(97/622)-27
PA3
3
5514
IQ
CJ/SCH
O
pp.
158808219
TTCT/G
15
N
o
5' 4 untem
p 
SpIRE(97/622)-30
PA3
3
5636
135541350
TTTC/T
14
N
o
5' 8 untem
p
SpIRE(97/622)-34
PA3
3
5501
TH
RB
O
pp. 
24321589
G
CTT/A
13
N
o
5' one  m
ism
atch
SpIRE(97/622)-36
PA3
4
5498
CXCL13
O
pp.
78440573
CTTT/G
18
N
o
5' 2 m
ism
atch
SpIRE(97/622)-39
PA3
4
5498
116093532
CTTT/C
11
N
o
5' 6 untem
p, one m
ism
atch
SpIRE(97/622)-42
PA3
4
5628
128781215
CTTT/C
7
N
o
5' one m
ism
atch
SpIRE(97/622)-43
PA3
5
5511
132521914
ATTT/C
17
N
o
5' 2 m
ism
atch, 3 untem
p, 1 
SpIRE(97/622)-44
PA3
5
5491
AN
KH
D
1
Sam
e
139895037
TTTT/C
9
N
o
SpIRE(97/622)-45
PA3
5
5527
8159176
TTAA/C
14
Yes
5' 3 m
ism
atch, 3' 1036 untem
p
SpIRE(97/622)-46
PA3
5
5504
H
TR4
O
pp.
147989751
CTTT/C
15
N
o
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Table 2.1: Additional information for each SpIRE. 
N
am
e - Clone num
ber
L1 Subfam
ily
Chrom
osom
e
Length
G
ene
O
rientation
Location Start
Consensus Site
TSD
 Length
Transduction
Extra
Additional deletions
Type of deletion
SpIRE(97/622)-47
PA3
5
5444
108962938
TTTA/G
15
N
o
5' 2 m
ism
atch, 2 untem
p
SpIRE(97/622)-48
PA3
5
5463
U
28131
Sam
e
104053455
TCTT/A
12
N
o
SpIRE(97/622)-53
PA3
6
5483
77455377
TAAA/G
9
N
o
5' 1 m
ism
atch
SpIRE(97/622)-54
PA3
6
5500
115330140
TTCT/A
18
N
o
5' 2 m
ism
atch, 8 untem
p
SpIRE(97/622)-56
PA3
6
5431
83342492
ATTT/A
14
N
o
5' 2 m
ism
atch, 1 untem
p
SpIRE(97/622)-57
PA3
6
5382
81530481
TTTT/A
13
N
o
5' 3 untem
p
SpIRE(97/622)-58
PA3
6
5512
AF086303
Sam
e
75194248
AATT/A
17
N
o
5' 2 m
issing
SpIRE(97/622)-59
PA3
6
5638
SLC35F1
Sam
e
118317486
TTTA/G
16
N
o
5' 2 m
ism
atch, 3' 17 untem
p
SpIRE(97/622)-61
PA3
7
5503
86867995
CTCT/C
7
N
o
5' 1 m
ism
atch, 6 untem
p
SpIRE(97/622)-63
PA3
7
5479
89531713
TCTT/A
14
N
o
SpIRE(97/622)-66
PA3
7
5628
83378686
N
O
N
E
N
O
N
E
N
o
SpIRE(97/622)-71
PA3
8
5494
CSM
D
1
Sam
e
3133943
TCTT/A
14
N
o
5' 4 untem
p
SpIRE(97/622)-73
PA3
8
5525
130336552
TTTT/A
15
N
o
SpIRE(97/622)-76
PA3
10
5496
55557605
TTTC/G
10
N
o
SpIRE(97/622)-77
PA3
10
5528
11365205
TCAT/C
18
N
o
5' 2 m
ism
atch
SpIRE(97/622)-82
PA3
10
5502
50454181
TTTT/A
15
N
o
5' 1 untem
p
SpIRE(97/622)-83
PA3
11
5532
13820879
TTTT/A
11
N
o
SpIRE(97/622)-84
PA3
11
5499
100523754
CTTT/C
10
N
o
5' 1 m
ism
atch, 1 untem
p
SpIRE(97/622)-85
PA3
11
5503
29437673
TTTT/A
10
N
o
SpIRE(97/622)-89
PA3
12
5487
61160740
TTTT/A
9
N
o
5' 1 m
ism
atch, 2 untem
p
SpIRE(97/622)-98
PA3
13
5621
47952791
TTTT/A
17
N
o
5' 3 m
ism
atch, 10 untem
p
SpIRE(97/622)-100
PA3
14
5610
66327000
ACCC/C
8
Yes
5' one m
ism
atch, 3' 199 untem
p
SpIRE(97/622)-106
PA3
15
5618
BC04142
O
pp .
72090979
TG
TT/A
14
N
o
5' 1 m
ism
atch, 2 untem
p
SpIRE(97/622)-107
PA3
15
5600
Pcak1
O
pp.
77553007
TTTT/C
7
N
o
SpIRE(97/622)-108
PA3
16
5581
63181610
TTTT/A
7
Yes
5' 560 untem
p
SpIRE(97/622)-111
PA3
18
5484
47302933
TATT/C
7
N
o
5' 9 untem
p
SpIRE(97/622)-114
PA3
20
5622
TM
EM
90B
O
pp.
2453871
CTTT/A
13
N
o
SpIRE(97/622)-115
PA3
20
5573
12643330
TTTT/C
15
N
o
5' 1 untem
p
SpIRE(97/622)-116
PA3
21
5489
18535862
AAAT/T
13
N
o
5' 7 untem
p
SpIRE(97/622)-17
PA4
1
5624
197798790
TTTT/G
16
N
o
5' 2 m
ism
atch
SpIRE(97/622)-21
PA4
2
4100
FSH
R
O
pp.
49309153
TTTA/A
16
N
o
5' 1 m
ism
atch, 1 m
issing
 del (4025-5465)
Internal deletion
SpIRE(97/622)-29
PA4
3
5588
U
BE2E2
O
pp. 
23343396
TCTT/C
12
N
o
5' 1 m
ism
atch, 4 untem
p
SpIRE(97/622)-32
PA4
3
5626
43986936
TTTT/A
10
N
o
5' 1 m
ism
atch, 5 untem
p
SpIRE(97/622)-33
PA4
3
5619
24126062
TCTT/A
17
N
o
5' 1 m
ism
atch
SpIRE(97/622)-37
PA4
4
5576
53371143
CCAA/A
9
Yes
5' 1 m
ism
atch, 3' 61 untem
p
SpIRE(97/622)-40
PA4
4
5629
64819421
N
O
N
E
N
O
N
E
N
o
SpIRE(97/622)-49
PA4
5
5627
RN
U
5E
Sam
e
80572990
TTTT/C
13
N
o
5' 3 m
ism
atch
SpIRE(97/622)-60
PA4
6
5639
SM
AP1
Sam
e
71492534
TTCC/A
8
N
o
5' 8 untem
p, 3' 12 untem
p
SpIRE(97/622)-67
PA4
7
5612
140414028
TTTT/G
10
N
o
5' 1 m
ism
atch, 16 untem
p
SpIRE(97/622)-68
PA4
7
5618
RELN
O
pp.
103382253
AATA/T
6
N
o
5' 3 untep, 3' 3 untem
p
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Table 2.1: Additional information for each SpIRE. 
Nam
e - Clone num
ber
L1 Subfam
ily
Chrom
osom
e
Length
Gene
Orientation
Location Start
Consensus Site
TSD Length
Transduction
Extra
Additional deletions
Type of deletion
SpIRE(97/622)-74
PA4
9
5585
129755879
TGTA/A
15
Yes
5' 1 m
issing, 1 m
ism
atch, 20 untem
p, 3' 250 untem
p
SpIRE(97/622)-80
PA4
10
5614
36302656
TCTT/A
15
No
5' 2 m
ism
atch, 5 untem
p
SpIRE(97/622)-81
PA4
10
5612
ITGA8
Sam
e
15712129
TCTT/A
11
No
5' 6 untem
p
SpIRE(97/622)-86
PA4
11
5621
48588752
TATT/G
11
No
5' 1 untem
p
SpIRE(97/622)-88
PA4
11
5628
87662913
CTGG/C
6
Yes
3' 200 untem
p
SpIRE(97/622)-93
PA4
12
5625
23674212
TTTT/A
16
No
SpIRE(97/622)-94
PA4
12
5644
RAb3IP
Opp
70204301
TTTT/G
14
No
5' 13 untem
p
SpIRE(97/622)-95
PA4
12
5631
11467678
TGTA/A
8
No
5' 4 untem
p
SpIRE(97/622)-99
PA4
13
5590
82039335
TTTT/A
16
No
5' 8 untem
p
SpIRE(97/622)-102
PA4
14
5577
44945977
TTTT/C
16
No
5' 3 m
ism
atch
SpIRE(97/622)-112
PA4
18
5641
44508670
TTTT/C
14
No
5' 3 untem
p
SpIRE(97/622)-3
PA5
X
5668
SPANX
Opp.
140536398
GTTT/C
11
Yes
5' 3 untem
p, 2 m
ism
atch, 3' 150 untem
p
SpIRE(97/622)-5
PA5
X
5624
C1orf146
Opp.
151493710
TTTC/A
14
No
SpIRE(97/622)-15
PA5
1
1641
HHAT
Opp.
210789405
TTTT/A
10
No
5' 5 untem
p
3' deletion (1294-end)
In transposon
SpIRE(97/622)-16
PA5
1
5622
114730873
TTTG/T
18
Yes
5' 1 untem
p, 2 m
ism
atch, 3' 112 untem
p
SpIRE(97/622)-22
PA5
2
5630
48285651
CTTT/G
23
No
5' 1 untm
p, 7 m
ism
atch
SpIRE(97/622)-24
PA5
2
5602
LRRTM
4
Opp.
77363150
CTTT/A
12
No
5' 8 untem
p, 3 m
ism
atch
SpIRE(97/622)-31
PA5
3
5607
57592523
CTTT/A
13
No
5' 13 untem
p
SpIRE(97/622)-41
PA5
4
5620
M
ir5684
Sam
e
165570450
GATA/A
15
Yes
5' 1 untem
p, 3 m
ism
atch, 3' 214 untem
p
SpIRE(97/622)-51
PA5
6
5488
30215660
ATTT/G
30
No
5' 2 untem
p, 9 m
ism
atch, 4 m
issing
SpIRE(97/622)-69
PA5
7
5621
152819737
TTTC/T
12
No
5' 1 untem
p
SpIRE(97/622)-92
PA5
12
5633
55939783
TTTT/A
15
No
5' 5 untem
p
SpIRE(97/622)-96
PA5
12
5475
4450452
TTGT/G
20
No
5' 7 m
ism
atch, 17 untem
p
SpIRE(97/622)-97
PA5
12
5618
108116424
TTTT/A
40
No
5' 4 m
ism
atch, 7 m
issing
SpIRE(97/622)-101
PA5
14
5638
50539565
TTTC/A
14
No
5' 22 untem
p
SpIRE(97/622)-103
PA5
14
5577
KIAA0391
Opp.
35649534
TCTT/A
14
No
5' 4 untem
p, 1 m
ism
atch
SpIRE(97/622)-109
PA5
17
5639
ACCN1
Sam
e
31391824
CTTT/G
17
No
5' 12 untem
p, 1 m
ism
atch
SpIRE(97/622)-110
PA5
17
5589
15258532
GGTT/A
7
Yes
5' 11 untem
p, 3' 239 untem
p
SpIRE(97/622)-50
PA6
5
5607
125422191
TTTT/G
15
No
5' 2 untem
p, 2 m
ism
atch
SpIRE(97/622)-55
PA2-3
6
2765
LACE1
Opp.
108712189
NONE
NONE
No
3' truncation (3309-end)
3' truncation
SpIRE(97/622)-7
PA2-3
7
5509
SRGAP2P
Opp.
148086250
NONE
NONE
No
SpIRE(97/622)-91
PA2-3
12
4125
77658384
NONE
NONE
No
del (4693-end)
3' truncation
SpIRE(97/622)-87
PA4-6
11
3236
ANO3
Opp. 
26314602
NONE
NONE
No
3'truncation (3634-end)
3' truncation
SpIRE(97/622)-113
PA4-6
19
2282
35348802
NONE
NONE
No
3' deletion (2842-end)
In transposon
SpIRE(97/622)-65
PA2-3
7
1015
CNTNAP2
Opp.
148086130
CTTT/A
18
No
del (1111-5730)
internal deletion
SpIRE(97/622)-26
PA2-3
2
240
21071818
NONE
NONE
No
3' truncation (783-end)
In transposon
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Table 2.1: Additional information for each SpIRE. 
N
am
e - Clone N
um
ber
L1 Subfam
ily
Chrom
osom
e
Length
G
ene
O
rientation
Location Start
Concensus Site
TSD
 Length
Transduction
Extra
Additional deletions
Type of deletion
SpIRE(97-790)-1
PA2
1
5342
40831200
TTCT/A
18
N
O
5' 8 untem
p
SpIRE(97-790)-2
PA2
9
5335
M
IR31H
G
O
pp.
21536613
CCTT/G
12
N
O
SpIRE(97-790)-3
PA1
3
5331
CO
L6A6
Sam
e
130347579
TCTT/A
11
N
O
5' 1 untem
p
SpIRE(97-790)-4
PA2
11
5334
RN
F169
O
pp.
74473673
TTTA/A
14
N
O
5' 1 m
ism
atch
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Table 2.1: Additional information for each SpIRE. 
N
am
e-Clone N
um
ber
L1 Subfam
ily
Chrom
osom
e
Length
G
ene
O
rientation
Location Start
Consensus Site
TSD
Transduction
extra
Additional deletions
Type of deletion
SpIRE(97/976)-1
PA2
14
5157
56460057
G
CCT/G
27
N
o
5' 1 untem
p
SpIRE(97/976)-2
PA2
3
5146
CAD
PS 
Sam
e
62838102
CTTT/G
14
N
o
5' 1 untem
p
SpIRE(97/976)-3
PA3
12
5181
28161108
AAAT/A
18
N
o
5' 2 untem
p, 2 m
ism
atch
SpIRE(97/976)-4
PA3
1
5136
157315230
TTTT/A
32
N
o
5' 8 m
ism
atch
SpIRE(97/976)-5
PA3
6
5123
85079405
TTTT/G
26
N
o
5' 3 m
ism
atch
SpIRE(97/976)-6
PA3
6
5161
FIG
4 
O
pp.
110078291
TTTT/A
18
N
o
5' 1 m
ism
atch
SpIRE(97/976)-7
PA4-PA6
4
4058
150049502
TTTC/A
8
N
o
5' 1 m
ism
atch
SpIRE(97/976)-8
PA4
X
5232
KLH
L13
O
pp.
117227851
TTTT/G
16
N
o
5' 1 m
ism
atch, 5 untem
p
SpIRE(97/976)-9
PA4
12
5101
22499733
TTAT/C
19
N
o
5' 1 m
issing, 3 untem
p
SpIRE(97/976)-10
PA4
2
5064
U
N
C13C
Sam
e
162385954
TCTT/A
11
N
o
SpIRE(97/976)-11
PA4
15
3229
54347959
TCTT/G
14
N
o
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Chapter 3 
 
A Genome Wide Screen to Identify Factors Inhibiting Expression of 
Retrotransposed LINE-1 Elements in Embryonic Carcinoma Cells 
 
 
Experiments and results discussed in this chapter were performed in collaboration with 
Dr. Jacob Kitzman and Mr. Trenton Frisbie. Mr. Trenton Frisbie will continue this line of 
inquiry and investigation. 
 
Justification for Study 
Long INterspersed Element-1 (LINE-1 or L1) is an endogenous non-LTR 
retrotransposon that comprises ~17% of the human genome (Lander et al., 2001). L1s 
move in the genome via a copy-paste mechanism called retrotransposition (Boeke et 
al., 1985). The mechanism of L1 genomic integration is termed target-site primed 
reverse transcription (TPRT) (Luan et al., 1993; Feng et al., 1996; Cost et al., 2002; 
Kulpa and Moran 2006). Importantly, TPRT is a mechanism unique to non-LTR 
retrotransposition, and differs from integration mechanisms used by LTR 
retrotransposons, DNA transposons, and retroviruses. L1s have been demonstrated to 
retrotranspose in various human cell lines, as well as in certain somatic cells, germ line 
cells, and in early embryonic development (Evrony et al., 2010; Upton et al., 2015; 
Muotri et al., 2005; Garcia-Perez et al., 2007b; Ostertag et al., 2002). Previous 
experimentation in human embryonic carcinoma-derived cells (hECs) revealed that 
engineered L1s (herein referred to as an L1-reporter) successfully retrotranspose into 
hEC genomic DNA (Garcia-Perez et al., 2010). However, either during, or immediately 
after genomic integration, expression of the L1-reporter is silenced in hECs. 
Interestingly, hEC cells treated with histone deacetylase (HDAC) inhibitors rapidly 
reverse L1-reporter silencing (Garcia-Perez et al., 2010). Here, we performed proof-of-
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principle experiments and designed a CRISPR/Cas9 genetic knockout screen in an 
attempt to identify factors that may be involved with L1-reporter silencing.  
Introduction 
 Previous work from our lab demonstrated that a human embryonic carcinoma (hEC) 
cell line (PA-1) permits retrotransposition of an engineered L1 tagged with an enhanced 
green fluorescent protein  (EGFP) retrotransposition indicator cassette (L1-EGFP). 
However, the resultant integrated L1-retro-EGFP is silenced either during or 
immediately after retrotransposition and, as a result, does not express EGFP (Garcia-
Perez et al., 2010). A small number of cells containing L1-retro-EGFP events (<0.3%) 
express EGFP, suggesting that silencing is not absolute in PA-1 cells (Garcia-Perez et 
al., 2010). Notably, treatment of PA-1 cell populations harboring L1-retro-EGFP events 
with pan-histone deacetylase (HDAC) inhibitors rapidly reversed L1-retro-EGFP 
silencing and resulted in a ~20 fold increase of EGFP expressing cells when compared 
untreated PA-1 cells. Thus, these data suggest L1-retro-EGFP is silenced during or 
immediately after integration (Garcia-Perez et al., 2010).  
Isolation of a clonal PA-1 cell line (called pk-5 cells) containing a single, stably 
integrated, full-length, L1-retro-EGFP event faithfully did not express EGFP. Addition of 
HDAC inhibitors to pk-5 cells also reactivated EGFP expression (Garcia-Perez et al., 
2010). Subsequent removal of the HDAC inhibitors from pk-5 cells re-established 
silencing of L1-retro-EGFP. These data suggest the presence of a memory mechanism 
in PA-1 cells that can re-establish L1-retro-EGFP silencing. Thus, evidence suggests 
L1-retro-EGFP silencing is a two-step process that requires: 1) an initiation step that is 
mediated by host factor(s); and 2) a maintenance step that uses the same or an 
additional host factors(s) (Garcia-Perez et al., 2010).  
Additional experiments demonstrated that an EGFP reporter delivered by natural 
or synthetic mouse L1s, or zebrafish L2 retrotransposons were readily silenced in PA-1 
cells (Garcia-Perez et al., 2010). Thus, sequence composition of the retrotransposon 
did not affect silencing.  In contrast, EGFP delivered by HIV or MMLV retroviral vectors 
or by stable transfection were not efficiently silenced in PA-1 cells, although the 
treatment of retroviral-infected cells with HDAC inhibitors resulted in a modest (2-3 fold) 
increase of EGFP expression (Garcia-Perez et al., 2010). These data suggest reporter 
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genes delivered by retrotransposon-mediated TPRT may be specifically recognized and 
targeted for silencing.  
PA-1 cells are diploid, but contain a reciprocal translocation between 
chromosomes 15 and 20 (Garcia-Perez et al., 2010; Sarraf et al., 2005) and 
preferentially differentiate into an ectodermal-like lineage (Garcia-Perez et al., 2010). 
PA-1 cells transfected with L1-EGFP and grown in differentiation media exhibited a ~30 
fold increase in EGFP expressing cells compared to L1-EGFP transfected PA-1 cells 
grown in normal media (Garcia-Perez et al., 2010). Additionally, L1-EGFP transfected 
PA-1 cells grown in differentiation media exhibited a notable increase in EGFP 
expressing cells upon treatment with HDAC inhibitors (Garcia-Perez et al., 2010). 
Together, these data suggest L1-retro-EGFP silencing is more efficient in PA-1 cells 
than in actively differentiating PA-1 cells; however, addition of HDAC inhibitors to 
differentiating cells activates expression from additional L1-retro-EGFP events (Garcia-
Perez et al., 2010). 
Interestingly, differentiation is not sufficient to reactivate previously silenced L1-
retro-EGFP events (Garcia-Perez et al., 2010). Culture of the clonal pk-5 cell line in 
differentiation media resulted in only a minor reactivation of EGFP expressing cells 
(Garcia-Perez et al., 2010). This phenomenon was recapitulated in populations of L1-
retro-EGFP containing PA-1 cells that demonstrated a very low level of L1-retro-EGFP 
reactivation when grown in differentiation media (Garcia-Perez et al., 2010).  
Here, we wanted to further explore L1-retro-EGFP silencing in PA-1 cells. We 
hypothesized that there are additional proteins that participate in L1-retro-EGFP 
silencing. We sought to develop a forward genetic screen that would potentially identify 
candidate genes involved with L1-retro-EGFP silencing.  We employed CRISPR/Cas9 
genome editing technology for this purpose (Barrangou et al., 2007; Ishino et al., 1987; 
Jinek et al., 2012). We used a commercially available platform called Genome wide 
CRISPR Cas9 Knock Out (GeCKOv2) (Shalem et al., 2014). This platform includes a 
lentiviral plasmid (lentiCRISPRv2 or LCv2) containing a single-guide RNA (sgRNA) 
sequence and a human codon-optimized Cas9 protein that can be packaged in a single 
lentivirus (Figure 3.1B) (Shalem et al., 2014). Using this platform we attempted to knock 
out nearly every gene in the PA-1 genome. Following gene knockout we performed 
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retrotransposition assays in knockout cell populations and assed their ability to express 
a neomycin phosphotransferase resistance gene delivered by an engineered L1 
construct (L1-mneoI).  
We determined the efficiency of genome editing over time and found that twenty-
one days after transduction, PA-1 cells were sufficiently edited for use in our 
retrotransposition experiments. Using the same logic as in Garcia-Perez et al., 2010, we 
transfected edited PA-1 cells with pJM101/L1.3. (L1-mneoI). We reasoned that 
knockout of a gene involved in L1-retro-mneoI silencing would permit expression of the 
integrated neomycin phosphotransferase, rendering that cell resistant to the drug G418.  
We observed ~5X more G418 resistant colonies in edited PA-1 cells than in unedited 
PA-1 cells. These data suggest that in some edited PA-1 cells L1-retro-mneoI events 
escape silencing. Edited PA-1 cells resistant to G418 were then collected and inspected 
to determine guide sequence representation. Our preliminary screen uncovered 
potential candidate genes involved in L1-retro-mneoI silencing and we further 
investigated one of those here. 
Results  
PA-1 cells silence an L1-reporter  
 We first sought to verify that a neomycin phosphotransferase resistance gene 
delivered by an engineered L1 construct pJM101/L1.3 (L1-mneoI) is silenced in PA-1 
cells. We employed a transient cell culture-based L1 retrotransposition assay (Moran et 
al., 1996; Wei et al., 2001).  The L1 retrotransposition assay utilizes an episomal, 
engineered L1 expression construct containing a retrotransposition indicator cassette 
within the L1 3’UTR. The retrotransposition indicator cassette consists of an anti-sense 
copy of the neomycin phosphotransferase gene (mneoI) (Freeman et al., 1994; Moran 
et al., 1996). The coding sequence of mneoI is interrupted by an intron residing in the 
same transcriptional orientation as L1. This arrangement ensures that functional a 
neomycin phosphotransferase gene will only be activated upon L1 retrotransposition 
into genomic DNA (Freeman et al., 1994; Moran et al., 1996). Retrotransposition of 
mneoI confers resistance to the drug G418. If mneoI is delivered into the genome and 
	   137	  
expressed, the resultant drug resistant foci provide a quantitative readout of L1 
retrotransposition.     
We transiently transfected PA-1 cells with a retrotransposition-competent L1 
(RC-L1; pJM101/L1.3). In agreement with previous reports (Garcia-Perez et al., 2010), 
we found that PA-1 cells transfected with an RC-L1 were not resistant to the drug G418 
and thus concluded L1-retro-mneoI events are efficiently silenced in PA-1 cells (Figure 
3.1A). An additional control confirmed that these cells acquire G418 resistance when 
transfected with a plasmid that constitutively expresses the neomycin 
phosphotransferase resistance gene (pCDNA3) (Figure 3.1A). Given these results, and 
those from previous publications, we hypothesized that a genetic component was 
responsible for the silencing of L1-retro-mneoI (Garcia-Perez et al., 2010). We sought to 
investigate this hypothesis by taking advantage of CRISPR/Cas9 mediated genome 
editing technology. Our goal was to knock out genes individually in PA-1 cells and 
assess the effect of gene knockout on L1-retro-mneoI silencing.  
PA-1 cells support transduction of lentivirus 
We took advantage of a CRISPR/Cas9 editing platform called Genome wide 
CRISPR Cas9 Knock Out (GeCKO) (Shalem et al., 2014). This platform packages a 
plasmid (lentiCRISPRv2 or LCv2) containing a single-guide RNA (sgRNA) sequence 
and a human codon-optimized triple FLAG-tagged Cas9 protein in a single lentiviral 
particle (Figure 3.1B) (Shalem et al., 2014). The LCv2 plasmid also contains the 
puromycin N-acetyl-transferase (pac) gene that confers resistance to the drug 
puromycin (Shalem et al., 2014). Thus, successful transduction and integration of LCv2 
into genomic DNA confers resistance to the drug puromycin. 
We utilized the GeCKOv2 human sgRNA library (Sanjana et al., 2014; Shalem et 
al., 2014). The GeCKOv2 library contains 123,411 guide sequences (sgRNAs) divided 
equally between two libraries (A and B). Guide sequences in the GeCKOv2 library 
target 19,050 genes with six sgRNAs targeting each gene, 1,864 miRNAs with four 
sgRNAs targeting each miRNA, and 1000 control non-targeting sgRNAs (Sanjana et al. 
2014).   
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Libraries A and B were first independently bulk-amplified using PCR, digested, 
and ligated into digested LCv2 vector. The resultant LCv2 plasmids contain a single 
guide sequence. To ensure that PCR amplification and cloning did not result in an 
artificial dropout of guide sequences, we submitted the LCv2 “A” library plasmids for 
deep sequencing on an Illumina Hi-Seq 2000. Of the 63,317 guide sequences in library 
“A”, 62,764 (>99%) were represented in our final plasmid pool (performed in the 
Kitzman Laboratory) (Figure 3.2A). These results suggest we efficiently amplified and 
cloned guide sequences into the LCv2 plasmid. LCv2 “A” and “B” plasmids were 
separately packaged into a self-inactivating lentivirus expressing the vesicular stomatitis 
virus glycoprotein (VSV-G) with the aid of the University of Michigan Vector Core 
(Directed by Dr. Thomas Lanigan). Subsequent viral supernatants contained LCv2 “A” 
or LCv2 “B” lentivirus.  
We first determined the viral titer of the “A” and “B” libraries to be ~1.62x107 
infectious particles per milliliter of supernatant. Next we wanted to determine the 
kinetics of gene editing in PA-1 cells. We reasoned that guide sequences targeting 
critical cell survival genes would be lost over time (Blomen et al., 2015; Hart et al., 2014; 
Hart et al., 2015). In order to ensure that we did not artificially lose guide sequences 
because of under-transduction, which could thus confound our downstream analyses, 
we initially transduced 1.2x108 million PA-1 cells at a multiplicity of infection (MOI) of 
0.35 to ensure that each cell was infected by only one viral particle. Thus, each guide 
sequence in the transduced population was represented with ~295X coverage. 
Separate cultures of cells transduced with the “A” and “B” libraries were maintained.  
Transduced PA-1 cells were cultured in puromycin selection media for 31 days 
and were passaged only upon reaching confluency (Figure 3.1C). Transduced PA-1 
cells were collected at 8, 14, 21, 24, 28, and 31 days post-transduction (Figure 3.1C). At 
each passage cells were counted (~1X109 cells at each passage) and one third (~3X108 
cells) of the cells were re-plated and cultured for continued growth, one third were 
retained for genomic DNA (gDNA) extraction, and one third were cryopreserved as cell 
stocks. The high density of re-plating was to ensure we retained a robust representation 
of guide sequences.  
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Cas9 is efficiently expressed from a transduced PA-1 cell line 
We first wanted to determine the profile of Cas9 expression in our transduced 
PA-1 cells. Western blot analyses were conducted using whole cell lysates (WCLs) 
derived from LCv2 transduced PA-1 cells, from each of the six time points (collected 8, 
14, 21, 24, 28, 31 days post-transduction). An anti-FLAG mouse monoclonal antibody 
(Sigma-Aldrich, F1804) was used for detection of triple FLAG-tagged Cas9 expression. 
We detected robust Cas9 expression from WCLs at each of the six time points (Figure 
3.2A). These data verify that expression of Cas9 delivered by a lentivirus is maintained 
for at least 31 days in PA-1 cells.     
The above result is important for two reasons. Firstly, sustained expression of 
Cas9 suggests that Cas9 mediated editing of genomic loci could continue throughout 
the course of our experiment. Sustained expression of Cas9 increases the likelihood 
that any given genomic loci is edited until it can no longer be recognized by the 
targeting sgRNA. Secondly, sustained expression of Cas9, coupled with the fact that 
transduced PA-1 cells remain puromycin resistant after 31 days, indicates that lentiviral 
delivered sequences are not silenced in PA-1 cells. These data are in agreement with a 
previous publication and support our hypothesis that genomic silencing of reporter 
genes delivered by L1 is a potentially distinct mechanism from silencing of lentiviral 
delivered sequences (Garcia-Perez et al., 2010). 
CRISPR/Cas9 efficiently knocks out genes in the PA-1 cell line 
To determine the editing status of PA-1 cells, we analyzed the complement of 
guide sequences present from cells collected 8 (T8), 21 (T21), and 31 (T31) days post-
transduction (Figure 3.1C). After gDNA collection, guide sequences were bulk PCR 
amplified from both the “A” and “B” libraries using two rounds of PCR. The first round of 
PCR uses primers that flank the guide sequence of the integrated LCv2 and results in a 
product ~280 nt long. The second round of PCR adds eight nucleotide Illumina 
barcodes that allow multiplex sequencing, and complimentary sequences that bind to 
the flow cell oligonucleotide, resulting in products of ~330 nt. Amplified second round 
PCR products were size selected for products larger than 300 nt using Solid Phase 
Reversible Immobilization (SPRI). The 62,764 guide sequences from the LCv2 “A” 
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plasmid pool were deep sequenced on an Illumina Hi-Seq 2000 and were represented 
by ~55 million reads with a median coverage of 664 reads and 877 reads per guide 
sequence  (performed by Dr. Jacob Kitzman) (Figure 3.2A). As we only had access to 
the sequencing data from the LCv2 “A” plasmid pool, we only analyzed guide 
sequences corresponding to the “A” library in our time course experiment. 
 We submitted our PCR products for sequencing on an Illumina MiSeq. At T8, 
45,599 guide sequences were represented by 208,499 reads at a median coverage of 2 
reads and a mean of 4.5 reads per guide (Figure 3.2B). At T21, 49,017 guide 
sequences were represented by 310,942 reads at a median coverage of 3 reads and a 
mean of 6.3 reads per guide (Figure 3.2B). At T31, 51,124 guide sequences were 
represented by 443,982 reads at a median coverage of 4 reads and a mean of 8.6 
reads per guide (Figure 3.2B). The increase in represented guide sequences over time 
is likely due to increased sequencing depth at each time point. 
We reasoned that the LCv2 “A” plasmid pool represented the starting population 
of guide sequences available for viral packaging and subsequent infection. To 
determine loss of guide sequences, we compared guides represented at T8, T21, and 
T31 to the guides represented in the original LCv2 “A” plasmid pool (Figure 3.2B).  We 
used the Model-based Analysis of Genome-wide CRISPR-Cas9 Knockout (MAGeCK) 
pipeline (Li et al., 2014) to analyze guide drop-out (Figure 3.2C). Additionally, MAGeCK 
performs a pathway analysis to determine if genes corresponding to pathways are over- 
or underrepresented in T8, T21, and T31 cells compared to LCv2 “A” plasmid pool.  
  MAGeCK pathway analysis uncovered that at T8 only genes associated with the 
spliceosome, 40/125 genes (KEGG id: hsa03040) and proteasome, 18/44 genes 
(KEGG id: hsa03050) were significantly (p<1X10-4) depleted when compared to the 
LCv2 “A” plasmid pool (Figure 3.2D). In contrast, at T21, 60/125 spliceosome genes 
were depleted as well as 23/44 proteosome genes when compared to LCv2 “A” plasmid 
pool (Figure 3.2D). Additionally at T21, the ribosome, 39/86 genes (KEGG id: 
hsa03008), aminoacyl tRNA biosynthesis, 24/41 genes (KEGG id: hsa00970), RNA 
polymerase, 16/29 genes KEGG id: hsa03020), and RNA degradation pathway, 25/56 
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genes (KEGG id: hsa03018) pathways exhibited significant gene depletion (p<1X10-4) 
when compared to LCv2 “A” plasmid pool (Figure 3.2D).  
At T31, we observed a similar number of genes depleted in the same KEGG 
pathways as at T21 (Figure 3.2D). However, genes in two additional pathways, the 
pyrimidine metabolism, 46/96 genes (KEGG id: hsa00240) and valine, leucine, and 
isoleucine biosynthesis, 8/11 genes (KEGG id: hsa00290) pathways were also depleted 
(p<1X10-4) when compared to LCv2 “A” plasmid pool (Figure 3.2D). These data are 
suggestive that 21 days post-transduction some genes representing pathways critical 
for cell survival are edited and effectively knocked out. Due to low read counts, our data 
set is likely underrepresenting the actual efficiency of our experimental design and 
deeper sequencing of our experimental populations should more accurately describe 
knockout efficiency.  
PA-1 cells transduced with LCv2 support increased expression of L1-retro-mneoI 
compared to untransduced PA-1 cells 
 Our data suggested that T21 transduced PA-1 cells are efficiently edited. We 
reasoned that using the T21 population for our retrotransposition experiments would 
decrease the number of potential off-target effects mediated by sgRNA/Cas9 editing 
while also maintaining a high representation of guide sequences (Sanjana et al., 2014; 
Shalem et al., 2014). We combined T21 cells from both the “A” and “B” libraries and 
seeded ~1x107 cells in media containing puromycin. Roughly 72 hours after seeding we 
recovered ~9X107 T21 cells. Approximately 8.4x106 T21 cells were seeded and 
subsequently transfected (see methods) in eight separate 15 cm plates; seven were 
transfected with the RC-L1, pJM101/L1.3, and one plate was left untransfected (Figure 
3.3A).  The seven individual transfections served as technical replicates. Previous 
experiments demonstrated that a small number of PA-1 cells (<.3%) do not silence L1-
retro-EGFP (Garcia-Perez et al., 2010). To determine the background level of L1-retro-
mneoI events that escape silencing in wild-type PA-1 cells, we transfected ~8.4x106 
wild-type PA-1 cells with pJM101/L1.3.  
 Approximately seventy-two hours post transfection, cells were selected with 
200ug/ml of the drug G418 (Figure 3.3A). By 14 days post transfection no un-
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transfected T21 cells remained, indicating efficient drug selection. In contrast, 15 cm 
plates containing T21 cells transfected with pJM101/L1.3 contained ~150-300 visible 
G418 resistant colonies per plate. These colonies represent possible L1-retro-mneoI 
events that escaped silencing. In contrast the wild-type PA-1 cells transfected with the 
RC-L1 contained ~35 G418 resistant colonies, indicating the level of background of L1-
retro-mneoI events that escape silencing (Figure 3.4A). To maximize our recovery of 
guide sequences we did not fix and stain any of these replicates and we are likely 
underestimating the true number of G418 resistant colonies (discussed further below) 
(Figure 3.4A). Thus, we observed that T21 cells exhibited at least a 5-fold increase in 
G418 resistant colonies compared to wild-type PA-1 cells.  
 We allowed the transfected plates containing colonies to grow for an additional 
two days in G418 selection media to increase cell number and quantity of genomic 
DNA. Roughly 4x106 -1.2x107 G418 resistant T21 cells were collected from each of the 
seven 15 cm plates. We collected gDNA from each of the 15 cm plates keeping the 
samples separate. Guide sequences present in collected gDNA were PCR amplified 
using two rounds of amplification as described in the above section. Each of the seven 
samples was amplified with a different bar code allowing us to maintain independent 
replicates. PCR amplified guide sequences were then subject to deep sequencing on an 
Illumina MiSEq, as described above.  
Sequencing these 7 samples yielded ~2 million total mappable reads with an 
average of ~2.8x105 reads per replicate plate. In total, 18,478 unique guide sequences 
were recovered for an average of 2,639 guides per replicate, and an average of 108 
reads per guide. Closer inspection of the data revealed that the minority of guides 
represented the majority of sequencing reads. The top 100 most abundant guides 
represented ~15% of all reads, the top 200 most abundant guides represented ~23%, 
the top 1000 guides represented ~48%, and the top 5000 guides represented ~83% of 
all reads. Thus ~1% of the guide sequences (200/18,478) represented ~23% of all 
sequencing reads, and ~27% (5000/18478) of the guide sequences identified 
represented ~83% of all sequencing reads.  
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Analysis of potential candidate genes that silence L1-retro-mneoI in PA-1 cells 
 We generated a list of potential candidate genes using a very simple metric. We 
reasoned that if knockout of a gene resulted in expression of L1-retro-mneoI, then the 
guide sequence targeting that gene should be present in more than one of the seven 
replicates. Notably, this analysis was blind to the depth of sequencing reads 
represented for each guide. These criteria whittled our list of 18,478 guide sequences 
down to 2,850. These data suggest that most of the guide sequences we recovered are 
“one-offs” and may represent background in our system. We then determined which of 
the 2,850 guide sequences corresponded to the same gene. To be considered a 
potential candidate gene, we required that at least two different guides targeting a gene 
had to each be represented on at least two different replicates. Thus, our final list 
included 161 candidate genes, represented by at least two guides in at least two 
replicates (Figure 3.3B). 
 It could be that of the six guides targeting each gene, only one is highly efficient 
(HE-guide). To safeguard against the possibility that our selection criteria was too 
stringent, we added an additional criteria. We observed that 91 guides were present in 
four or more replicates and considered that these guides were likely highly HE-guides. 
We determined which genes the HE-guides targeted and then asked if at least one 
other single replicate guide targeted an HE-guide gene. As an example, an HE-guide 
targeting the Tumor Protein 53 gene, TP53, was present in six replicates. Two other 
guides targeting TP53 were also recovered, but each was present in only a single 
replicate. These criteria added an additional 27 potential candidate genes (Figure 3.3C). 
An analysis of the top candidate gene, NF2 
 We further inspected the top candidate gene Neurofibromin 2 (NF2 or MERLIN) 
which was targeted by five of six guide sequences (Figure 3.3B). Notably, two of the five 
guides were HE-guides represented in 7, and 6, replicates, respectively. The additional 
three guides were each represented in two replicates. NF2 is generally considered to be 
a tumor suppressor gene and loss of NF2 results in the formation of tumors composed 
of Schwann cells (schwannomas) on cranial and peripheral nerves (Welling et al., 
2007). 
	   144	  
  In an initial attempt to validate NF2 as a potential factor that silences L1-retro-
menoI we sought to knock out NF2 in wild-type PA-1 cells using a transient transfection 
assay. The JKP116 plasmid, (generously provided by Dr. Jacob Kitzman) contains 
restriction sites for guide sequence cloning, a human codon optimized Cas9 gene, and 
a puromycin N-acetyl-transferase gene, and can be used as an empty vector control 
(Ran et al., 2013). We designed three oligonucleotides containing a unique guide 
sequence targeting NF2. The guide sequences are identical to three of the five guide 
sequences recovered in our screen. Oligonucleotides were designed with additional 
sequences at their 5’ and 3’ ends that facilitate cloning into JKP116 (see methods). 
Successful cloning resulted in three plasmids, pPL_NF2_31760, pPL_NF2_31761, and 
pPL_NF2_31718, each targeting a unique sequence in the NF2 gene. Wild-type PA-1 
cells were seeded and concomitantly transiently transfected with pPL_NF2_31760, 
pPL_NF2_31761, pPL_NF2_31718, JKP116, or left untransfected. Approximately 48 
hours after transfection cells were selected with 2ug/ml of the drug puromycin (Figure 
3.4A). Approximately 72 hours post-selection no untransfected cells remained. PA-1 
cells containing pPL_NF2_31760, pPL_NF2_31761, pPL_NF2_31718 or JKP116 were 
passaged into T-75 tissue culture flasks, and then into T-175 tissue culture flasks to 
increase cell number.  
Once sufficient cell numbers were attained, we performed L1 retrotransposition 
assays. Wild-type PA-1 cells, or pPL_NF2_31760, pPL_NF2_31761, pPL_NF2_31718 
or JKP116 PA-1 cells were transfected with pJM101/L1.3 and subject to selection 
exactly as described for the above retrotransposition assay (Figure 3.4A). As a control, 
we included untransfected pPL_NF2_31760, pPL_NF2_31761, and pPL_NF2_31718 
PA-1 cells. Approximately 14 days after selection with the drug G418, cells were fixed 
and stained (Figure 3.4A). In pPL_NF2_31760, pPL_NF2_31761, and pPL_NF2_31718 
PA-1 cells, we readily observed colonies resistant to the drug G418 (Figure 3.4B). This 
observation suggests that in some pPL_NF2_31760, pPL_NF2_31761, and 
pPL_NF2_31718 PA-1 cells, L1-retro-mneoI events escaped silencing. In JKP116 cells, 
and wild-type transfected PA-1 cells no such G418 resistant colonies were observed 
(Figure 3.4B). Crucially, untransfected pPL_NF2_31760, pPL_NF2_31761, and 
pPL_NF2_31718 PA-1 cells were susceptible to G418 treatment, which strongly 
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suggests knockout of NF2 does not simply confer drug resistance to PA-1 cells (Figure 
3.4C). These preliminary data suggest that NF2 may act directly or indirectly to silence 
expression of L1-retro-mneoI in PA-1 cells. Additional experiments are necessary to 
validate editing and knockout of NF2.  
Discussion 
PA-1 cells are edited by a CRISPR/Cas9 based genome-editing platform 
We verified previous reports that PA-1 cells efficiently silence L1-retro-mneoI 
(Figure 3.1A) (Garcia-Perez et al., 2010). In an effort to identify factors that might be 
involved in L1-retro-mneoI silencing in PA-1 cells, we developed a forward genetic 
screen. We utilized a CRISPR/Cas9 based platform that packages an LCv2 plasmid into 
a lentivirus. The LCv2 plasmid contains a single-guide RNA (sgRNA) sequence, a 
human codon-optimized triple flag-tagged Cas9 protein, and puromycin N-acetyl-
transferase gene that confers resistance to the drug puromycin (Shalem et al., 2014). 
Our first goal was to validate that the platform worked in our hands. We developed a 
scheme where we transduced PA-1 cells with LCv2 and analyzed genome editing at 
eight (T8), twenty-one (T21), and thirty-one (T31) days post-transduction (Figure 3.1C). 
We first determined Cas9 protein expression at T8, T21, and T31. Western blot 
experiments demonstrated that PA-1 cells transduced with LCv2 robustly express Cas9 
at least thirty-one days post-transduction (Figure 3.2A). In agreement with previous 
results, these data demonstrate that, unlike sequences delivered into the genomes of 
PA-1 cells by TPRT; sequences delivered by a lentivirus are not efficiently silenced in 
PA-1 cells (Garcia-Perez et al., 2010).  
We next sought to determine the kinetics of gene editing in PA-1 cells. We 
reasoned that guide sequences targeting genes essential for cell survival would be lost 
in our population over time. We compared the complement of guide sequences in our 
T8, T21, and T31 populations to the complement of guide sequences present in the 
initial LCv2 plasmid pool using the MAGeCK software (Li et al., 2014). Analysis 
revealed that at T8, only genes in the proteasome, and spliceosome pathways were 
depleted, whereas at T21, genes in the spliceosome, proteasome, aminoacyl tRNA 
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biosynthesis, ribosome, RNA polyermase, and RNA degradtaon pathways were 
depleted (Figure 3.2D). Gene depletion was only modestly increased by T31 compared 
to T21 (Figure 3.2D). Thus, we decided to use T21 cells for our further analysis.  
Detection of L1-retro-mneoI in PA-1 cells 
Our goal was to identify genes that potentially silence L1-retro-mneoI events in 
PA-1 cells. We subjected T21 cells, and wild-type PA-1 cells to retrotransposition 
assays in an effort to satisfy this goal (Figure 3.3A). Successful retrotransposition and 
expression of L1-retro-mneoI results in resistance to the drug G418.  We observed a ~5 
fold increase in G418 resistant colonies in T21 cells compared to wild-type PA-1 cells. 
These data suggest a population of T21 cells were unable to silence L1-retro-mneoI 
events (Figure 3.A). We subsequently determined the complement of guide sequences 
present in the G418 resistant cells. 
Our strategy for candidate gene selection was based on the seven technical 
replicates built within our experiment. We leveraged the idea that if a single guide was 
represented on more than one replicate it was more likely to be a true positive. We 
reasoned that any guides that are present on only a single replicate likely represented 
background. Surprisingly, 18,478 unique guide sequences were recovered across the 
seven replicates. We estimated that each replicate contained ~150-300 visible L1-retro-
mneoI colonies. If each colony contains only one guide, and we assume the upper limit 
of colony number, then we would expect a maximum of 2,100 unique guides (300 
colonies x 7 replicates). Thus, it appears that more guide sequences are present in our 
population than visible colonies. There are three possible explanations for this 
observation.  
The first explanation is that we drastically underestimated the viral titer of the 
LCv2 lentivirus, resulting in multiple infections in each cell. This explanation is possible, 
but unlikely. Viral titer was determined independently three times by a colony-forming 
assay. Other assays for determining viral titer include qPCR as well as ELISA. Both 
qPCR and ELISA are reported to be more sensitive and reproducible than a colony-
forming assay. It may be beneficial to subject our viral lysates to an additional assay to 
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more accurately determine titer and bolster our confidence that we accurately 
transduced PA-1 cells with an MOI of 0.35 
The second explanation is that there are many more G418 resistant cells than 
what we observe visually. Estimation of colony number was based on observing live 
colonies as opposed to fixing and staining. It is very likely that we drastically 
underestimated the number of colonies present in each replicate. It could be that each 
replicate contained thousands of colonies represented by a small number of cells too 
small to see with the naked eye. Our two-step PCR could potentially amplify even the 
most rare guide sequences represented by only a few cells. It will be beneficial to fix 
and stain some 15 cm plates in future experiments to better determine the level of 
background G418 resistant cells. 
The third explanation is coupled with the second explanation. Though we 
estimated a ~5 fold increase in G418 resistant colonies in T21 cells compared to wild-
type PA-1 cells, the background in wild-type PA-1 cells may be higher. This notion is 
bolstered by the observation that of the 18,478 recovered guides in the G418 resistant 
T21 population, 1000 guides represented almost half of our total number of reads. Thus, 
it seems possible that there is a higher level of L1-retro-mneoI events that escape 
silencing than we initially determined. Future investigation will likely need to adjust drug 
selection parameters to increase the signal to noise ratio.  
Additional modifications to the retrotransposition assay should also be 
considered to optimize and clarify downstream analysis. It is likely there are many single 
cells or small clusters of cells that are G418 resistant independent of an L1 
retrotransposition event. Some of these cells could be differentiated cells that have 
stopped dividing, whereas others could stochastically remain affixed to the culture 
vessel. After completion of drug selection, resistant cells could be trypsinized and re-
plated in a new culture vessel in the presence of G418. Differentiated cells are unlikely 
to adhere to the vessel after re-plating and G418 enforces maintained expression of the 
L1-retro-mneoI. Alternatively, cells could be transfected with an L1 containing an EGFP 
retrotransposition indicator cassette and subsequently be subject to flow cytometry. In 
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this way, only L1-retro-EGFP expressing cells that escape silencing due to a genetic 
mechanism will be identified.    
Analysis of NF2 
 In this preliminary screen we identified 188 candidate genes that may silence L1-
retro-mneoI in PA-1 cells (Figure 3.3B, C). Our investigation determined that, when 
knocked out, L1-retro-mneoI events were not silenced and thus conferred resistance to 
the drug G418. We investigated the top ranked gene, NF2, in an attempt to determine if 
we could recapitulate the result observed in the screen. We used a previously published 
method that relies on transient transfection of a plasmid as opposed to viral integration, 
to knock out NF2 (Ran et al., 2013). We targeted NF2 for knockout in wild-type PA-1 
cells using three different guide sequences. We then subsequently subjected those cells 
to retrotransposition assays to determine if L1-retro-mneoI events escaped silencing 
(Figure 3.4A).  
 In all three knockout conditions we readily observed G418 resistant foci 
suggesting L1-retro-mneoI events escaped silencing in these cells. Control experiments 
yielded no such foci and importantly demonstrate that knockout of NF2 does not result 
in the conferral of drug resistance (Figure 3.4B, C). These preliminary data suggest that 
NF2 and its protein product, MERLIN, silence expression of L1-retro-mneoI in PA-1 
cells. Additional experiments are required to validate that the PA-1 cells used for these 
experiments contain appropriately edited NF2 loci. NF2 knockout cells should also be 
transfected with an L1 that delivers an EGFP or blasticidin resistant gene. The 
expectation is that transfected NF2 knockout cells should robustly express EGFP, or be 
resistant to the drug blasticidin, respectively. These experiments would further validate 
that NF2 directly, or indirectly silences L1-reporter in PA-1 cells. Finally, only three of 
the five guide sequences targeting NF2 were tested and it will be important to determine 
if the remaining two guide sequences similarly effect silencing of L1-reporter genes in 
PA-1 cells.  
 Here, we described the design and implementation of a genome wide screen to 
identify potential candidate genes that silence L1-retro-mneoI events in PA-1 cells.  The 
188 candidate genes identified here provide a starting point for further investigation. 
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Certainly, the parameters of the screen require additional optimization. However, 
through preliminary experimentation, we began to validate our top candidate gene as a 
potential factor that silences L1-retro-mneoI in PA-1 cells. These data are promising and 
suggest that with some minor improvements we will be able to confidently identify 
factors that may play a role in silencing sequences delivered by an engineered L1.  
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MATERIALS and METHODS 
E. coli and the Propagation of Plasmids 
All plasmids were propagated in DH5α E. coli (genotype: F- φ80lacZ∆M15 ∆(lacZYA-
argF) U169 recA1 endA1 hsdR17 (rk-, mk+) phoA supE44 λ- thi-1 gyrA96 relA1) 
(Invitrogen, Carlsbad, CA). Competent cells were generated as described previously 
(Inoue et al., 1990). Plasmids were prepared using the Plasmid Midi Kit (Qiagen, 
Germany) according to the protocol provided by the manufacturer.  
Cell Lines and Cell Culture Conditions 
PA-1 cells were cultured as previously described (Garcia-Perez et al., 2010).  Briefly 
cells were grown in Minimum Essential Media (MEM) supplemented with 10% heat 
inactivated fetal bovine serum, 0.1 mM non-essential amino acids, 2mM L-Glutamine, 
100U/ml penicillin, and 0.1 mg/ml streptomycin and subsequently filtered with a 0.22 uM 
filter (PA-1 Complete media). Cells were grown at 37ºC in a humidified incubator in the 
presence of  7% CO2. 
Plasmids 
pJM101/L1.3: contains a full-length version of L1.3 in the pCEP4 backbone. The 3’UTR 
of L1.3 contains the mneoI retrotransposition indicator cassette (Dombroski et al., 1993; 
Moran et al., 1996; Sassaman et al., 1997). 
pCDNA3: expresses a neomycin resistance gene and was acquired from Invitrogen. 
LentiCRISPRv2: the packaging vector that containing the targeting guide sequence and 
Cas9 protein (Sanjana et al., 2014). The plasmid contains a psi+ packaging signal, a rev 
response element (RRE), central polypurine tract (cPPT), and a human U6 snRNA 
promoter driving expression of the guide sequence (Sanjana et al., 2014). The 
elongation factor 1α (EFS) short promoter drives expression of a Streptococcus 
pyogenes human codon-optomized Cas9/C-terminal FLAG octapeptide fusion protein 
as well as the puromycin resistance gene (Sanjana et al., 2014). A P2A self-cleaving 
peptide separates the Cas9/FLAG fusion protein from the puromycin resistance gene 
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(Sanjana et al., 2014). A woodchuck hepatitis virus posttranscriptional regulatory 
element (WPRE) is at the 3’ end of the EFS transcriptional unit to enhance expression. 
Following transcription and translation the P2A self-cleaving peptide mediates the 
cleavage of the Cas9/FLAG tag peptide from the puromycin resistance peptide.  
sgRNA libraries: the GeCKOv2 sgRNA libraries have been previously described 
(Sanjana et al., 2014; Shalem et al., 2014). Briefly, the GeCKOv2 library contains 
123,411 guide sequences (sgRNAs) divided equally between two libraries (A and B). 
Guide sequences in the GeCKOv2 library target 19,050 genes with six guides targeting 
each gene, 1,864 miRNAs with four guides targeting each miRNA, and 1000 control 
non-targeting guides (Sanjana et al. 2014).  The libraries are separated into two sub-
libraires (A and B) each containing half of the total complement of guides. GeCKOv2 
library was purchased from Addgene.  
Cloning sgRNAs into lentiCRISPRv2 (note: these experiments performed in the Kitzman 
laboratory): 
The GeCKOv2 plasmid library was first digested with BsmBI to release the guide 
sequences. The BsmBI insert sequences were then PCR amplified using custom 
primers to increase guide copy number. PCR products were then digested with BsmBI 
and ligated into BsmBI digested LentiCRISPRv2 plasmids (Sanjana et al., 2014; 
Shalem et al., 2014). The resultant LentiCRISPRv2 plasmid contains a single guide 
sequence and can be subsequently packaged into lentivirus.  
Viral production and packaging of LentiCRISPRv2 
Lentivirus packaging was performed at the University of Michigan Vector Core (Dr. 
Thomas Lannigan). For each sub library 650 µg of purified proviral plasmid were 
packaged into lentiviral particles using the psPAX2 plasmid containing the gag and pol 
genes and the vesicular stomatitis virus G glycoprotein (VSV-G) envelope protein 
expressing plasmid. Human embryonic kidney A293T cells were used for lentiviral 
production. Supernatants were subsequently collected and contained the mature viral 
particles. Mature viral particles contain the lentiCRISPRv2 proviral sequence and can 
	   152	  
be used to transduce cells. Note viral supernatants from sub-libraries A and B were 
maintained separately.  
Viral transduction and growth of PA-1 cells 
PA-1 cells were plated in 20 15 cm dishes (BD Biosciences) at a density of 6X106 
cells/plate in 20 plates—yielding 1.2X108 cells total. Twenty-four hours post-plating 10, 
15 cm dishes were transduced by replacing PA1-Complete media with PA1-Complete 
media that contained the viral supernatant from either sub-library A, or sub-library B at 
an MOI of 0.3 and 8 µg/ml Polybrene (Sigma). Transduced PA-1 cells from each sub-
library were maintained separately throughout the duration of selection. Twenty-four 
hours post transduction media was replaced with fresh PA-1 Complete media. Forty-
eight hours post transduction cells were selected with PA-1 Complaete media 
containing (1 ug/ml) of the drug puromycin daily for the remainder of the experiment. 
Cells were collected and reseeded on days 8, 14, 21, 24, 28, and 31. At each time point 
over 1X109 cells were collected; ~4X107 cells from each sub-library were reseeded into 
10, 15 cm dishes and allowed to grow until they reached confluency, 5X107 cells were 
cryofrozen to be maintained as cell stocks; and 2X108 cells were frozen at -30 C and 
saved for gDNA collection.  
gDNA collection  
Cell pellets were thawed and genomic DNA was extracted using the QIAGEN DNeasy 
Blood and Tissue Kit per the manufacturers recommendations. DNA was extracted from 
2X108 cells in supplied elution buffer and stored at 4C for further analysis. We typically 
recovered ~150 ug gDNA from each time point. Genomic DNA collected from PA-1 cells 
subject to retrotransposition assays was performed as above. Genomic DNA from each 
of the 7 replicate plates were collected independently yielding ~7.5 ug gDNA per plate.    
PCR amplification of guide sequences recovered from genomic DNA for drop-out 
analysis  
Genomic DNA collected drop-out analysis was subjected to two rounds of PCR 
amplification. PCRs were performed as previously described (Sanjana et al., 2014; 
Shalem et al., 2014). To ensure complete coverage guide sequences and to avoid 
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artificial dropout  multiple PCR reactions from the same sample were performed. Eight 
PCR reactions from each time point (T8, T21, T31) were performed with the 
KAPABIOSYSTEMS HiFi PCR kit (KapaBiosystems). Reactions were performed as 
recommended by the manufacturer with the following exception that 2.5ug of DNA was 
used per reaction. An initial denaturation time of 5 minutes at 95 °C was followed by 27 
cycles of amplification, using a 20 second annealing step at 60 °C, and a 30 second 
elongation step at 72 °C (Sanjana et al., 2014; Shalem et al., 2014). Primers used for 
PCR1 added sequences necessary for MiSEQ sequencing and are available upon 
request. Round 2 PCR amplification was performed using the same protocol as PCR 1 
with the following exceptions: 5 ul of PCR 1 product was used in the reaction, initial 
denaturation was 2 minutes at 95 °C and the was cycled seven times. Primers used in 
PCR 2 are P7 and P5 barcode adaptor primers provided by Illumina. All concentrations 
of reagents with the exception of starting gDNA material were followed as 
recommended by the manufacturer. Oligos for round 2 PCR add 8 bp barcodes onto the 
PCR 1 product allowing multiplexing and sequencing of numerous samples on a single 
MiSEQ run. Each of the 3 time point samples received their own unique combination of 
P5 and P7 barcodes. PCR products from PCR 2 were size selected to enrich for 
products greater than 300 bp using the SPRI-cleanup based Beckman Coulter 
Agencourt AMPure XP purification system following the manufacturers 
recommendations.   
PCR amplification of guide sequences recovered from genomic DNA collected from 
retrotransposition assays 
Genomic DNA from each of the seven replicates was collected as described above and 
was subjected to two rounds of PCR amplification. PCRs were performed as previously 
described (Sanjana et al., 2014; Shalem et al., 2014). A single PCR reaction was 
performed independently for each of the 7 replicates using the KAPABIOSYSTEMS HiFi 
PCR kit. Reactions were performed as described for time point analysis except 0.5 ug of 
gDNA was used. In addition to amplifying the guide sequence, primers added 
sequences used for MiSEQ sequencing and are available upon request. Round 2 PCR 
amplification was performed using the same protocol as PCR 1 with the following 
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exceptions:  5 ul of PCR 1 product was used in the reaction, initial denaturation was 2 
minutes at 95 °C and the reaction was cycled seven times. Primers used in PCR 2 are 
P7 and P5 barcode adaptor primers provided by Illumina. All concentrations of reagents 
with the exception of starting gDNA material were followed as recommended by the 
manufacturer. Primers for round 2 PCR add 8 bp barcodes onto the PCR 1 product 
allowing multiplexing and sequencing of numerous samples on a single MiSEQ run. 
Each of the seven technical replicates received their own unique combination of P5 and 
P7 barcodes. PCR products from PCR 2 were size selected to enrich for products 
greater than 300 bp using the SPRI-cleanup based Beckman Coulter Agencourt 
AMPure XP purification system following the manufacturers recommendations.   
MiSEQ sequencing of PCR amplified guide sequences from gDNA 
Sequencing of T8, T21, and T31 PCR were performed on a MiSEQ (Illumina) using 
MiSEQ Reagent Kits V3 with a 2 X 75 output. The final concentration of the the T8, T21, 
and T31 PCR products together was 12 pmol total. Cleaned, size selected products 
from all three time points were multiplexed on one MiSeq run. Sequencing of PCR 
products from the seven technical replicates was performed as above maintaining 12 
pmol final concentration and all 7 samples were multiplexed on the same sequencing 
run.  
MAGeCK data analysis 
Raw FASTQ files were downloaded and demultiplexed and trimmed to contain only the 
raw guide sequence. Alignment of reads required construction of an indexed reference 
of all guide sequences. Sequenced guides were then mapped to that reference index. 
For time T8, T21, and T31 time point analysis the number of reads for each unique 
guide sequence was normalized to the total number of reads for that timepoint. As each 
different time point produced a different number of reads, guide sequence read 
normalization compared to the plasmid pool was normalized independently for each 
timepoint. To determine enrichment and depletion of genes we compared guide 
sequences present in the plasmid pool to guide sequences present at T8, T21, and T31. 
To accurately perform the analysis reads from the plasmid pool and from the various 
time points were median normalized. MAGeCK (Li et al., 2014) was downloaded from 
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(https://sourceforge.net/p/mageck/wiki/Home/) using versioin 0.5.4. to analyze gene 
enrichment and depletion. Analysis was performed as described in Li et al.  2014.  
Protein collection 
The portion of the cells that were collected from the time course experiment and frozen 
at -30 °C were thawed and used for protein collection. After thawing, ~5X106 cells were 
lysed for 15 minutes on ice and incubated in 0.5 mL of lysis buffer: 10% glycerol, 20 mM 
Tris-HCl pH 7.5, 150 mM NaCl, 0.1% NP-40 (IGPAL) (Sigma-Aldrich, St. Louis, MO), 
and 1X Complete Mini EDTA-free Protease Inhibitor Cocktail (Roche Applied Science, 
Germany). The resultant protein lysates then were centrifuged at 15,000 x g for 30 
minutes to clear the lysate. The resultant supernatant (approximately 0.4mls) was 
designated as the whole cell lysate (WCL). Bradford assays (Bio-Rad Laboratories, 
Hercules, CA) were used to determine protein concentrations. WCLs generally yielded 
~10 µg/µl of protein. The protein samples were stored at -80 oC. 
Western blots 
Protein samples were collected as described above and then were incubated with a 2X 
solution of NuPAGE reducing buffer (containing 1.75-3.25% lithium dodecyl sulfate and 
50 mM dithiothreitol (DTT)) (ThermoFisher Scientific). An aliquot (20 µg) of the reduced 
proteins were incubated at 100oC for 10 minutes and then were separated by 
electrophoresis on 10% precast mini-PROTEAN® TGX gels (Bio-Rad Laboratories, 
Hercules, CA) run at 200V for 1 hour in 1X Tris/Glycine/SDS (25 mM Tris-HCL, 192 mM 
glycine, 0.1% SDS, pH 8.3) buffer (Bio-Rad Laboratories). Transfer was performed 
using the Trans-Blot® Turbo™ Mini PVDF Transfer Packs (BioRad Laboratories) with 
the Trans-Blot® Turbo™ Transfer System (BioRad Laboratories) at 25V for 7 minutes. 
The membranes then were incubated at room temperature in LI-COR blocking solution 
(LI-COR Biosciences, Lincoln, NE) for 30 minutes. Following blocking, fresh blocking 
solution was added with the following antibodies: FLAGM2 antibody (Agilent 
Technologies, Santa Clara, CA, cat # 200472) was diluted at 1:2,000; actin antibody 
(ThermoFisher Scientific, MA1-744) was diluted at 1:2,000. The membrane was 
incubated overnight at 4 C. After incubation the membrane was washed 3X with 1X 
PBS and secondary antibody was applied. Fresh blocking solution was added with the 
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following secondary antibodies: Anti-Mouse IRDye 680LT (LICOR Biosciences, Lincoln, 
NE, cat # 925-68022) diluted at 1:10,000 was used to visualize the actin loading control, 
and anti-Rabbit IRDye 800CW (LI-COR Biosciences, cat # 925-32213) was diluted at 
1:10,000 and used to visualize FLAGM2. The membrane was incubated for 2 hours at 
room temperature with secondary antibody. Following incubation the membrane was 
washed 3X with 1X PBS and fluorescent signals were detected with an Odyssey CLx 
(LI-COR Biosciences).  
L1 Retrotransposition Assay  
T21 cryofrozen cells from both sub-library A and B were thawed and cultured 
together in three T-175 flasks (BD Biosciences) and allowed to grow to confluency.. 
Seven, 15 cm dishes (BD Biosciences) were seeded with 8.4×106 T21 cells/dish in 20 
ml of PA-1 Complete media containing the transfection cocktail. The transfection 
cocktail is as follows; 1.68 ml of Opti-MEM® (Life Technologies), 67.2 µl FuGENE6 
(Promega) transfection reagent, and 16.8 µg pJM101/L1.3 plasmid DNA per 15 cm dish. 
Approximately 24 hours post-transfection, the media was replaced with PA-1 Complete 
media to stop the transfection. Three days post-transfection, the tissue culture medium 
was replaced and the cells were grown in PA-1 Complete media supplemented with 200 
µg/mL of G418 (Life Technologies) to select for retrotransposition events. After 16 days 
of G418 selection, the resultant G418-resistant foci were washed with ice cold 1X 
Phosphate-Buffered Saline (PBS) and collected using a cell scraper. Cells from each 
plate were collected separately and subsequently frozen at -30 C to be used for future 
gDNA collection and analysis. 
Cloning of NF2 knockout plasmids 
 Cloning of oligos into JKP116 was performed as described in Ran et al., 2013. 
Oligos used in cloning reactions were ordered from Integrated DNA Technologies (IDT), 
see below for oligo sequences. Sense and antisense oligos were used at a 
concentration of 100 uM and were first phosphorylated using T4 PNK (NEB) following 
the manufacturers recommendation and subsequently annealed at 37 °C for 30 
minutes. Enzyme was subsequently heat killed at 95 °C for five minutes, and 
temperature was ramped down to 25 °C at 5 °C /min. Annealed oligos were stored at 4 
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°C until future use. Plasmid JKP116 was generously provided by the Kitzman 
laboratory. ~ 100 ng of JKP116 plasmid was digested with the enzyme BbsI (NEB) 
following manufacturers recommendations. Following digestion annealed oligos at a 
concentration of 0.25 uM were incubated with the digested JKP116 plasmid at 37 °C for 
5 minutes, followed by 23 °C for five minutes and repeated 6 times.  Resultant plasmids 
were transformed into competent bacteria and plated on ampicillin containing plates to 
select for drug resistant bacteria. Individual bacterial clones were picked and expanded. 
Plasmid DNA extracted from  clones was sequenced to ensure it contained the proper 
guide sequence insert. 
Oligonucleotide guide sequences 
 Oligonucleotides are designed so they can easily be cloned into digested BbsI 
JKP116 plasmid (Ran et al., 2013). Underline indicates the actual sequence targeting 
the NF2 gene. 
NF2_31718_TOP: 5’-CACCGATTCCACGGGAAGGAGATCT-3’ 
NF2_31718_BOT: 5’-AAACAGATCTCCTTCCCGTGGAATC-3’ 
NF2_31760_TOP: 5’-CACCGCCTGGCTTCTTACGCCGTCC-3’ 
NF2_31760_BOT: 5’-AAACGGTCGGCGTAAGAAGCCAGGC-3’ 
NF2_31761_TOP: 5’-CACCGAAACATCTCGTACAGTGACA-3’ 
NF2_31761_BOT: 5’-AAACTGTCACTGTACGAGATGTTTC-3’ 
Cloning of annealed oligonucleotides into JKP116 yielded pPL_NF2_31718, 
pPL_NF2_31760, and pPL_NF2_31761, resultant plasmids are resistant to the drug 
puromycin and contain a Cas9 expression sequence. 
Knock out of NF2 in PA-1 cells 
 PA-1 cells were seeded in PA-1 Complete media at a density of 2x105 cell/well in 
each well of a six-well dish. Five of six wells were seeded in the presence of the 
transfection cocktail. Transfection cocktail contained 100 µl Opti-MEM® (Life 
Technologies), 3 µl FuGENE6 (Promega) transfection reagent, and 1 µg of 
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pPL_NF2_31718, pPL_NF2_31760, pPL_NF2_31761, or JKP116 plasmid DNA per well 
of a 6-well plate, the sixth well remained untransfected. Twenty-four post transfection 
media was changed with PA-1 complete media to stop the transfection. Fort-eight hours 
post transfection cells were selected with cells were selected with PA-1 Complete media 
containing 2 ug/ul of the drug puromycin. Seventy-two hours of drug selection resulted 
in no untransfected cells remaining. Resultant cells were grown in PA-1 Complete 
media lacking puromycin. Cells from all five remaining wells were passaged twice to 
increase cell number.  
L1 Retrotransposition Assay in knockout cell lines 
The cultured cell retrotransposition assay was conducted as described previously 
(Garcia-Perez et al., 2010; Kopera et al., 2016; Moran et al., 1996; Wei et al., 2001). 
Briefly, 2×105 PA-1 pPL_NF2_31718, pPL_NF2_31760, pPL_NF2_31761, JKP116, or 
wild-type PA-1 cells/well were plated in 6-well tissue culture dishes (BD Biosciences). 
Approximately 24 hours post-plating, transfections were performed in three of the six 
wells using a mixture containing 100 µl Opti-MEM® (Life Technologies), 3 µl FuGENE6 
(Promega) transfection reagent, and 1 µg pLM101/L1.3 DNA per well of a 6-well plate. 
Three wells were left untransfected. Approximately 24 hours post-transfection, the 
media was replaced with PA-1 Complete medium to stop the transfection. Three days 
post-transfection, the tissue culture medium was replaced and the cells were grown in 
PA-1 complete medium supplemented with 200 µg/mL of G418 (Life Technologies) to 
select for retrotransposition events. After approximately 14 days of G418 selection, the 
resultant G418-resistant foci were washed with ice cold 1X Phosphate-Buffered Saline 
(PBS), fixed to the tissue culture plate by treating them for 10 minutes at room 
temperature in a 1X PBS solution containing 2% paraformaldehyde (Sigma Aldrich) and 
0.4% glutaraldehyde (Sigma Aldrich), and stained with a 0.1% crystal violet solution for 
30 minutes at room temperature to visualize the G418-resistant foci. 
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Figure 3.1: Schematic design of PA-1 screen. 
A) L1-retro-mneoI events are silenced in PA-1 cells. PA-1 cells were transfected with 
pJM101/L1.3, left image. The retrotransposition of pJM101/L1.3 delivers a neomycin 
phosphotransferase resistance gene (mneoI) conferring resistance to the drug G418 
only if the integrated mneoI reporter (L1-retro-mneoI) is expressed. The pJM101/L1.3 
transfected PA-1 cells are susceptible to the drug G418, indicating silencing of L1-retro-
mneoI. PA-1 cells transfected with pCDNA3, which constitutively express neomycin 
phosphotransferase, are resistant to G418 B) Cartoon of the LentiCrispr version two 
(LCv2) plasmid. Light blue arrow indicates U6 promoter driving expression of the 
sgRNA sequence. Purple box is variable guide sequence. Blue arrow indicates 
elongation factor 1 (EFS) promoter driving expression of Cas9. Yellow box indicates 
Cas9, containing a red 3X-FLAG tag at its 3’ end. The entire sequence is flanked by 
Long Terminal Repeates (LTRs) indicated by white boxes. C) Design of PA-1 
transduction experiment with LCv2 lentivirus. On Day, 1 PA-1 cells are transduced with 
virus. On Day 8, PA-1 cells reached confluency and were trypsinized. Roughly 1/3 of all 
cells collected were then either reseeded into new plates (Reseed), cryofrozen as cell 
stocks (Cell Stocks), or collected for genomic DNA extractions (gDNA). That process 
occurred every day indicated on the schematic (Day 8, 14, 21, 24, 28, 31). The red box 
around Day 8, Day 21, and Day 31 (corresponding to T8, T21, and T31 in Figure 3.2B, 
D) depicts which gDNAs were used for time point analysis (see text).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
